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ABSTRACT

INHIBITION OF LUNG CARCINOGENESIS BY POLYMETHOXYFLAVONES
SEPTEMBER, 2013
NOPPAWAT CHAROENSINPHON,
B.S., CHULALONGKORN UNIVERSITY, BANGKOK, THAILAND
Ph.D., UNIVERSITY OF MASSACHUSETTS, AMHERST, MA
Directed by: Associated Professor Hang Xiao
Lung cancer is the leading cause of cancer-related death worldwide. Exclusively
found in citrus peels, the inhibitory effects of polymethoxyflavones (PMFs) on 3 human
non-small cell lung cancer cells have been investigated. Results showed that
monodemethylated PMFs at 5-position potently inhibited lung cancer cells than those of
their permethoxylated counterparts. The inhibition of cancer cells caused by
monodemethylated PMFs was associated with both extensive cell cycle arrest and
apoptosis as a result of modulation of key oncogenic signaling proteins. Treatment with
different bioactive compounds in combination may enhance inhibitory effects on lung
cancer due to their synergistic interaction among these agents. Results showed that
both nobiletin/atorvastatin (NBT/ATST) and tangeretin/atorvastatin (TAN/ATST) cotreatments at low doses exerted strong synergy as confirmed by isobologram analysis,
and also produced much stronger inhibitory effects on lung cancer cells in comparison
to those produced by NBT, TAN, or ATST alone at higher doses. Flow cytometry analysis
showed both NBT/ATST and TAN/ATST co-treatments significantly induced cell cycle
arrest and apoptosis, and these molecular events were involved with prenylation of
RhoA which subsequently resulted in alteration of key signaling proteins.
Supplementation of mevalonate or geranylgeranyl pyrophosphate significantly
counteracted the effects caused by NBT/ATST. Inhibitory effects of metabolites of PMFs
against lung cancer cells were significantly stronger than those produced by their
parental compounds. Treatments of PMFs significantly inhibited lung tumorsphere
formation and aldehyde dehydrogenase bright cells implicating the potential utilization
of these compounds to target lung cancer stem cells.
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CHAPTER 1
INTRODUCTION

Cancer and heart disease are the major causes of death worldwide. According to
the report from National Cancer of Health Statistics in 2012, total of estimated
1,638,910 new cancer cases and 577,190 mortalities are projected only in the United
States (1). Non-small cell lung cancer (NSCLC) accounts for approximately 80 - 85% of all
cases of lung cancer, and represents the leading cause of cancer-related mortality in
both men and women not only in the United States, but also worldwide. This
malignancy alone causes more deaths than the next three most colon, breast, and
prostate cancer deaths combined. Even though cancer research has been running at
breathtaking speed and many improved advance lung cancer treatments have been
discovered, the five year survival in NSCLC patients in overall stages is still below 16%.
The major reasons for this are that NSCLC tends to become resistant to
chemotherapeutic treatments and radiation therapy. Also, NSCLC is generally diagnosed
at the very late stages that are belatedly for surgical intervention (2).
Chemotherapy is a strategy of drugs treatment intended to eliminate cancer cells
in cancer patients with various forms of carcinoma. Although chemotherapy can be
effective cancer-treatments in some individual patients, accumulating evidence has
been demonstrating many adverse side-effects during and after treatments ranging
from annoying to life-threatening. These effects occur because chemotherapy aims to
eradicate rapidly proliferating cells, such as cancer cells, but also wipes out the fast
growing normal cells, such as hair cells, at the same time. Moreover, unsuccessful
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results and cancer recurrence in many cancer patients from using this strategy have
been increasingly revealed. In addition, the cost of chemotherapeutic treatments can be
very expensive, particularly if long-term treatments are necessity, despite an individual
has a covered medical insurance. Taken together, these facts are calling for urgent
necessitate for identifying improved novel strategies for lung cancer treatments and
prevention.
It is widely accepted that prevention is far more preferable than therapy. Since
ancient time, natural products such as herbs, spices, fruits, and vegetables have been
utilized to prevent and alleviate various diseases. It has been projected that more than
65% of human cancer incidences can be prevented by eating habits alteration.
Moreover, research indicated that approximately 35% of human cancer death was
associated with diet (3). Chemoprevention refers to the selective use of dietary
components or their analogs to inhibit, reverse, or delay carcinogenesis (4). Since
current treatments for lung cancer are still ineffective, the concept of chemoprevention
is exponentially receiving spotlighted attention. Chemoprevention has showed to be the
cost-effective alternative to general cancer therapies. Furthermore, because safely is
the greatest concern in cancer treatment, chemoprevention has been displayed to be a
promising strategy for cancer prevention as it exhibits no or very little unwanted sideeffects. At present, chemoprevention has been focused on identification of molecular
mechanisms of each effective bioactive chemopreventive agent as accumulating
evidence has been showed that numerous dietary bioactive components derived from
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edible plants have been documented to intervene with specific stages of carcinogenesis
process (5, 6).
Flavonoids have long been displayed to ameliorate human health. Existing in
fruits and vegetables, more than 8000 flavonoids structure have been identified to date.
Three broad classes of flavonoids including the flavanone glycoside, the flavones
glycoside, and polymethoxyflavones are found in Citrus (7). Almost exclusively found in
citrus peels, polymethoxyflavones (PMFs), a unique class of flavonoid, have been of
particular attention as they have been demonstrated to promote human health by
exerting a broad spectrum of biological activities including anti-inflammatory (8, 9, 10),
anti-carcinogenic (11, 12, 13, 14, 15), and anti-atherogenic properties (16, 17, 18).
Recently, hydroxylated PMFs, mainly 5-hydroxylated PMFs, have been isolated from
orange peel. Accumulating reports have indicated that hydroxylated PMFs exerted more
potent biological effects including anti-cancer (13, 14) and anti-inflammation (9, 10)
than those of their permethoxylated PMFs counterparts.
Atorvastatin calcium (Lipitor, ATST) belongs to a statin drug family, and is one of
the most prescribed drugs for hypercholesterolemia in the United States due to its
cholesterol-lowering properties. Recently, growing reports have showed that statins
including ATST exerted some of the cholesterol-independent or “pleiotropic” activities
which might provide another health benefits beyond lowering cholesterol levels
including anti-carcinogenic effects. These effects could be explained by the statins’ main
function in which they target and inhibit 3-hydroxy-methylgluraryl CoA reductase. This
blockage eventually leads to the reduced levels of many downstream isoprenoids
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intermediates that play pivotal roles in various cellular signaling pathways. Even if the
results were still inconclusive, many studies showed that ATST was capable to exhibit its
anticancer activities in both in vitro and in vivo (19, 20).
Combined treatments of two agents or more at the lower doses that target
different molecular sites can possibly cause significantly enhanced effects that those
produced by an individual agent alone at the higher doses because of their synergistic
interaction. The enhanced efficacy by the combination regimen can also reduce the
required dose for each single agent in combination, and in turn can minimize adverse
side-effects possibly resulted from the high dose of individual treatment. ATST has
proven to be a competent candidate in cancer prevention drug combination strategies
with multiple drugs and dietary components in both in vitro and in vivo(21, 22, 23, 24,
25, 26).
Biotransformation plays important roles in the biological activities of orally
ingested bioactive compounds. Besides exhibiting direct biological effects, flavanoids
including PMFs were also documented to act as pro-anticarcinogen, which are become
active after being converted by selectively cytochrome P450 1- dependent conversion
(27). Many studies suggested that the metabolites of PMFs were found to exhibit
stronger biological activities than those of their parental compounds (9, 10, 28, 29).
Cancer stem cell theory states that cancers are maintained by small
subpopulations of tumors cells that possess stem cell and progenitor characteristics
(30). Evidence has indicated that tumors comprised of heterogeneous population of
cells (referred as tumor heterogeneity, which shows hierarchical organization of cells
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within a tumor (31)) and tumor progression is driven by only a subpopulation of tumorpropagating cells (30, 32, 33). Growing evidence has reported the isolation of lung
cancer stem cells (CSCs) from both lung cancer cell lines (34, 35, 36, 37) and lung solidtumor (38, 39). Also, identifiable lung stem cells which exhibit same properties as
normal stem cells (self-renewal, clonogenicity, and multipotentiality) have recently been
discovered in human lungs (40).
Taken all these together, our long term goal is to improve lung cancer
chemoprevention strategy by using dietary components. To achieve that goal, the
overall objective of this research is to develop chemopreventive-based strategies that
target NSCLC carcinogenesis by using PMFs. Also, we would like to investigate whether
PMFs and their combinations with ATST could synergistically inhibit human NSCLC cell
proliferation. Our central hypothesis is that PMFs are able to exert their anticarcinogenic activities and also interfere with specific carcinogenesis stages to potently
inhibit NSCLC. Our hypothesis has been formulated on the basis of our and other
preliminary results that displayed that PMFs potently produced anticancer effects in
various cancers such as lung (14), colon (13, 15), and breast (41). Moreover, the results
obtained from this study will provide detailed molecular mechanisms of how NSCLC
could be inhibited which will be helpful to the ongoing chemopreventive cancer
research. Also these obtained results might provide promising data for further in vivo
investigations, and eventually encourage the use of drug combination strategy in lung
cancer, particularly NSCLC, chemoprevention.
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We plan to test our central hypothesis, and thereby, achieve our objective of this
project by pursuing these following specific aims:
1. Determine the growth inhibitory effects and molecular mechanisms by which
PMFs act on NSCLC cells. The growth inhibitory effects of PMFs will be determined using
cell viability assay. Flow cytometry analysis will be utilized to determine the effects of
PMFs on cell cycle arrest and apoptosis. We anticipate observing potent growth
inhibitory effects of PMFs on NSCLC cells.
2. Determine the synergistic interaction of growth inhibitory effects and the
underlying molecular mechanisms of PMFs and ATST in combination on NSCLC cells.
The growth inhibitory effects of PMFs, ATST, and their combinations will be determined
using cell viability assay. Isobologram analysis will be constructed to determine if the
exerted effects will be synergistic. Flow cytometry analysis will be utilized to determine
the effects of PMFs on cell cycle arrest and apoptosis. It is our expectation to observe
the synergistic inhibition by PMFs and ATST on NSCLC cells.
3. Determine the inhibitory effects and mechanism of actions of PMFs and their
metabolites in inhibiting NSCLC cell proliferation. PMFs and its metabolites will be
investigated by using the same techniques as described in specific aim 1. We anticipate
observing stronger growth inhibitory effects from metabolites of PMFs than those of
their parental compounds.
4. Determine the inhibitory effects and mechanism of actions of PMFs and their
metabolites in inhibiting lung cancer stem cells. The growth inhibitory effects of PMFs
and its metabolites as well as the combined treatment with ATST on lung tumorspheres
6

will be determined by using lung tumorsphere formation assay. Stem cell markers
expression profiles will be analyzed to identify lung CSCs from bulk cell population by
using fluorescence-activated cell sorting (FACS) technique. It is our expectation that
PMFs and their metabolites will significantly inhibit lung CSCs proliferation in vitro.
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CHAPTER 2
LITERATURE REVIEW

2.1 Introduction to lung cancer
At present, lung cancer is one of the most malignancies worldwide. It is also the
leading cause of mortalities among cancer in the United States in both men and women
approximately 87,750 and 72,590 estimated deaths in men and women respectively.
Markedly, as demonstrated in figure 2.1, more patients die of lung cancer than of colon,
breast and prostate cancers combined (1). In Japan and China, approximately 70,000
and 130,000 annual cancer-related deaths are currently attributed to lung cancer
respectively (42). Results obtained from the analysis of data of 22 cancer registries in 5
continents showed that cumulative lung cancer risks were higher in males than females.
African American has the highest incidence of lung cancer in both men and women.
Swedish has the lowest cumulative incidence in men. Among women, French and
Korean have the lowest cumulative risk of lung cancer (43).
Lung cancer has been categorized into small cell lung cancer (SCLC), and nonsmall cell lung cancer (NSCLC) to facilitate treatments and prognostic decisions. NSCLC
is further categorized into three major histological classes: adenocarcinoma, large cell
carcinoma, and squamous cell carcinoma (44). The incidence of SCLC has been declining
in the United States. Tobacco use is the strongest environmental factor associated with
the development of lung cancer as it has been estimated that 9 out of 10 lung cancer
cases are directly caused by smoking. A lifetime smoker has a risk of developing lung
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carcinoma between 20- to 30- fold higher than that of a lifetime non-smoker. Since the
tobacco smokers have a higher chance of lung carcinogenesis than lifetime nonsmokers,
this indicates that genetic factors affect the risk of lung cancer among those who are
exposed to carcinogens (45). Cigarette smoke contains a complex mixture of
carcinogens such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) nicotine,
benzo(a)pyrene, and cadmium, and vapor phase such as formaldehyde and
ethylcarbamate which can influence respiratory cells (46). The progressive of genetic as
well as epigenetic alterations coinciding with malignant transformation in cultured
human respiratory epithelia purified activated tobacco carcinogen can be induced by
cigarette smoke condensate or purified activated tobacco carcinogens such as
benzo(a)pyrene-diolepoxide-1 (47). Moreover, purified tobacco carcinogens including
NNK and ethylcarbamate advance lung carcinomas in rodents showing histological and
molecular genetics profiles virtually identical to human pulmonary carcinomas (48).
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Figure 2.1 Ten leading cancer types for the estimated cancer mortality by sex in United
States 2012 (Adapted from Siegel et al.,2012)(1).

2.2 Chemoprevention
2.2.1 Introduction to chemoprevention
Prevention of any disease is absolutely preferable over treatments, which
indicates one has already been suffered from that malignancy. Including cancer, eating
healthy food along with regularly exercise has been found to be related to the
prevention of various chronic diseases. Research indicated that around 30% - 40% of
cancer incidents could be prevented by having regular exercise, maintaining of optimum
body weight, and consuming healthy diet. Furthermore, Glade et al also suggested that
by consuming fruits and vegetables, the risk of cancer occurrence could be decreased by
20%.
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Chemoprevention, by definition, is a means of cancer control by which the
occurrence of the disease can be entirely prevented, slowed down, or reversed by the
administration of one or more naturally occurring and/or chemically synthesized agents.
The concept of chemopreventive has recently been in the spotlight as this strategy is an
alternatively cost-effective treatment compared to modern cancer therapy. Generally,
ideal chemoprevention agents should be nontoxic, exhibit high efficacy at low
concentrations, cost-effective, and easily available. At present, the issue of toxicity
continues to be a subject of great concern. For instance, the unwanted adverse effects
are normally accompanied the utilization of chemotherapeutic drugs on cancer patients.
Yet, these side-effects are tolerable since the benefits obtained from them overshadow
the risks.

2.2.2 The role of dietary components in cancer prevention and therapy
Natural products or dietary bioactive components can often act as both
chemopreventive as well as chemotherapeutics agents. Plant-derived drugs such as
texanes (paclitaxel) and vincaalkeloids (vimblastin) were discovered, yet repeatedly
associated with adverse high toxicity with their uses (5). On the contrary,
chemopreventive agents can be delivered in foods or as dietary supplements with very
little or no concern of their toxicities. The final goal of cancer chemopreventive strategy
is to reduce side-effects and eliminate cancer. Safety along with toxicity is always the
primary concerns in any human clinical trial experiments, particularly in the subjects
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without evidence for overt cancer. Cancer chemopreventive agents should be safe for
any individual regardless of his/her cancer status (Figure 2.2).
Healthy individuals

Phytochemicals
and natural products

High-risk
Individuals

Post-therapy
cancer patients

Cancer patients

Phytochemicals +
pharmacological agents

Chemotherapeutic agents

Phytochemicals and
pharmacological agents

Chemotherapy
Chemoquiescence
Chemoprevention

Figure 2.2 A schematic diagram displaying selective responsiveness of healthy
population as well as cancer patients to chemopreventive agents. Generally,
chemopreventive agents should be beneficial for every population. In cancer patients, it
is feasible that combination regimens of chemopreventive agents and
chemotherapeutic agents should be utilized. Moreover, modification of diet along with
intervention should be considered for retarding and inhibiting cancer recurrence in
post-therapy cancer patients (Adapted from Metha et al., 2010) (5).

Recently, it has become increasingly ambiguous as to when the role of a dietary
cancer preventive agents begin when integrate them into the sequence of events in
carcinogenesis processes, and even in the process of cancer treatment. An undefined
gray line, illustrating a venue for using dietary bioactive chemopreventive agents as an
addition to therapeutic drugs, can be drawn since most chemopreventive agents were
reported to exert potent anticancer effects in reducing cell proliferation as well as were
showed to be able to modulate and interfere with various molecular pathways in cancer
cells which ultimately led to cell death. The chemopreventive effects typically take place
during both initiation and promotion of carcinogenesis. Moreover, effects of
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phytochemicals on cancer cells during the different phases of carcinogenesis have
recently gained interest from experts since accumulating clinical reports demonstrated
that exposure to dietary phytochemicals via both diets or at pharmalogical doses can
modulate diverse cell signaling regulators which may stop or delay carcinogenesis
process. In healthy individuals, chemoprevention is clinically applicable in whom a diet
rich in bioactive components can exhibit their protective activities. Furthermore, in
individuals who have high risk of developing cancer, such as patients who had cancer
surgical interventions, persons who have high risk of developing cancer because of
family history, or individuals who are usually exposed to carcinogens including workers
who often have high exposure with asbestos, the pharmacological agents which are
classified as chemopreventive agents and have been purified and identified as individual
phytochemicals may be utilized as treatments. Markedly, cancer chemoprevention
agents may be used in combination strategy with advance chemotherapeutic drugs as
they may produce synergistic effects to enhance the anticancer activities. Since
recurrence of the diseases after chemotherapy is often showed up, the objective would
be to prevent the relapses, delay the metastasis, and inhibit the occurrence of second
primary tumors. The termed “chemoquiescence” defines the processes of protection
that allow for the silencing or decreasing of the growth rate of the cancer. Hence, while
active disease requires chemotherapeutic intervention in order to eliminate cancer cells,
both dietary and pharmacological doses of chemopreventive agents may also prove to
be beneficial to prevent the recurrence and aggressive progression of the disease.
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The process of carcinogenesis from initiation to advanced metastasis stages is
orchestrated by complex mechanisms of genetic materials which lead to the diverse
protein expression as well as the alteration of the signal transduction process within a
cell necessary to acquire transformed phenotype or to reacquire the normal cellular
function (49). Consequently, chemoprevention should be redefined as the use of
chemical agents - which can be natural or synthetic bioactive components, or the
combination of them, which can inhibit or reverse genetic materials (DNAs, RNAs)
and/or protein expression of molecular targets responsible for transforming normal cells
or the proliferation and progression of the transformed cells (5).

2.2.3 Molecular targets and signaling pathways critical to chemoprevention
Cancer originates from a single cell. Carcinogenesis, the process in which a
normal cell becomes a malignant cell, comprises of multiple complex molecular signaling
pathways. In a simplified manner, the process is associated with the changes in
structure and function of genetic information coded in the DNA. Furthermore, during
carcinogenesis, various molecular key signaling pathways become uncontrollable and
ultimately lead to their malfunctions. Dietary bioactive phytochemicals have been
documented to be able to intervene one or more of the deregulated molecular
pathways highly related to carcinogenesis including carcinogen metabolism, DNA repair,
cell growth, cellular apoptosis, cell cycle progression, angiogenesis, and metastasis (5).
Carcinogenesis from initiation to metastasis involves a large number of molecular
dysfunctions as showed in figure 2.3.
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Figure 2.3 The role of phytochemicals in carcinogenesis process. The process of
carcinogenesis is defined as initiation, promotion, and progression. Carcinogenesis is
initiated with the transformed of a normal cell to an initiated cell. Then, the initiated cell
undergoes tumor promotion and turns into a pre-neoplastic cell, which subsequently
progress to a neoplastic cell after progression stage. Dietary bioactive components can
interfere with different stages of the carcinogenesis. In this diagram for each of stages,
various major mechanisms of phytochemicals involving signaling pathways are
summarized. Some phytochemicals act as cancer blocking agents, preventing caner
initiation. Other phytochemicals are capable to suppress and retard carcinogenesis in
later steps including promotion and progression. In addition, some dietary components
can act as both blocking and suppressing agents.
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The course of initiation or the transformation of a cell requires gene mutations,
carcinogen metabolism, and the dysfunction of DNA repair. In this stage, environment
carcinogens (e.g., certain toxic compounds, tobacco, and pollution) cause one or more
simple mutations such as transitions or small deletions in the key genes controlling the
process of carcinogenesis. Two types of enzymes balance this initiation process.
Biotransformation enzymes (phase I enzyme, including the cytochrome p450 system)
convert the pro-carcinogens to the ultimate (active) carcinogens. On the other hand, the
phase II enzymes (e.g., glucoronidases, and sulfotransferases) play a vital role in the
detoxification of ultimate carcinogens. As a consequence, the detoxified carcinogens are
excreted to the urine. In addition, there is also a chance that enzymes may change a
particular chemical into a more reactive form that binds to DNA more efficiently.
Reactive oxygen species (ROS) are generally initiated as part of the normal oxidative
metabolism, or may be generated as end-products of the breakdown of xenobiotic
agents. The escalating rate of mutation is associated to the extensive DNA damage
occurred by ROS, and thereby leading to oncogenic transformation. To date, many
groups of small molecules isolated from fruits and vegetables have been demonstrated
to act as anti-initiators such as genistein, indoles, resveratol, and allyl sulfur compounds
(4). Ultimate carcinogens cause DNA damage by forming covalent adducts with
individual nucleic acids of DNA or RNA, which finally may result in gene mutation by
mistranslation of DNA sequence or deletions of genetic materials. Many mechanisms
are served to repair damaged DNAs in human. However, if an adducted base has not
been repaired when DNA replication starts, mutations in the critical genes involved in
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the oncogenic process, such as oncogenes or tumor suppressors, could occur. Research
suggested that dietary chemopreventive agents such as vitamin C, genistein, and
compounds from cruciferous vegetables that scavenge ROS have been showed to induce
the repair of oxidative DNA damage.
The stage of promotion is characterized by uncontrollable cellular signaling
pathways that manifest cell proliferation and programmed cell death (apoptosis). In
cancer including lung cancer, genes that regulate cell cycle progression are often
mutated. This leads to the deregulated proteins playing pivotal role in controlling cell
proliferation such as cyclins, and cyclin-dependent kinases (CDK-4, CDK-2), and cyclindependent kinase inhibitors (p16, p21, and p27). As a consequence, mutations in these
genes stimulate growth and result in endlessly proliferation of transformed cells.
Overall, the growth of the transform cells exceeds that of normal cells.
During this promotion stage, key signaling pathways related to apoptosis are
deregulated and altered. In general, apoptosis is divided into two distinct pathways; (1)
intrinsic (mitochondrial) pathway and (2) the extrinsic (death receptor) pathway (50).
The intrinsic pathway is induced by various stimuli that send signals to trigger cellular
damage including ionizing radiation, cytotoxic agents, hypoxia, DNA damage, and
growth factor starvation. On the other hand, the extrinsic pathway is initiated when a
pro-apoptotic ligand binds to pro-apoptotic receptors on the surface of cells.
Nevertheless, common in both intrinsic and extrinsic pathway, caspases are proteases in
the family of cysteine proteases which play the pivotal roles in triggering apoptosis
response and are considered as one of the hallmarks of apoptosis. Caspase-3 is a main
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executioner of programmed cell death which can be activated by an initiator caspase
such as caspase 9. Then, the activated caspase-3 further cleaved Poly ADP-ribose
polymerase (PARP). Cleavage of PARP results in inactivated PARP, subsequently causing
the loss of DNA repair functions which eventually leads to ultimate apoptosis. For
intrinsic pathway, the apoptotic cascade initiates when the collapse of the
mitochondrial membrane potential and the redistribution of cytochrome C take place.
Cytochrome C is an important factor in apoptosis. It is released from mitochondria and
transported into cytosol during cellular apoptosis. The released cytochrome c then
forms a complex structure with Apaf-1 and cascape-9 in order to become an activated
complex. Subsequently, this complex cleaves the effector caspase-3 to let it become an
active executioner form. Besides, apoptotic signaling through intrinsic pathway involves
the activation of pro-apoptotic Bcl-2 family proteins members, which control the release
of cytochrome C to further activate caspases. Bcl-2 and its homologues are antiapoptotic Bcl-2 family proteins which are able to inhibit mitochondrial membrane
disruption and the release of cytochrome C, whereas Bax, a pro-apoptotic protein in Bcl2 family, generates the disruption. Therefore, the ratio of Bcl-2: Bax is usually
recognized as a criterion in apoptosis. Research has been showed that dietary
components were capable to target and intervene various processes in carcinogenesis
promotion stage discuss above.
Lastly, progression stage is characterized by genetic alterations within karyotype
of the cells brought about by accumulation of mutated genes resulting in chromosomal
abnormalities. The stage of progression constitutes of invasion, angiogenesis, and
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metastasis. Chemopreventive agents can play a significant role in inhibiting or retarding
cancer cell progression to metastasis. Moreover, some agents can also exert antiangiogenesis activity, the inhibition of the development of new blood vessels formation
from endothelial cells, which has considerable importance since angiogenesis is a crucial
step that allows the malignant cell to gather required nutrients and oxygen in order to
expand itself. During angiogenesis, diverse growth factors including vascular endothelial
growth factor (VEGF) and fibroblast growth factor (FGF) are stimulated by endothelial
cells, and are recruited to the site where new blood vessels are required. Therefore, by
inhibiting angiogenesis, the size of tumor and metastasis may be diminished as the
supply of nutrients and oxygen is reduced. Evidence showed that dietary bioactive
components including EGCG, resveratol, curcumin, and genistein were demonstrated to
block angiogenesis. Flavonoids including apigenin, luteolin, and naringenin have been
reported to reduce lung metastasis in vivo (51).

2.3 Polymethoxyflavones
2.3.1 Introduction to polymethoxyflavones
Due to their unique flavors and beneficial nutritional values, citrus fruits have
long impacted commercial importance. The estimated number of citrus production in
selected major producing countries worldwide in 2007-2008 was 72 million metric tons
(approximately 159 billion lbs) (52). According to the National Agricultural Statistic
Service, total citrus production in the United States was 10.6 million metric tons which
approximately 34% of these were utilized for juice production. With a large amount of
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citrus has been processed into juice, a large number of by-products including peels,
membranes, seeds, and other remaining have been generated so far. In the United
States alone, approximately 44% of peels (4 -5 billion lbs) were yielded as by-products
from juice production during 2004-2005 (53, 54).
In some of Asian countries such as China, citrus peels has long been utilized as
traditional medicines for alleviating many diseases including cough, skin inflammation,
stomach upset, muscle pain, as well as hypertension from the ancient time (54). Two
centuries ago, Lebreton discovered the first flavonoids in citrus (55). Since then, citrus
flavonoids have increasingly gained public interest as dietary flavonoids and other
polyphenolic bioactive dietary components found in citrus have been suggested to
exhibit anti-carcinogenic properties both at the initiation and the promotion stages of
chemically carcinogenesis (7). Citrus flavonoids can be classified into three broad classes
including the flavanone glycoside, the flavones glycoside, and polymethoxyflavones (7).
Polymethoxyflavones (PMFs) define a generic term describing flavonoid compounds
merging two or more methoxy groups on their basic benzo- γ -pyrone (15-carbon, C6-C3C6) skeleton with a carbonyl group at the C4 position (Figure 2.4 A) (54). In nature, PMFs
are almost exclusively found in citrus plant, particularly in the sweet oranges (Citrus
sinensis) and mandarin oranges (Citrus reticulate) peels (13). At present, more than
twenty PMFs have been isolated and identified from different parts of citrus plants.
Nobiletin, 3,5,6,7,8,3´,4´-heptamethoxyflavone (HMF), and tangeretin are major
permethoxylated PMFs found in the orange peels (53, 56). Aged orange peels are vital
ingredients for traditional Chinese medicines. The repeated heating and drying process
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used to produce aged orange peels, or the auto-hydrolysis occurred during long-term
storage are able to convert nobiletin, HMF, and tangeretin into 5-hydroxy-6,7,8,3´,4´pentamethoxyflavone (5-demethylnobiletin, 5DN), 5-hydroxy-3,6,7,8,3´,4´hexamethoxyflavone (5DH), and 5-hydroxy-6,7,8,4´-tetramethoxyflavone (5demethyltangeretin, 5DT), respectively, by demethylation at 5-position in the A-ring of
the tangeretin structure (Figure 2.4 B) (53, 56).
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Figure 2.4 Chemical structures of polymethoxyflavones (PMFs). (A) Chemical structure
of nobiletin. (B) Nobiletin, 3,5,6,7,8,3´,4´-heptamethoxyflavone (HMF), and tangeretin
are major abundant permethoxylated PMFs found in the peels of sweet oranges. During
aging process, 5-hydroxy-6,7,8,3´,4´-pentamethoxyflavone (5-demethylnoblietin, 5DN),
5-hydroxy-3,6,7,8,3´,4´-hexamethoxyflavone (5DH), and 5-hydroxy-6,7,8,4´tetramethoxyflavone (5-demethyltangeretin, 5DT) can be converted from nobiletin,
HMF, and tangeretin, respectively (Adapted from Qiu et al., 2011) (13).

2.3.2 Biological activities of polymethoxyflavones
PMFs have been progressively gained attentions since accumulating evidence
demonstrated that they exhibited a various biological properties that help ameliorate
human health including anti-inflammatory (57), anti-carcinogenic (13, 14, 15, 58, 59),
anti-atherogenic (16, 17), anti-viral(7), and anti-oxidative one (52). Recent studies
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revealed that some hydroxylated PMFs exerted more potent biological activities than
those of their permethoxylated counterparts, including anti-inflammation (10) and anticarcinogenesis (13, 15, 59).

2.3.2.1 Anti-inflammatory activity of PMFs
Accumulating findings indicated that PMFs exhibited their anti-inflammatory by
inhibiting enzymes involved in the inflammation. Nobiletin has been showed to suppress
the production of pro-matrix metallo-proteinase-9 (MMP-9) and prostaglandin E2
(PGE2) in human synovial fibroblasts by selectively downregulating cyclooxygenase-2
(COX-2), which eventually led to the inhibition of matrix degradation of the articular
cartilage and pannus formation in osteoarthritis and rheumatoid arthritis (60). A recent
study from Yoon et al. showed that tangeretin suppressed COX-2 gene expression, and
dose-dependently inhibited UVB-induced transactivation of NF-κB and AP-1 (61).

2.3.2.2 Anti-carcinogenic activity of PMFs
Numerous reports have indicated that inflammation and infection had a strong
connection to cancer initiation and promotion. Ohshima et al proposed three main
mechanisms responsible for inflammation-associated carcinogenesis: (1) Direct
integration of viral DNA into the host genome which modulated host DNA, (2)
Immunosuppression caused by viral infection leading to a failure to inhibit malignancy,
and (3) the production of reactive oxygen species (ROS) and reactive nitrogen species
(RNS) which directly caused damage to host DNA (62).
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Increasing numbers of both in vitro and in vivo studies have showed protective
effects of PMFs against carcinogenesis. Research showed that anti-carcinogenic
activities of PMFs included anti-proliferation, induction of cell cycle arrest, induction of
cellular apoptosis, inhibition of angiogenesis, inhibition of cell mobility, induction of cell
differentiation, and inhibition of metastasis cascade. PMFs also reduced the invasion of
tumors in animal models. Since nobiletin and tangeretin are two most abundant PMFs in
citrus peels, they have been primarily focused on their bioactivities. Last decade,
Kandaswami et al. conducted the comparative studies of the growth inhibitory effects
between PMFs including nobiletin, tangeretin, and polyhydroxyflavonoids such as
quercetin and taxifolin on HTB43 human squamous-cell carcinoma. Nobiletin and
tangeretin were observed to significantly inhibit HTB43 proliferation, while two
hydroxyflavonoids did not show any significant inhibition at any concentration used
(63). One reason for this could due to the difference in permeability of PMFs that were
much greater than those of two polyhydroxyflavonoids, which might lead to greater
activity due to the enhanced cellular uptake (63). Morley et al. reported that both
nobiletin and tangeretin were able to potentiate breast and colon cancer cells at G1
stage (12). Tangeretin was showed to influence cancer cell growth and metastasis by
inhibiting cell invasion and adhesion (64). Moreover, Lust et al. also showed that
tangeretin exerted its anticancer activity in erythroleukemia K562 by activating the
unfolded protein response (65). For in vivo study, Tang et al. reported that nobiletin was
showed to suppress prostate cancer cells proliferation as well as significantly protected
the development of adenocarcinoma of the prostate (TRAP) transgenic rats (66). In
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addition, Suzuki et al. also showed that the incidence of colonic adenocarcinoma in
azoxymethane (AOM)-induced F344 rats after being fed by 0.05% nobiletin for 34 weeks
were significantly reduced 67% to 35%; p < 0.05) (67).
Recent in vitro investigations revealed that hydroxylated PMFs exhibited much
stronger anticancer activities than those of their permethoxylated counterparts. Using
the same concentrations, 5DN and 5DH were found to induce both cell cycle arrest and
apoptosis in human lung cancer cells, while their permethoxylated counterparts,
nobiletin and HMF, did not cause any significant induction (14). Moreover, the similar
trend were also found in colon cancer cells by Qiu et al. in which 5DN, 5DH, and 5DT
were observed to show significantly superior anticancer activities than their
permethoxylated counterpart, nobiletin, HMF, and tangeretin, respectively. For
example, all 5DN, 5DH, and 5DT were able to significantly induce cell cycle arrest and
apoptosis even if they were utilized at lower concentrations, whereas nobiletin, HMF,
and tangeretin did not cause any significant alterations. By far, 5DT provided the
strongest growth inhibition among PMFs used in their study (13). Furthermore, another
two recent studies also proved that 3´-hydroxy-5,6,7,4´-tetramethoxyflavone and 5DH
showed stronger inhibitory effects on the growth of human breast (41)and leukemia
cells (68) than those exhibited by their permethoxylated counterparts, 5,6,7,3´,4´pentamethoxyflavones and HMF respectively.
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2.3.2.3 Anti-atherosclerosis activity of PMFs
Citrus flavonoids have been showed to help decreasing cardiovascular diseases
as they were capable to influence and reduce hepatic production of cholesterol
containing lipoproteins which resulted in the decreased levels of total cholesterol
concentration in plasma (17). A study by Whitman et al. displayed that nobiletin, but not
tangeretin, were able to diminish the circulating concentrations of very low-density
lipoproteins (VLDLs) and low-density lipoproteins (LDLs) in the blood, and also could
directly inhibit macrophage-derived foam-cell formation at the site of the lesion
development within a vessel wall by modulating macrophage metabolism of the specific
class A scavenger receptor (SR-A) ligand, acetylated LDL (69). Even though Whitman et
al. did not find any significant in tangeretin-induced anti-atherosclerosis, Kurowska et al.
reported that tangeretin were able to decrease the total plasma cholesterol as well as
levels of VLDL, LDL, and triacylglycerols in HepG2 cells (16, 17).

2.3.4 The bioavailability and metabolism of polymethoxyflavones
Intracellular accumulation and metabolisms of chemopreventive compounds are
vital factors that dictate the efficacy of chemopreventive compounds in the
physiological condition. Bioavailability can be defined in various methods. For bioactive
compounds which the route of administration is usually oral, bioavailability can be
simply defined as the proportion of the nutrient that is digested and absorbed from
gastrointestinal tract (GIT) , and finally metabolized through normal pathways (70). In
other words, it is the amount of the drug or a compound which reaches the blood
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circulatory system and the target tissues. Generally, bioavailability of drug or a nutrient
is often characterized as plasma concentration (71). The bioavailability integrates a total
effect of absorption, distribution, metabolism, and excretion (ADME). Therefore, the
combined rate of these aforementioned factors must be considered in order to
determine the bioavailability. Absorption defines an ability of a drug or a bioactive
compound that is able to transport into the blood circulation following oral
administration. Distribution refers how well a drug or a bioactive compound reaches the
designated tissues. Metabolism defines as the rate that a drug or a bioactive compound
is eliminated from the systematic circulation. Lastly, excretion refers to the rate at which
a drug or a nutrient is excreted from the systematic circulation (72).
Absorption is one of the key factors of bioavailability, which could be explained
as the solubility and permeability of a compound. In order for a drug or a bioactive
agent to be absorbed, it must be solubilized. As a consequence, the fraction of an agent
absorbed into the circulatory system refers to the ability of the aqueous solubility of
that compound. Permeability is an ability of a compound to cross through intestinal
membranes and reach blood circulatory system. Taken together, both solubility and
permeability influence the absorption of bioactive agents. Therefore, they must be
taken into account altogether when studies absorption. Normally, compounds with high
solubility and high permeability are usually well-absorbed. On the other hand,
compounds that have low solubility and permeability function are poorly absorbed.
Permeability does not have a clear-cut definition. Therefore, currently, US Food and
Drug Administration (FDA) accepts three absolute permeability criteria: (1) mass
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balance, absolute bioavailability, or intestinal perfusion studies in human participants;
(2) in vivo intestinal perfusion studies in animals; and (3) in vitro permeation
experiments across a monolayer of cultured human intestinal cells such as Caco-2 cells
(72).
Even though numerous studies have report the health beneficial biological
properties of PMFs in recent years, knowledge of their bioavailability is still limited.
Earlier, most knowledge of PMFs absorption and bioavailability was based on the
assumption of their high hydrophobicity owing to the natural existence of the multiple
methoxy groups. Murakami et al. showed that nobiletin accumulated in Caco-2 cell
monolayer and after 4 hrs of incubation, more than 48% of nobiletin permeated to the
baso-lateral side which indicated that nobiletin has high permeability and tendency to
accumulate in the intracellular compartment. Additional study of the distribution of
nobiletin in SD male rats revealed that nobiletin were likely to be localized in the
mucous membrane and in muscularis during 1 – 4 hr after administration, and were
detected in liver and kidney. Even though there was no distinct pharmacokinetic result
collected from Murakami et al. nobiletin’s study, they reported that nobiletin indeed
was found accumulating in many organs including stomach, intestines, liver, and kidney
during 1 – 4 hrs after a single dose administration (73, 74).
A recent pharmacokinetic study of nobiletin and tangeretin by Manthey et al in
2011 reported that overall, nobiletin was approximately 10-fold more bioavailable than
tangeretin. In their experiment, both nobiletin and tangeretin (50 mg/kg of body
weight) were administrated to rats and the plasma concentration of these compounds
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and their metabolites were monitored. According to their results, both nobiletin and
tangeretin were detected in rat serum for prolonged periods up to 24 hr after
administration. Particularly, nobiletin dissolved in corn oil showed was firstly detected
at 0.5 h in the amount of 9.3 µg/ml in rat blood serum, in which the level of nobiletin
remained > 4 µg/ml at 4 hr, and remained stable at 2 µg/mL at 12 hr. Unlike nobiletin,
tangeretin showed much lower plasma concentration when being gavaged at the same
amount (0.49 µg/ml of tangeretin versus 9.3 µg/ml of nobiletin in rat blood serum).
Moreover, they also reported that prior solubilization of nobiletin strongly affected its
pharmacokinetics as gavage administration of nobiletin suspended as an insoluble
particulate led to slower absorption (Tmax =2 h versus Tmax = 30min) and also lower
maximum nobiletin plasma concentration (9.3 µg/ml versus 3.56 µg/ml) (75).

2.4 Statin
2.4.1 Introduction to statins
Statins are a collection of small-molecule inhibitors of 3-hydroxy-3-methyglutaryl
coenzyme-A (HMG-CoA) reductase that sits at the summit of the mevalonate cascade.
They inhibit the conversion of HMG-CoA to mevalonate due to structural analogs of
HMG-CoA reductase (76). Because of their properties, statins have been extensively
prescribed to lessen cholesterol levels and has mostly recognized for ameliorating
cardiovascular outcomes in both general population as well as in cardiovascular disease
(CVD) patients (77). Statins are either derived from fungal fermentation or chemically
synthesized. The statins family consists of several drugs: lovastatin (Mevacor®),
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simvastatin (Zocor®), mevastatin (Compactin®), fluvastatin (Lescol®), pravastatin
(Pravachol®), atorvastatin (Lipitor®), rosuvastatin (Crestor®), and cerivastatin (Baycol®;
which was withdrawn from the market in 2001.) Simvastatin and lovastatin are the most
lipophilic statins followed by mevastatin, fluvastatin, atorvastatin, rosuvastatin, and
pravastatin, respectively. Pravastatin is the most hydrophilic when compared to other
statin drugs (19). Chemical structures of statins are illustrated in figure 2.5. There has
been a growing interest in investigating the other salubrious effects of statins beyond
their renowned beneficial properties in preventing CVD. Besides targeting HMG-CoA
reductase, statins can also function through other mechanisms. Experimental and
clinical evaluation showed that statins could exert pleiotropic effects and these may
ameliorate human health by help preventing a number of chronic human diseases such
as cancer. These pleiotropic effects could be elucidated by the fact that statins could
also block the synthesis of diverse metabolites while inhibit cholesterol synthesis
especially isoprenoids, which act as the substrate of the post-translational modification
of a large number of proteins that are not associated with cholesterol pathway (20).
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Figure 2.5 Chemical structures of HMG-CoA reductase inhibitors (statins). Among
statins, simvastatin, lovastatin, pravastatin are derivatives of fungal products as they
have a hydronaphthalene ring in common, whereas other developed statins are
chemically synthesized. In lactone form, simvastatin and lovastatin are orally
administrated as pro-drugs whereas pravastatin is already in the active open acid
structure as well as the other five chemically synthesis statins that also have an open
acid HMG-like moiety. Differences in the statins’ structure yield different solubility in
water (Adapted from Shitara et al., 2006) (78).

2.4.2 The molecular mechanisms of anticancer activities of statins
Numerous in vitro reports have documented that statins exerted anticancer
effects against many cancerous cell lines and solid tumor cells including lung (79, 80,
81), colon(82, 83, 84), leukemia (85, 86), breast (87, 88), pancreatic (89), and prostate
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(90, 91) cancer cells. Conclusions could be drawn from these studies. First, anticarcinogenic activities of statins varied among different type of statins, and also were
cell-type specific. While all lovastatin, fluvastatin, atorvastatin, and cerivastatin
displayed the anti-proliferative against acute myeloid leukemia, ceribastatin exerted the
highest effects among these four statins (86). Second, interestingly, only lipophilic
statins (lovastatin, simvastatin, atorvastatin, fluvastatin, and cerivastatin), but not
hydrophilic statin (pravastatin), were found to exhibit antiproliferative effects. For
instance, while atorvastatin, lovastatin, simvastatin, and fluvastatin displayed growth
inhibitory effects against melanoma and myeloma, pravastatin failed to induce any
effect on those cells (92). Last but not least, it is important to investigate if treatment of
statins affects normal cells. Unfortunately, only few studies compared the effects of
statins between normal and cancer cells. For instance, Kotamraju et al. showed that
simvastatin and fluvastatin were able to inhibited breast cancer cells, but did not inhibit
normal epithelial cells (93). Furthermore, cell proliferation of ovarian and colon cancer
was inhibited by simvastatin, lovastatin, and mevastatin, whereas normal embryonic
stem cells growth was not affected by all of these four statins (94).
Mevalonate sits at the apex of cholesterol synthesis pathway. The inhibition of
HMG-CoA reductase by statins resulted in the reduced level of mevalonate and its
downstream products. Statins inhibit the transformation of HMG-CoA into mevalonate.
ATPs are used to phospholyrate mevalonate to pyrophosphomevalonate, which is
subsequently converted into isopentenyl pyrophosphate (Ipp), which can be converted
to dimethylallyl pyrophosphate (DMApp). Then, the combination of Ipp and DMpp yields
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10-carbon isoprenoid geranyl pyrophosphate (Gpp). An addition of Ipp to Gpp generates
15-carbon isoprenoid farnersyl pyrophosphate (Fpp). Furthermore, another addition of
Ipp to Fpp produces 20-carbon isoprenoid geranylgeranyl pyrophosphate (GGpp).
Inhibition of mevalonate cascade pathway by statins results in the reduced formation of
mevalonate and its intermediate downstream isoprenoids. However, this inhibition by
statin can be counteracted by restoring mevalonate back into system. Addition of Fpp
will only refresh farnersylated proteins (Ras, Rheb, and PTP4A3 families) since Ipp is not
available to transform Fpp into GGpp. Likewise, supplementation of GGpp will only
restore geranylgeranylated proteins (Rho, Rac, and Cdc42 families). In addition, Fpp can
be utilized to produce squalene which can be further converted to cholesterol (Adapted
from Demierre et al. 2005, and Osmak, 2012) (19, 20). Figure 2.6 extensively illustrates
mevalonate pathways. The lipid isoprenoids such as farnesyl pyrophosphate (Fpp) and
geranylgeranyl pyrophosphate (GGpp) which are the downstream intermediate
isoprenoid products play the pivotal roles in post-translational modification of
membrane related proteins such as Ras and Rho small GTP-binding proteins. One of the
main functions of Fpp and GGpp is to prenylate proteins in order to facilitate the protein
translocation from cytosol to membrane. Moreover, they also regulate and promote
protein-protein, and protein-membrane interactions and functions (95). Activated Ras
and Rho GTPases interact with a large number of key oncogenic proteins, which play
essential roles in multiple molecular pathways that are critical for carcinogenesis
including membrane integrity, cell adhesion, cell signaling, cell motility, cell cycle
progression, cell survival, cell transformation, angiogenesis, endocytosis, oxidative
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stress, and the cellular response to genotoxic stress (19, 96, 97). Therefore, by inhibiting
the biosynthesis of mevalonate, statins also inhibit the formation of downstream lipid
isoprenoids. Then, the reduced levels of isoprenoids such as Fpp and GGpp by statins
leads to the reduced levels of isoprenylation of Ras and Rho proteins such as K-Ras, HRas, RhoA, RhoB, and RhoC. As the results, this eventually leads to the impairment of
cell functions and inhibits cell proliferation. Although studies reported that anticancer
activities of statins integrated growth inhibition resulted from the induction of cell cycle
arrest and apoptosis, the inhibition of cell invasion and metastasis, and the suppression
of angiogenesis and tumor differentiation, this literature review focuses on cell cycle
arrest and apoptosis.
Research suggested that effects of statins on inducing cell cycle arrest and
apoptosis varied among different types of cells even though these effects could occur in
the same cell line but at different concentrations. (98). Statins was found to inhibit
cellular proliferation by inducing G1/S cell cycle arrest (99) and/or G2/M arrest (100).
More recent studies showed that statins potentiated cancer cells by upregulating cyclin
dependent kinase (CDK) inhibitors p21 (23, 84, 88, 101)and p27 (81, 84, 102), and/or by
downregulating cell cycle promoting factors including cyclins and CDKs (21, 22, 23). To
identify the critical mechanisms in which how statins induced cell cycle arrest, Crick et
al. performed adding-back experiments to determine downstream products of
mevalonate caspase that were essential to suppress this statin response (103). They
found that the synchronization of C6 glioma cells induced by lovastatin was reversed by
addition of free geranylgeraniol, suggesting that geranylgeranylated proteins were
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important for cell progression into S phase (103). This hypothesis that GGpp could
counteract statins-induced cell cycle arrest was further confirmed in human prostate
cancer cells by Lee et al. in which that addition of GGpp and mevalonate, but not Fpp or
cholesterol, and by expression of constitutively active RhoA protein reversed lovastatininduced G1/S cell cycle arrest (90). Moreover, Denoyelle et al. also reported the same
finding in cerivastatin-induced breast cancer cell cycle arrest (88). The inhibition of RhoA
induced by statins could lead to the increase in p21 levels (104). Also, Rao et al.
demonstrated that the stabilization of both p27 and p21 might results from the
inhibition of proteasome degradation (105). Moreover, recent article published by Lin et
al. show that statin could increase p21 through the blockage of histone deacetylase
activity and the release of the promoter-associated histone deacetylase (HDAC)1/2
(106).
The ability to evade and escape programmed cell death (apoptosis) is one of the
hallmarks of carcinogenesis (107). Therefore, triggering apoptosis can be a promising
strategy for cancer chemoprevention. Beside cell cycle arrest, statins also have been
found to induce cellular apoptosis in various cancer cells including lung (80, 81), colon
(82, 83, 84), breast (87), and prostate (101) cancer. Again, in order to define the
molecular mechanism underlying statin-induced apoptosis, GGpp and Fpp adding-back
experiments were conducted. Xia et al. reported that mevalonate and GGpp reversed
the cellular apoptosis induction of lovastatin in acute myeloid leukemia cells, indicating
that inhibiting geranylgeranylation of target proteins is the major mechanism of
lovastatin-induced apoptosis (85). The hypothesis of this essential role of protein
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geranylgeranylation in suppressing apoptosis was confirmed in solid tumor cells (108).
Apoptosis could be triggered by two different molecular pathways, the intrinsic and the
extrinsic pathway (109). Apoptosis triggered by the mitochondrial signaling (intrinsic)
pathway involved the imbalance of the expression of the pro- and anti- apoptotic of
proteins in Bcl-2 family. Research showed that statins were able to decrease Bcl-2
expression (87, 110), increase Bax expression level (81, 82), and increase the level
expression of Bim (82). Also, studies also showed that statins were capable to activate
p53 tumor suppressor protein (81). In addition, the activation of caspase-2, caspase-3,
caspase-8 and caspase-9 as well as poly Adenosine diphosphate ribose polymerase
(PARP) cleavage were also observed (81, 92, 108, 111).
The promising in vitro anti-carcinogenic activities of statins have drawn
attentions to their further investigations of the association between their
administrations and risk of cancer, and also their possible strategy as a single anticancer treatment. Evidence displayed that the potential effectiveness of statins for
human cancer prevention has still remained controversial and needed further
verification in spite of many randomized human clinical trials and observational
epidemiological studies. In study of 334,754 Danish population, No significantly
increased or decreased rate ratios were observed for any of the studied site-specific
cancers (liver, colorectal, lung, breast, prostate, female genital organs and lymphatic
and hematopoietic tissue). However, a modest reduction in the overall cancer risk was
found in the statin users (112). In large population case-control study in the United
States involving 476,453 veterans conducted by Khurana et al., the use of statins for 6
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month or longer was found to significantly decreased the lung cancer risk by 55% (OR =
0.45, 95% CI = 0.42-0.48) (113). This result suggested the protective role of long-term
use of statins against lung cancer. However, Setoguchi et al did not observe any
protective role of statin against lung, breast, and colon cancer in a large population
study in the US (114). Vinogradova et al also did not find any association between statin
usage and the decreased risk of colorectal cancer in a large population study (115).
Moreover, a recent study from Vinogradova et al. demonstrated that prolonged use of
statins resulted in the increased of lung cancer risk (116).
So far, conflicting results in clinical trials have been reported regarding their
efficacy as cancer treatments. In phase I study of lovastatin usage in solid tumors
patients, Thibault et al. showed that lovastatin concentration reached up to 3.9 mM
which was associated to the anti-proliferative activity in vitro. However, in 88 patients,
they only found that lovastatin induced a minor response maintained for eight months
in only one patient with aplastic astrocytom (117). In the study of 349 non-metastatic
rectal cancer patients, Katz et al. reported that the complete response in statin group
was almost double that of the control group (30% versus 17%) (118). In another study
in leukemia, a case report showed that lovastatin decreased the growth of leukemia
cells in elderly patients associated with acute myeloblastic leukemia (119). In contrast,
many clinical studies reported that statins failed to show effective results. Vitols et al
demonstrated that simvastatin did not potently affect patients with chronic lymphatic
leukemia cells (120). Moreover, In phase I trial, Knox et al. showed that treatment of
7.5mg/kg/day for 21 days of lovastatin did not show the positive response patients with
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squamous cell carcinoma or the head and neck (121). In addition, in phase II study, Kim
et al. displayed that lovastatin did not stimulate a response in advanced gastric cancer
patients despite the stable disease for 16 week was observed in one patient (122).
The concentrations of statins required in order to inhibit cell proliferation in vitro
were up to 100 times higher than the clinically relevant doses utilized against high
cholesterol levels. Therefore, in order to reach the desired concentrations comparable
to those that exhibited anti-carcinogenic activities, considerably higher dosages must be
administrated. Nevertheless, no conclusive responses were observed in some clinical
studies with the administration of high doses of statins even if the in vitro comparable
concentrations were achieved. For example, 35mg/kg/day of lovastatin did not induce a
significant positive response in patients with gastric tumors (122). Also, the escalating
doses of 2-5mg/kg/day of lovastatin only exerted the modest effects in Thibault et al.
study (117). Overall, accumulate evidence revealed the inconsistent results of utilizing
statins as cancer treatments, indicating that the anti-carcinogenic activities of statins
acquired from in vitro studies could not wholly translated into clinical situations.
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2.5 Potential enhancement of cancer inhibition by using statins in combination with
bioactive dietary compounds
Evidence showed that fruits and vegetable may decrease the risk of cancer, and
this effect has been related to the presence of small molecule dietary bioactive
components in these foods. Since statins did not show promising results as an effective
individual cancer treatment, studies have now turned their viewpoints to utilize and
establish statins in combination treatments. Recently, accumulating reports has been
suggesting that the combination of cancer chemopreventive agents with different
modes of action may produce stronger protective effects against carcinogenesis than
each individual agent could due to their possible synergistic interaction. The enhanced
efficacy by the combination can also lower the required dose for each single agent in
combination, and in turn minimizes unwanted side-effects possibly caused by the use of
high individual dose administration.
Studies have indicated the combinational effects of statins with dietary agents in
both in vitro and in vivo. As for in vitro studies, Ledezma et al. showed for the first time
that atorvastatin or pravastatin when combined with ajoene, a bioactive compound
from garlic, caused cytotoxicity in murine melanoma B116F10 cells. They reported that
atorvastatin/ajoene or pravastatin/ajoene showed much stronger growth inhibitory
effects than those exhibited by each single compound alone (123). A part of the reason
for this effect might be due to the activity of ajoene that can inhibit both
farnesyltransferase and geranylgeranyltransferase, which when combined with the
effect of atorvastatin or pravastatin, can eventually lead to the dramatic decreased of
intermediate isoprenoid necessary for B1116F10 survival (124). Wali et al. showed that
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the combined treatments of statins (simvastatin, lovastatin, mevastatin, or pravastatin)
and ɣ-tocotrienol (an isoform of vitamin E) significantly showed synergistic antiproliferative effects (125) and also potentiated cell at G0/G1 stage resulting from an
increase in expression levels of p27 and decrease in the levels of cyclin D1, CDK2, and
hyperphosphorylation of Rb protein in highly malignant mouse +SA mammary
adenocarcinoma cells (126). Additional study by Yang et al. also demonstrated that the
combination of atorvastatin and γ -tocotrienol exerted much stronger growth inhibitory
effects on human colon cancer cells. They also confirmed that the enhanced effects
observed in the combination treatment were synergistic by using isobologram analysis
(23). Lu et al. reported that the combination of polyphenon E from green tea and
atorvastatin were able to produce synergistic inhibition of human lung cancer cells.
They also computed the isobologram analysis to confirm that the anti-proliferative
effect produced by co-treatment of polyphenon E/atorvastation was synergistic. Also
this synergistic effect was associated with the increased apoptosis as it was detected by
the terminal deoxyribunucleotide transferase-mediated nick-end labeling (TUNEL) assay,
and further confirmed by detecting key signaling proteins related to apoptosis. For
example, polyphenon E/atorvastatin synergistically decreased levels of Mcl-1, an antiapoptotic protein which is usually overexperssed in lung cancer. In addition, Lu et al also
observed that the expression levels of cyclin D1 and CDK-6 were decrease by polyphenol
E/atorvastatin (22). As for in vivo study, Lu et al. again demonstrated that polyphenon
E/atorvastatin synergistically decreased tumor multiplicity and tumor size (by 56 and
55%, respectively; p<0.05) in 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK, a
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carcinogen from tobacco) induced female A/J strain mice. However, polyphenon E or
atorvastatin alone did not produce any significant effect in reducing neither tumor
multiplicity nor tumor size (22). Isobologram analysis again revealed that the effect
caused by these polyphenon E and ATST was synergistic.
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CHAPTER 3
INHIBITORY EFFECTS OF POLYMETHOXYFLAVONES ON HUMAN NON-SMALL CELL
LUNG CANCER CELLS

3.1 Introduction
Epidemiological studies have suggested that certain phytochemicals derived
from edible plants may prevent disease and promote human health.
Polymethoxyflavones (PMFs) are a class of flavonoid compounds that are almost
exclusively found in the peels of citrus fruits such as sweet oranges (Citrus sinensis) and
mandarin oranges (Citrus reticulata) (53). Accumulating evidence has demonstrated that
PMFs had broad spectrum of biological activities including anti-carcinogenic, antiinflammatory, anti-atherogenic, anti-viral, and anti-oxidative activities (54). More than
twenty PMFs have been identified, and among them, tangeretin and nobiletin are the
most studied in terms of their potential health-promoting effects.
Among different types of PMFs, 5-hydroxylated PMFs are a unique subclass (53).
Although they are relatively less abundant in fresh orange peel in comparison to their
permethoxylated counterparts e.g. tangeretin and nobiletin, 5-hydroxylated PMFs can
be generated by autohydrolysis from the permethoxylated PMFs during long-term
storage (53, 56). Recently, we and others have demonstrated anti-carcinogenic potential
of 5-hydroxylated PMFs against different types of cancers. For example, 5-hydroxylated
PMFs have been shown to have strong antiproliferative effects on human lung (14),
colon (13, 15, 58), breast (41), and leukemia (68) cancer cells. More interestingly, 5-

43

hydroxylated PMFs generally exhibited more potent inhibitory effects on cancer cells
than their permethoxylated counterparts. For example, we have demonstrated that 5hydroxylated PMFs, namely 5-hydroxy-6,7,8,3’,4’-pentamethoxyflavone, 5-hydroxy3,6,7,8,3’,4-hexamethoxyflavone, and 5-hydroxy-6,7,8,4’-tetramethoxyflavone (5DT, 5demethyltangeretin) significantly induced apoptosis and exhibited stronger growth
inhibitory effects than their permethoxylated counterparts, namely nobiletin,
3,5,6,7,8,3’,4-heptamethoxyflavone and tangeretin, respectively, in colon cancer cells
(13).
Lung carcinoma is the most common cause of cancer mortality among all types
of cancers in both men and women (127). Non-small cell lung cancer (NSCLC) accounts
for more than 80 percent of lung cancer cases including adenocarinoma, squamous cell
carcinoma, and large-cell carcinoma. Generally, the survival rate for lung cancer patients
is very low (5 years of less than 15%), and this is due to the fact that NSCLC tends to
become resistant to chemotherapeutic treatments and radiation therapy, and NSCLC is
usually diagnosed at stages that are belatedly for surgical intervention (2).
Chemoprevention is considered a promising strategy to controlling cancer death
because it potentially reduces the incidence of malignant cancer by reversing and/or
delaying carcinogenesis. However, no effective chemoprevention strategy has been
successfully developed for lung cancer, especially NSCLC. Herein, for the first time, we
investigated the inhibitory effects of a unique 5-hydroxylated PMF, 5DT (Fig. 1) in three
different human NSCLC cells, and compared these effects with those produced by the
permethoxylated counterpart of 5DT, tangeretin.
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3.2 Materials and Methods
3.2.1 Cell culture and treatments
H460, H1299, and A549 human NSCLC cell lines were obtained from American
Type Cell Collection (ATCC, Manassas, VA, USA), and maintained in RPMI 1640 media
(Mediatech, Herndon, VA, USA) supplemented with 5% heat-inactivated FBS and
100U/ml of penicillin and 0.1mg/ml of streptomycin at 37 oC with 5% CO2 and 95% air.
Cells were kept sub-confluent and media were changed every 3-4 days. All cells used in
experiments were between 4 and 25 passages. Tangeretin and 5DT were isolated and
identified as we previously described (14, 56, 128). DMSO was used as a vehicle to
deliver tangeretin and 5DT to the cells. The final concentration of DMSO in all
experiments was 0.1% v/v in cell culture media.

3.2.2 Cell viability assay
H460, H1299, or A549 (2,000 cells/well) cells were seeded in 96-well plates. At
24 hrs, cells were treated with serial concentrations of tangeretin and 5DT in 200 µL of
complete media. After desired treatment times, the media were replaced with 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich) dissolved
in complete RPMI medium at 0.05% g/mL. After 2 hrs of incubation at 37OC, MTTcontaining media were discarded and the intracellular reduced formazan dye was
solublized by adding 100 µL of DMSO to each well. The absorbance was determined at
570 nm after gentle mixing by using a plate reader (Elx800TM, BioTek Instrument, VT,
USA).
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3.2.3 Colony formation assay
H460 (750 cells/well) cells were seeded in 6-well plates. At 24 hrs, cells were
treated with serial concentrations of tangeretin and 5DT in 2 mL of serum complete
media. The media were refreshed every 4 days. After 12 days of incubation, media were
discarded. Colonies were washed with PBS, and then stained with 0.2% crystal violet for
10 minutes. After being washed with double distilled water to remove any residual dye,
plates were scanned with a high resolution scanner (HP Inc.) and colonies formed were
counted.

3.2.4 Flow cytometric analysis of cell cycle distribution
H460, H1299, or A549 (5x104 cells/well) were seeded in 6-well plates. After 24
hrs of incubation for cell attachment, cells were treated with serial concentrations of
tangeretin and 5DT in 2 mL of serum complete media. Media containing any floating
cells were harvested and combined with adherent cells that were detached by brief
trypsinization (0.25% trypsin-EDTA; Mediatech). Cell pellets were washed with 1 mL of
ice-cold PBS then re-suspended in 1 mL of 70% ethanol and kept at -20oC overnight.
Supernatant was discarded by centrifugation (3,000 rpm, 1 min), and cells were
incubated with 0.3 mL of PBS containing 30 µg of heat-treated RNase (Sigma-Aldrich)
and 3 µg of propidium iodine (Sigma-Aldrich) for 30 min at room temperature. Single
cell suspension was generated by gentle pipetting. Cell cycle distribution was
determined by using a BD LSRII cell analyzer (BD Biosciences) at the analytical cytometry
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facility (University of Massachusetts, Amherst) and data were processed with Modifit LT
software.

3.2.5 Detection of apoptosis
H460, or H1299, or A549 (5x104 cells/well) were seeded in 6-well plates. After 24
hrs of incubation, cells were treated with different concentrations of tangeretin and 5DT
in 2 mL of serum complete media. Apoptotic cells were quantified by apoptotic
detection kit (BioVision, Mountain View, CA, USA) following the manufacturer’s
instruction. In brief, media were collected and combined with adherent cells that were
detached by trypsinization (0.25% trypsin-EDTA; Mediatech). Cell pellets were first
washed with 1 mL of ice-cold PBS and then with binding buffer. Cells were re-suspended
in 0.3 mL of Annexin V binding buffer containing Annexin V and PI and incubate for 5
min at room temperature before analysis by flow cytometer. Early apoptotic cells were
identified as Annexin V-positive/PI-negative cells, while late apoptotic/necrotic cells
were identified as Annexin V-positive/PI-positive cells using BD LSRII cell analyzer at the
analytical cytometry facility (University of Massachusetts Amherst).

3.2.6 Immunoblotting
Whole Cell lysate were prepared as previously described (14). Cells were seeded
in 150 mm culture dishes. After 24 hrs of incubation, cells were treated with serial
concentrations of tangeretin and 5DT. After another 24 or 48 hrs of incubation, cells
were washed with ice-cold PBS, and collected with cell-scrapers. Cells were combined
with floating cells, if any, and incubated on ice for 10 min in lysis buffer (cell signaling,
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Beverly, MA, USA) supplemented with cocktails of protease inhibitor (1:100),
phosphotase inhibitor I (1:100), and phosphatase inhibitor II (1:100) (Boston
Bioproducts, Boston, MA, USA). After sonication (4 seconds, 4 times), cells were
incubated for 20 min on ice and followed by centrifugation at 14,000 rpm using a bench
top Eppendorf centrifuge for 20 min at 4OC. Supernatants were collected as whole cell
lysates. Proteins were quantified by BCATM protein assay kit (Pierce Biotechnology,
Rockford, IL, USA), and 50-150 μg of proteins were resolved either by 8% or 12% SDSpolyacrylamide gel electrophoresis and then transferred to nitrocellulose membrane.
The membrane containing the transferred protein were blocked in blocking buffer (5%
nonfat dry milk, 1% Tween-20 in 20 mM Tris-buffered saline, pH 7.4) for 2 hr at room
temperature, and then incubated with appropriate primary antibodies in blocking buffer
overnight at 4oC. After incubation with appropriate secondary antibodies for 2 hr at
room temperature, the membranes were washed with Tris buffer containing 1% of
Tween-20, and then visualized using enhanced chemiluminescence kit (Boston
Bioproducts, Ashland, MA, USA). Antibodies for Bax, p21Cip1/Waf1, p53, cdc-2(cdk-1),
cyclin B1, cleaved caspase-3 (Asp175), and poly ADP ribose polymerase (PARP) were
obtained from Cell Signaling Technology (Beverly, MA, USA). β-Actin was used as a
loading control, and antibody for β-actin was purchased from Sigma-Aldrich.
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3.2.7 Determination of intracellular levels of tangeretin and 5DT
H460, H1299, and A549 (106 cells) were suspended in 1 mL of complete culture
media containing serial concentrations of tangeretin and 5DT and then incubated at
37oC for 30, 90, and 180 minutes. The cell suspensions were then centrifuged at 2,147 x
g, 15 min at 4oC using a bench top Eppendorf centrifuge for 1 minute at 4oC and the
supernatant was discarded. The cell pellets were washed twice with 1 mL of ice-cold
PBS, re-suspended in 1 mL of PBS, and then sonicated with a probe sonicator (4 sec, 4
times). After another centrifugation (2,147 x g, 15 min at 4oC), the supernatant was
collected and mixed with equal volume of methanol. The mixtures were subject to HPLC
analysis to determine the intracellular levels of tangeretin and 5DT using method we
developed previously (129).

3.2.8 Statistical analysis
All data were presented as mean ± SD. Analyses of variance (ANOVA) model was
used to compare the differences among more than two groups followed by a post-hoc
test for multiple comparisons (Dunnett’s test or The Tukey’s Range Honesty Significant
Difference test as described in figure legends). A 1% significant level was used for all
tests.
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3.3 Results
3.3.1 Hydroxylated PMFs, particularly 5DT, showed much stronger growth inhibitory
effects than those of permethoxylated PMFs on human NSCLC cells
First, we investigated the growth inhibitory effects of 6 unique PMFs namely
nobiletin, HMF, tangeretin, 5DN, 5DH, and 5DT on human NSCLC cells. H460, H1299,
and A549 were subjected to the treatments for 72h. In H460, cells were treated with
nobiletin (20 – 100 μM), HMF (20 – 100 μM), tangeretin (12 – 60 μM), 5DN (4 – 20 μM),
5DH (3 – 15 μM), or 5DT (1 – 5 μM). In H1299, cells were treated with nobiletin (10 – 50
μM ), HMF (10 – 50 μM), tangeretin (7 – 35 μM), 5DN (3 – 15 μM), 5DH (3 – 15 μM), or
5DT(1 – 5 μM). In A549, cells were treated with nobiletin (20 – 100 μM ), HMF (20 – 100
μM), tangeretin (10 – 50 μM), 5DN (10 – 50 μM), 5DH (5 – 25 μM), or 5DT (2 – 10 μM).
We found that hydroxylated PMFs (5DN, 5DH, and 5DT) exhibited stronger growth
inhibition on all three NSCLC cells in dose-dependent fashion in comparison with their
permethoxylated counterparts (nobiletin, HMF, and tangeretin). The IC 50 values of 5DN
after 72h treatment were 10.2 μM, 12.2 μM, and 20.5 μM in H460, H1299, and A549
cells, respectively. On the other hand, the IC50 values of nobiletin after 72h treatment
were 64.5 μM, 63.5 μM, and 79 μM in H460, H1299, and A549 cells, respectively.
Moreover, the IC50 values of 5DH after 72h treatment were 3.6 μM, 1.9 μM, and 7.6 μM
in H460, H1299, and A549 cells, respectively. In contrast, the IC50 values of HMF after
72h treatment were 64.4 μM, 48.9 μM, and 83.2 μM in H460, H1299, and A549 cells,
respectively. Furthermore, the IC50 values of 5DT after 72h treatment were 1.2 μM, 2.0
μM, and 1.0 μM in H460, H1299, and A549 cells, respectively. On the other hand, the
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IC50 values of tangeretin were 52.2 μM, 52.7 μM, and 58.9 μM in H460, H1299, and
A549 cells, respectively (Figure 3.1 – Figure 3.3). The 72 hr IC50 for each compound was
summarized in Figure 3.4.
Based on our results, 5DT showed the lowest IC50 in all three human NSCLC cell
line. Therefore, in this experiment, we only focus on investigating the anticancer effects
of 5DT on human NSCLC cells, and compare these results to 5DT’s permethoxylated
counterpart, tangeretin. H460, H1299 and A549 cells were treated with 5DT (0.6 – 3 μM)
or tangeretin (8 – 40 μM) for 24, 48, or 72 hrs. Treatments with tangeretin showed
marginal inhibitory effects on all three NSCLC cells. At the highest concentration tested
(40 μM), tangeretin only inhibited cell growth by 36.0%, 27.5%, and 18.4% on H460,
H1299, and A549 cells, respectively, after 72 hrs of treatments. In contrast, 5DT showed
much more potent inhibition on all three NSCLC cells in a dose-dependent and timedependent fashion in comparison with tangeretin. At 3 μM, treatments with 5DT for 72
hrs inhibited cell growth by 93.4%, 93.0%, and 94.2% on H460 (Figure 3.5 A), H1299
(Figure 3.5 B), and A549 (Figure 3.5 C) cells, respectively. The IC50 values of 5DT after 72
hrs of treatment were 1.27 μM, 1.02 μM, and 0.99 μM in H460, H1299, and A549 cells,
respectively. On the other hand, the projected IC50 values of tangeretin after 72 hrs of
treatment were 72.6 μM, 54.5 μM, and 78.2 μM in H460, H1299, and A549 cells,
respectively. This means that IC50 values of 5DT were 57.2-fold, 56.3-fold, and 78.9-fold
lower than those of tangeretin in H460, H1299 and A549 cells, respectively (Table 3.1).
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Figure 3.1 The growth inhibitory effects of PMFs on H460 human NSCLC cells. H460 cells
were treated with serial concentrations of different PMFs for 72 hr. The growth
inhibition was measured by MTT assay as described in section 3.2.2. Hydroxylated PMFs
showed superior growth inhibitory effects in comparison to their permethoxylated
counterparts.
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Figure 3.2 The growth inhibitory effects of PMFs on human H1299 NSCLC cells. H1299
cells were treated with serial concentrations of different PMFs for 72 hr. The growth
inhibition was measured by MTT assay as described in section 3.2.2. Hydroxylated PMFs
showed superior growth inhibitory effects in comparison to their permethoxylated
counterparts.
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Figure 3.3 The growth inhibitory effects of PMFs on A549 human NSCLC cells. A549 cells
were treated with serial concentrations of different PMFs for 72 hr. The growth
inhibition was measured by MTT assay as described in section 3.2.2. Hydroxylated PMFs
showed superior growth inhibitory effects in comparison to their permethoxylated
counterparts.
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Figure 3.4 The 72 hr IC50s of PMFs on human NSCLC cells. Hydroxylated PMFs (5DN,
5DH, and 5DT) showed lower projected IC50s in all H460, H1299, and A549 in
comparison with their permethoxylated counterparts (nobiletin, HMF, and tangeretin).

55

Figure 3.5 5DT significantly inhibits the proliferation of H460, H1299, and A549 human
NSCLC cells. H460 (A), H1299 (B), and A549 (C) were seeded in 96-well plates, and after
24 hrs of incubation, cells were treated with serial concentrations of tangeretin and 5DT
as described in section 3.2.2. After another 24, 48, or 72h of treatment, cell viability
was measured by MTT assay as described in method Section. Data represent mean ± SD
(n = 6), and the asterisks (* for 24h, ** for 48h, and *** for 72h) indicate the statistical
significance between 5DT at different concentrations and tangeretin at the highest
concentration (40 µM)) at the same incubation time based on ANOVA test followed by
Dunnett's post-hoc test (p < 0.01, n = 6)
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Table 3.1 72 hr IC50 values of tangeretin and 5DT in H460, H1299, and A549 human
NSCLC cells.

Human NSCLC

IC50 of Tangeretin

72h IC50 of Tangeretin

72h IC50 of 5HT

H460

72.6μM

1.27μM

57.2-fold

H1299

57.5μM

1.02 μM

56.4-fold

A549

78.2μM

0.99μM

79.0-fold

Cell Line

IC50 of 5HT

3.3.2 5DT inhibited the colony formation of NSCLC cells
To further determine the difference between the effects of 5DT and tangeretin
on the growth of human NSCLC cells, we conducted colony formation assay on H460
cells. H460 cells were subjected to the treatments with tangeretin (10 μM or 20 μM) or
5DT (1 μM, 1.5 μM, or 2 μM). Tangeretin at 10 μM or 20 μM did not significantly
decrease the capability of cancer cells to form colonies (Figure 3.8A). However, 5DT
showed potent and dose-dependent inhibition on the formation of colonies, i.e., 5DT at
1 μM, 1.5 μM, and 2 μM inhibited the colony formation by 20%, 75%, and 99%,
respectively. The treatment with 5DT also caused distinct changes on the morphology of
H460 cells. As shown in figure 3.8B, 5DT-treated cells appeared smaller in size, had
much less defined nucleus region, and had poor attachment in comparison with the
control cells. Treatments with tangeretin did not cause any significant change on cell
morphology in comparison to the control (images not shown).
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Figure 3.6 Inhibitory effects of 5DT and tangeretin on colony formation of NSCLC cells.
A. 5DT potently inhibited colony formation of human H460 NSCLC cells. Cells were
seeded into 6-well plates. After 24 hrs of incubation, cells were subjected to treatments
with serial concentrations of tangeretin and 5DT as shown in the figure. After 12 days of
incubation, the numbers of colonies formed was photographed and counted as
described in the methods. Data represent mean  SD (n = 3), and all the 5DT-treated
groups showed significant difference in comparison with the control and tangeretintreated group based on ANOVA followed by Tukey's HSD post-hoc test. B. Phasecontrast pictures of control and 5DT-treated colonies of H460 NSCLC cells.
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3.3.3 5DT caused G2/M cell cycle arrest on NSCLC cells
To establish the mode of action of 5DT and tangeretin in inhibiting cell growth,
cell cycle analysis was conducted on the NSCLC cells treated with 5DT or tangeretin. As
shown in figure 3.9, tangeretin at 10 μM, 20 μM, or 30 μM did not cause significant
changes in cell cycle distribution of three NSCLC cells in comparison to the control cells.
In contrast, 5DT caused significant and dose-dependent increase in the percentage of
cells in G2/M phase in all three NSCLC cells (Figure 3.9). Treatments with 5DT at 3 μM
increased the percentage of G2/M cell population to 3.1-fold, 3.5-fold, and 3.7-fold of
the control cells in H460, H1299, and A549 cells, respectively.
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Figure 3.7 Effects of tangeretin and 5DT on cell cycle progression of human NSCLC cells.
H460 (A), H1299 (B), and A549 (C) were seeded in 6-well plates for 24h, and then
treated with serial concentrations of tangeretin and 5DT. After another 24h, cells were
collected and subjected to cell cycle analyses as described in methods section. All data
represent mean ± SD, and the asterisk in the bar charts indicated statistical significance
of 5DT-treated groups in comparison with the control and tangeretin-treated groups at
all concentrations based on ANOVA followed by Tukey's HSD post-hoc test (p < 0.01, n =
3).
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3.3.4 5DT induced extensive apoptosis in NSCLC cells
To determine the extent to which apoptosis contributed to the growth inhibition
caused by 5DT, we investigated the effects of 5DT on cellular apoptosis of NSCLC cells,
and compared them with those produced by tangeretin. After 48 hrs of treatments with
5DT and tangeretin at different concentrations, early and late apoptotic cells were
quantified by flow cytometry method with Annexin V/Propidium Iodine (PI) double
staining assay. As shown in figure 3.9, 5DT induced extensive apoptosis in all three
NSCLC cells in a dose-dependent manner, In H460 cells, 5DT at 2 µM and 3 µM increased
early apoptotic cell population by 5.2-fold (from 2.1% to 10.9%) and 16.4-fold (from
2.1% to 34.4%) compared to the control, respectively. Moreover, 5DT at 2 µM and 3 µM
also increased late apoptotic cell population by 5.3-fold (from 0.8% to 4.2%) and 13.8fold (from 0.8% to 11.0%) compared to the control, respectively (Figure 3.9A). Similar
trends were also observed in the H1299 and A549 cells after 5DT treatments (Figure.
3.9B and 3.9C). In contrast, tangeretin at 10 µM, 20 µM, and 30 µM did not cause any
significant change in apoptotic cell population in H460, H1299 and A549 NSCLC cells.
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Figure 3.8 Effects of tangeretin and 5DT on apoptosis of human NSCLC cells. H460 (A),
H1299 (B), and A549 (C) cells were seeded in 6-well plates for 24 hr, and then treated
with different concentrations of tangeretin and 5DT. After another 48h, cells were
collected and subjected to apoptosis analyses described in methods section. All data
represent mean ± SD, and the asterisk in the bar charts indicated statistical significance
of 5DT-treated groups in comparison with the control and tangeretin-treated groups at
all concentration based on ANOVA followed by Tukey's HSD post-hoc test (p < 0.01, n =
3).
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3.3.5 5DT modulated key proteins related to cell proliferation and apoptosis
In order to further elucidate the molecular mechanisms underlying the inhibitory
effects of 5DT on human NSCLC cells, we compared the effects of 5DT and tangeretin on
key protein markers related to cell proliferation and apoptosis. Immunoblotting analysis
demonstrated that 5DT caused extensive changes in these signaling proteins (Figure
3.11). In H460 and A549 cells, 5DT at different concentrations, especially 2 and 3 µM,
significantly increased expression levels of p53 and Bax, and decreased expression levels
of cdc-2(cdk1) and cyclin B1. In all three NSCLC (H460, H1299 and A549) cells, 5DT at
different concentrations, especially 2 and 3 µM, significantly increased expression levels
of p21Cip1/Waf1, cleaved caspase-3 and cleaved PARP. In contrast, tangeretin at much
higher concentrations (10, 20 or 30 µM) did not cause any changes in most of these
proteins, except for moderate effects in increasing p21Cip1/Waf1 levels in H460, H1299 and
A549 cells; increasing Bax levels in A549 cells; and decreasing cdc-2(cdk1) levels in A549
cells. All of these effects of tangeretin were much weaker than those produced by 5DT
at much lower concentrations.
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Figure 3.9 Effects of tangeretin and 5DT on cell cycle and apoptosis related key proteins
in human NSCLC cells. H460 (A), H1299 (B), and A549 (C) cells were seed into 15 cm
culture dishes for 24h, and then cells were treated with serial concentrations of
tangeretin and 5DT. After another 24h or 48h of incubation, cells were collected for
western blotting as described in methods section. The numbers underneath of the blots
represent band intensity (normalized to β-actin, means of three independent
experiments) measured by Image J software. The standard deviations (all within ± 15%
of the means) were not shown. β-actin served as an equal loading control
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3.3.6 5DT had the better intracellular uptake than tangeretin in NSCLC cells
Intracellular uptake is an important factor influencing the bioactivities of
chemopreventive compounds. Three NSCLC cells were incubated with different
concentrations of tangeretin (3, 20, or 30 μM) or 5DT (1, 2, or 3 μM) for 30, 90, and 180
min. Then, the intracellular levels (bioavailable fraction to the NSCLC cells) of tangeretin
and 5DT in NSCLC cells were determined by the HPLC method developed by us
previously (130). The results showed that the intracellular levels of 5DT and tangeretin
increased with increased concentrations of 5DT and tangeretin at 30, 90 and 180 min in
all H460 (Figure 3.12 A, upper panel), H1299 (Figure 3.12 B, upper panel), A549 (Figure
3.12 C, upper panel). Using the data from the intracellular uptake, the area under curve
(AUC) was calculated for tangeretin and 5DT from 0 to 180 min to represent the
cumulative amount of tangeretin and 5DT that have been exposed to intracellular
compartment of the lung cancer cells over time. Intracellular accumulation of 5DT were
4.9-fold, 2.8-fold, and 2.7-fold higher than those of tangeretin in H460 (Figure 3.12 A,
bottom panel), H1299 (Figure 3.12 B, bottom panel), and A549 (Figure 3.12 C, bottom
panel) cells, respectively, when cells were treated with 5DT or tangeretin at the same
concentration of 3 μM. Actually, the intracellular accumulation of tangeretin at 3 μM
was similar to that of 5DT at 1 μM, but lower than that of 5DT at 2 μM. It was also
observed that tangeretin at 20 and 30 μM resulted in higher intracellular accumulation
than that produced by 5DT at 2 and 3 μM. However, the differences were between 2.0 –
4.4-fold (much less than 10-fold). Our results demonstrated superior intracellular uptake
of 5DT to tangeretin in all three lung cancer cells.
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Figure 3.10 Intracellular levels of tangeretin and 5DT in human NSCLC cells. H460 (A),
H1299 (B), and A549 (C) cells were incubated with different concentrations of tangeretin
or 5DT for 30, 90, or 180 min. The intracellular concentrations of tangeretin and 5DT
were quantified by HPLC as previously described. Bar graphs in the lower panel were
based on the area under the curve calculated from the cellular uptake data in the upper
panel. All data represent mean ± SD (n = 3). All results for 5DT at 2-3 μM were
significantly higher than those for tangeretin at 3μM as tested by ANOVA followed by
Dunnett's post-hoc test (*, p < 0.01, n = 3).

66

3.4 Discussion
Phytochemicals from edible plants have been shown to provide potential
protection against carcinogenesis. Tangeretin is one of the most abundant PMFs found
in the peels of sweet oranges (C.senensis) and mandarin orange (C. reticulana), while
5DT exist in these peels in less abundance (53). Aged orange peels are important
ingredients for Traditional Chinese Medicine. The repeated heating and drying process
used to produce aged orange peels can convert tangeretin to 5DT by demethylation at
5-position in the A-ring of the tangeretin structure (53, 56). Herein, we reported, for the
first time, the inhibitory effects of 5DT on human NSCLC cells.
Flavones, including PMFs, have been showed to have anti-proliferative effects on
many cancerous cells (13, 14, 41, 63, 68), and their chemical structures dictates their
bioactivities. It was suggested that the presence of C2-C3 double bond in the C-ring core
structure of flavones played a pivotal role for their anticancer activities (131, 132).
Moreover, the number and position of substituents in the flavone core structures can
also influence the anti-proliferative activities of flavones on cancer cells (133).
Previously, we compared the effects of two 5-hydroxylated PMFs, namely 5-hydroxy6,7,8,3’,4’-pentamethoxyflavone and 5-hydroxy-3,6,7,8,3’,4-hexamethoxyflavone, with
those produced by their permethoxylated counterparts, namely nobiletin and
3,5,6,7,8,3’,4-heptamethoxyflavone, on human NSCLC cells (14). It was found that 5hydroxylated PMFs had much stronger inhibitory effects on cancer cells in comparison
with their permethoxylated counterparts. In this study, we further investigated the
effects of 5DT and its permethoxylated counterpart, tangeretin on human NSCLC cells.
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The results from cell viability assay indicated that 5DT was 55-80 fold more potent than
tangeretin in inhibiting NSCLC cell growth (Table 3.1). The colony formation assay
showed that 5DT was able to eliminate 99% of colonies from NSCLC cells, while
tangeretin at 10-fold higher concentration did not have any inhibitory effects on the
colonies (Figure 3.8). These results demonstrated that 5DT had much stronger inhibitory
effects on NSCLC cells than tangeretin. Since the only structural difference between 5DT
and tangeretin is the hydroxylation at 5-position in their A-ring core structure, our
results reinforced the notion that 5-hydroxylation can significantly enhance the
inhibitory effects of PMFs against cancer cell growth (13, 14, 41, 68).
One of the hallmarks of carcinogenesis is uncontrolled cell proliferation, which is
associated with deregulation of cell cycle progression and programmed cell death (107).
Therefore, inducing cell cycle arrest and apoptosis in cancer cells is potentially an
effective strategy for cancer prevention and treatment. The results from flow cytometry
analysis clearly demonstrated that 5DT treatments not only caused significant cell cycle
arrest at G2/M phase, but also led to extensive apoptosis in all NSCLC cells tested.
However, tangeretin at 10-fold higher concentrations did not cause any change on cell
cycle distribution or apoptosis of cancer cells. These findings suggested that 5DT was
able to inhibit cancer cell growth by impede cell cycle progression and increase
programmed cell death.
Cyclins, cyclin dependent kinases (CDKs), and CDK inhibitors act in concert to
regulate cell cycle progression, i.e. cyclin/CDK complexes promote cell cycle progression
whereas CDK inhibitors drive cell cycle arrest (134, 135). In H460 and A549 cells, 5DT
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significantly decreased the expression levels of both cyclin B1 and Cdc2 (cdk-1), which at
least in part, led to the G2/M arrest. This is because that the complex of cyclin B1/Cdc2
is required for entry into mitosis in G2/M transition (136). Furthermore, 5DT caused
drastic increases in the levels of p21Cip1/Waf1 in the NSCLC cells, which also contributed to
the cell cycle arrest observed. p21Cip1/Waf1 is a small 165 amino acid Cdk inhibitor that
inhibits activity of cyclin B1/Cdc2 complex by directly bound to the complex, which
blocks cells in G2/M phase (137, 138). In addition, p21Cip1/Waf1 could decrease Cdc2
protein levels by decreasing Cdc2 mRNA levels and its promoter activity (139). Both
H460 and A549 cells contain wild-type p53, a tumor suppressor. Our results showed that
5DT treatments dose-dependently increased expression levels of p53 in these cells. p53
has a broad range of cellular functions and plays key roles in inhibiting carcinogenesis
(140) by inducing cell cycle arrest (137, 141), cellular apoptosis (142), and DNA repair
(143). Increased levels of p53 can result in G2/M cell cycle arrest by downregulating
transcription of both cyclin B1 and Cdc2 (137, 139, 141, 144). Moreover, p21Cip1/Waf1 is
one of the transcriptional targets of p53, and increased levels of p53 can result in
increased levels of p21Cip1/Waf1, which in turn contributes to cell cycle arrest (137, 145).
The immunoblotting results illustrated that 5DT-mediated G2/M cell cycle arrest
in H460 and A549 (p53 wild-type) cells was associated with dose-dependent increases in
the levels of p53. However, we also observed the G2/M cell cycle arrest in 5DT-treated
H1299 cells that are p53-null NSCLC cells. In the mean time, 5DT also caused increased
levels of p21 and decreased levels of Cdc2 in H1299 cells. These findings suggested that
5DT-mediated cell cycle arrest at G2/M phase was at least partially independent of p53
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status of the NSCLC cells. Moreover, our results showed that 5DT dose-dependently
activated caspase 3 and PARP in all H460, A549, and H1299 cells, suggesting that
similarly to the 5DT-mediated cell cycle arrest, 5DT-mediated apoptosis was, at least
partially independent of p53 status of the NSCLC cells. These findings in NSCLC cells
were not consistent with our previous report showing that 5DT caused p53-dependent
cell cycle arrest and apoptosis in human colorectal cancer cells (58). This suggests that
the effects of 5DT may be cancer-type and/or cell-type specific.
Intracellular accumulation of chemopreventive compounds is one of key factors
that dictate the efficacy of chemopreventive compounds in inhibiting cancer cell
growth. Cancer cells, including NSCLC cells can acquire abilities to decrease intracellular
accumulation of cytotoxic agents by various mechanisms, such as overexperession of
multi-drug resistant efflux proteins that can pump the cytotoxic agents out of cancer
cells (146). Our results showed that NSCLC cells had much higher (2.7-4.9 fold)
intracellular accumulation of 5DT than tangeretin after incubation with 5DT or
tangeretin at the same concentration. This suggested that NSCLC cells may have better
uptake and/or less efflux of 5DT in comparison with tangeretin. HPLC analysis showed
that 5DT had stronger lipophilicity than tangeretin (129). Strong lipopholicity could
enhance binding of 5DT to the plasma membrane, which in turn may promote the
uptake of 5DT into cytosol of the cancer cells. It is of importance to elucidate the exact
mechanism by which 5DT accumulated more intracellularly than tangeretin in cancer
cells in future investigation. Our results from HPLC analysis further revealed that
tangeretin at 20-30 μM led to higher (2-4 fold) intracellular accumulation than 5DT at 270

3 μM. However, tangeretin at 20-30 μM still failed to significantly inhibit NSCLC cells,
while 5DT at 2-3 μM showed very strong inhibition on these cells. We demonstrated
that 5DT had profound effects in modulating cell cycle progression and apoptosis. These
effects are likely the results of interactions between 5DT and its direct protein targets in
cancer cells. The binding of 5DT to these protein targets could initiate a cascade of
signaling events that result in downstream phenotype outcomes such as cell cycle arrest
and apoptosis. Due to the difference in chemical structure, 5DT and tangeretin may bind
to different proteins and/or bind to same proteins but with different affinity, which
leads to different phenotype outcomes. The higher intracellular accumulation of 5DT in
comparison to tangeretin provides 5DT higher potential to interact with its protein
targets, which in turn potentially lead to stronger inhibitory effects on cancer cells.
In conclusion, we demonstrated, for the first time the potent inhibitory effects of
5DT on human NSCLC cells. These effects were associated with profound modulation of
cell cycle and apoptosis-regulating proteins by 5DT. Moreover, 5DT showed high
intracellular accumulation in cancer cells, which may enhance its anti-cancer potential.
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CHAPTER 4
SYNERGISTIC INHIBITION OF HUMAN NON-SMALL CELL LUNG CANCER CELL
PROLIFERATION BY POLYMETHOXYFLAVONES AND ATORVASTATIN

4.1 Introduction
Atorvastatin (commercially sold as Lipitor® or Torvast®, ATST) is one of the
recognizable statin drugs which is capable to lower the total cholesterol levels and
reduce density lipoproteins levels by inhibiting the activity of 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in
cholesterol synthesis pathway (147). In addition to the potent efficacy of statins in
reducing cardiovascular diseases risk and the relatively low adverse effects, stains are
found to also exert pleiotropic effects which have lead to their widespread utilization for
other chronic diseases including cancer (20). Various types of tumor including lung
carcinoma, colon carcinoma, hepatocellular carcinoma, lymphoma, and leukemia have
been found to have increased HMG-CoA activity (148). The cancer preventive effect
reported for statins is mainly suggested to their inhibition of HMG-CoA activity which
subsequently inhibits the isoprenylation of small G-proteins modulating membrane
protein trafficking and post-translational modification of proteins. Protein prenylation
(farnesylation or geranylgeranylation) is vital for cytosol-to-membrane translocation of
small G proteins including RhoA to exert their location-specific activities involving in the
control of cellular adhesion, proliferation, and survival (95, 97, 149). Remarkably, RhoA
was showed to associate with cell proliferation and apoptosis (95, 150). Recently,
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several studies have showed the cancer cells growth inhibitory effects of statins (84,
151). Moreover, our previous study reported the synergistic activities of atorvastatin
and green tea polyphenols in inhibiting lung tumorigenesis in NNK injected mouse
model as long as in human NSCLC cells (22).
Exclusively found in the citrus peels such as sweet oranges (Citrus sinensis) and
mandarin oranges (Citrus reticulata), polymethoxyflavones (PMFs) are a unique class of
flavonoid compounds that exhibit anti-carcinogenic activities (53) anti-imflammatory (8,
57), anti-atherogenic (17, 152), and anti-fungus properties(153). Nobiletin (NBT) and
tangeretin (TAN) are major PMFs found in the orange peels (56) which are also among
the effective citrus flavonoids at inhibition of human cancer cell proliferation (132).
Recently, we and other groups have reported the growth inhibitory activities of NBT and
TAN against lung (14), colon (12, 13), and breast (12) cancer cells.
At present, lung cancer is the leading cause of death in the United States (1).
Identification of cancer stem cells (CSCs) in lung solid tumors (38) and recent isolation of
identifiable lung stem cells in human lung (40) has opened the attractive approaches in
lung cancer treatments and prevention. Lack of efficacy of current chemotherapies in
treating lung CSCs underscores the need of novel strategies to specifically target CSCs
population. CSCs have been found to be more resistant to current chemotherapies (154)
and radiotherapies (155). Recently, the concept of using combination strategy of
bioactive dietary components with modern therapeutic drugs for cancer
chemoprevention has gained much attention. Despite the potent anticancer activities of
each individual cancer treatment drugs, the use of only a single compound requires a
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relatively high dose, which is usually linked with many side-effects. Combination of two
or more agents targeting at multiple sites or have distinct mechanism actions have been
suggested as a promising approach to enhance efficacy and diminish toxicity caused by
using individual drug treatment. Taken together, herein, we study the possible
synergistic actions of PMFs (namely NBT or TAN) and ATST in the inhibition of human
NSCLC cells growth.

4.2 Materials and methods
4.2.1 Cell cultures and treatments
H460, H1299, and A549 human NSCLC cell lines were acquired from American
Type Cell Collection (ATCC, Manassas, VA, USA), and maintained in RPMI 1640 media
(Mediatech, Herndon, VA, USA) supplemented with 5% heat inactivated FBS and 100
U/ml of penicillin and 0.1 mg/ml of streptomycin at 37oC with 5% CO2 and 95% air. Cells
were kept sub-confluent and media were changed every 3-4 days. All cells used in
experiments were between 4 and 25 passages. Nobiletin (NBT), tangeretin (TAN) and
atorvastatin (ATST) were purchased from from Bepharm Ltd. (Shanghai, China).
Mevalonate, squalene, farnesyl pyrophosphate (Fpp), and geranylgeranyl
pyrophosphate (GGpp) were purchased from Sigma-Aldrich. DMSO was used as a
vehicle to deliver NBT, TAN and ATST into cells while methanol was used as a vehicle to
deliver mevalonate, squalene, Fpp, and GGpp into cells. The final concentration of
DMSO and methanol in all experiments was 0.1% v/v in cell culture completed media.
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4.2.2 Cell viability assay
H460 (2000cells/well), H1299 (2000cells/well), and A549 (2000cells/well) cells
were seeded in 96-well plates (Corning). After 24 hr incubation for cell attachment, cells
were treated with compounds in 200 µL of serum complete media. After 72 hr, 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (MP-Biomedicals, LLC) was
dissolved in completed RPMI 1640 medium at 0.05% g/mL and applied to cells in order
to distinguish dead and viable cells. After 2 hr incubation at 37 OC, MTT-containing media
were discarded and the remaining reduced formazan dye was solublized by adding 100
µL of DMSO to each well. The absorbance was monitored at 570 nm after gentle mixing
by using a microplate reader (Elx800TM absorbance microplate reader, BioTek
Instrument, VT, USA).

4.2.3 Analyses of synergy
The analyses were based on Chou and talalay’s combination index method (156,
157) with modifications as described previously (21, 158). In NBT/ATST for example, it
was assumed that the dose response model follow log [E/(1-E)] = α(log d- log Dm), which
is a linear regression model with the response log [E/(1-E)] and the regressor log (d).
This model is used for NBT, tangeretin, ATST, the co-treament of NBT and ATST, and the
co-treatment of tangeretin and ATST with the fixed ratio of the doses of two agents. Use
the NBT/ATST as an example, E is the fraction of survived cell after treatments, d is the
subjected dose, Dm is the median effective dose of a treatment (IC50), and α is the slope
parameter. On the basis of the regression model, median effect plots were constructed
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using data from cell proliferation assay. Suppose that the combination (d1,d2) elicits the
same effect x as NBT alone at dose level Dx,1, and ATST alone at dose Dx,2, then the
interaction index of NBT/ATST = (d1/Dx,1) +(d2/Dx,2), (Dx,1 and Dx,2 were calculated from
median effect models). The combination index was used to determine additivity,
antagonism, and synergy of the combination treatment of NBT and ATST at dose (d1, d2)
depending on the combination index = 1, > 1, and < 1, respectively. The delta method
(159) was used to calculate the variance of the interaction index, which is given by
var(combination index) = var(Dx,1)(d12/Dx,14) + var(Dx,2)(d22/Dx,24). Data were further
analyzed by using R program software (http://www.r-project.org). Similar approach was
also used in TAN/ATST combination.

4.2.4 Colony formation assay
H460 (750cells/well) cells were seeded in 6-well plates. Cells were subjected to
treatments in 2 mL of serum complete media after 24 hr, and media were kept changing
with new treatment every 4 days. After 12 days incubation, media were discarded and
cell colonies were washed with PBS. Then, colonies were stained with 0.2% crystal violet
in 2% Ethanol in ddH2O for 10 minutes. After subsequently washed with double distilled
water for several times, plates were scanned by a high resolution scanner (HP Inc.) and
colonies formed were counted.
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4.2.5 Flow cytometric analysis of cell cycle distribution
H460 (5x104 cells/well), H1299 (5x104 cells/well), and A549 (5x104 cells/well)
were seeded in 6-well plates. After 24 hr of incubation for cell attachment, cells were
subjected to treatments in 2 mL of serum complete media. Media containing any
floating cells were harvested and combined with adherent cells that were detached by
brief trypsinization (0.25% trypsin-EDTA; Mediatech). Cell pellets were washed with 1
mL of ice-cold PBS then re-suspended in 1 mL of 70% ethanol and kept at -20oC
overnight. Supernatant was discarded by centrifugation (3000 rpm, 1min), and cells
were incubated with 0.3 mL of PBS containing 30 µg of heat-treated RNase (SigmaAldrich) and 3 µg of propidium iodine (Sigma-Aldrich) for 30 min at room temperature.
Single cell suspension was generated by gentle pipetting. Cell cycle distribution was
determined by using a BD LSRII cell analyzer (BD Biosciences) at the analytical cytometry
facility (University of Massachusetts Amherst) and data were processed with Modifit LT
software.

4.2.6 Detection of apoptosis
H460 (5x104 cells/well), or H1299 (5x104 cells/well), and A549 (5x104 cells/well)
were seeded in 6-well plates. After 24 hr of incubation, cells were treated subjected to
treatments in 2 mL of serum complete media. Apoptotic cells were quantified by
apoptotic detection kit (BioVision, Mountain View, CA, USA) following the
manufacturer’s instruction. In brief, Media were collected and combined with adherent
cells that were detached by trypsinization. Cell pellets were first washed with 1 mL of
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ice-cold PBS and then with binding buffer. Cells were re-suspended in 0.3 mL of Annexin
V binding buffer containing Annexin V and PI and incubated for 5 min at room
temperature before analysis by flow cytometer. Early apoptotic cells were identified as
Annexin V-positive/PI-negative cells, while late apoptotic/necrotic cells were identified
as Annexin V-positive/PI-positive cells using BD LSRII cell analyzer at the analytical
cytometry facility (University of Massachusetts Amherst).

4.2.7 Immunoblotting Analysis
Whole Cell lysate were prepared as previously described (14). Cells were seeded
in 150 mm culture dishes. After 24 hrs of incubation, cells were treated with
compounds. After another 24 or 48 hrs of incubation, cells were washed with ice-cold
PBS, and collected with cell-scrapers. Cells were then combined with floating cells, if
any, and incubated on ice for 10 min in lysis buffer (cell signaling, Beverly, MA, USA)
supplemented with cocktails of protease inhibitor (1:100), phosphotase inhibitor I
(1:100), and phosphatase inhibitor II (1:100) (Boston Bioproducts, Boston, MA, USA).
After sonication (4 seconds, 4 times), cells were incubated for 20 min on ice and
followed by centrifugation at 20,000xg using a bench top Eppendorf centrifuge for 20
mins at 4OC. Supernatants were collected as whole cell lysates. Proteins were quantified
by BCATM protein assay kit (Pierce Biotechnology, Rockford, IL, USA), and 50-150 μg of
proteins were resolved either by 8% or 12% SDS-polyacrylamide gel electrophoresis and
then transferred to nitrocellulose membrane. The membrane containing the transferred
protein were blocked in blocking buffer (5% nonfat dry milk, 1% Tween-20 in 20 mM
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Tris-buffered saline, pH 7.4) for 2 hr at room temperature, and then incubated with
appropriate primary antibodies in blocking buffer overnight at 4 oC. After incubation with
appropriate secondary antibodies for 2 hr at room temperature, the membranes were
washed with Tris buffer containing 1% of Tween-20, and then visualized using enhanced
chemiluminescence kit (Boston Bioproducts, Ashland, MA, USA). Antibodies for
phosphorylated EGFR, EGFR, phosphorylated AKT (Ser473), phosphorylated ERK1/2
(Thr202/Tyr204), p21Cip1/Waf1, p27Kip1, CDK-2, CDK-4, CDK-6, cyclin D1, phophorylated
retinoblastoma (RB) (Ser 795), RB, Mcl-1, cleaved caspase-3 (Asp175), and poly ADP
ribose polymerase (PARP) were obtained from Cell Signaling Technology (Beverly, MA,
USA). Antibodies for RhoA, and β-tubulin were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). β-Actin was used as a loading control for whole cell
lysate and cytosol fraction while β-tubulin was used as a loading control for membrane
fraction. Antibody for β-actin was purchased from Sigma-Aldrich.

4.2.8 Membrane Isolation
Cellular membranes were extracted and isolated as previously described (23).
Cells were seeded in 150 mm culture dishes. After 24 hrs of incubation, cells were
treated with compounds. Cell culture media were harvested and spun down to collect, if
any, floating cells. Adherent cells were washed with ice-cold PBS and then were
collected with cell scrapers in the presence of buffer (10mM Tris-HCl, pH 7.5, 1mM
EDTA, 1mM EGTA, 0.1mM DTT) supplemented with cocktails of protease inhibitor
(1:100), phosphotase inhibitor I (1:100), and phosphatase inhibitor II (1:100) (Boston
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Bioproducts, Boston, MA, USA). After combining with floating cells, cells were sonicated
on ice (5 sec four times) each, and then were centrifuged at 21000 x g for 30 min. The
pellet were then solubilized with lysis buffer (cell signaling Technology, Beverly, MA
USA) supplemented with cocktails of protease inhibitor (1:100), phosphotase inhibitor I
(1:100), and phosphatase inhibitor II (1:100) (Boston Bioproducts, Boston, MA, USA) on
ice for 30 min after through mixing. Membrane fractions were harvested as the
supernatant after centrifugation at 21000 x g for 20 min.

4.2.9 Lung tumorsphere formation assay
A549 human NSCLC cells were trypsinized from the petri-dished, washed twice
with PBS, and were then resuspended in serum-free Dulbecco modified Eagle medium:
Nutrient mixture F-12 (DMEM-F12)(Gibco) supplemented with 1x B27 (Invitrogen), 20
ng/mL epidermal growth factor (EGF) (Sigma), 20 ng/mL basic fibroblast growth factor
(bFGF) (Sigma), and /ml of penicillin and 0.1mg/ml of streptomycin (Cellgro). Cells were
then passed through sterile cell strainer (40 μm) in order to acquire single cell
suspension. The A549 single cell suspension then were seeded in 24-well ultra low
attachment plate (5000 cell/well) (Corning) in DMEM-F12 supplemented with 1x B27, 20
ng/mL epidermal growth factor (EGF), 20 ng/mL basic fibroblast growth factor (bFGF),
and /ml of penicillin and 0.1mg/ml of streptomycin. After 24h, treatments (NBT, ATST,
half-dose combination of NBT/ATST, and full-dose combination of NBT/ATST) were
directly added into the well, and cells were then incubated for 14 days. After that,
tumorspheres were gently collected with cell strainers, washed with PBS, and then
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transferred into 6-well plates that contained RPMI 1640 media supplemented with 5%
heat-inactivated FBS and 100U/ml of penicillin and 0.1mg/ml of streptomycin to allow
cell attachment and differentiation. After 20 hr incubation, tumorsphere were counted.
A colony that had cells less than 60 cells was discarded from the count.

4.2.10 Aldefluor assay
A549 cells were seeded in 10 cm culture dishes in serum-completed
media. After 24 hr, cells were treated with NBT, ATST, and their half-dose combination.
After 24 hr incubation, cell were then harvested and subjected to Aldufluor assay by
using Aldefluor assay kit (Stem cell Technologies). Aldehyde dehydrogenase1 (ALDH)
bright cells (ALDHbr) were quantified by using flow cytometer. The experiments were
undertaken according to manufacturer’s instruction.

4.2.11 Statistical analysis
All data were presented as mean ± SD. Student’s t-test was used to compare the
difference between two groups. Analyses of variance (ANOVA) model was used to
compare the differences among more than two groups followed by The Tukey’s Range
Honesty Significant Difference (Tukey’s HSD) post-hoc test for multiple comparisons. A
1% significant level was used for all tests.
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4.3 Results
4.3.1 Synergistic interaction between NBT/ATST and TAN/ATST
Resulting from the effect of combining different bioactive agents, the enhanced
growth inhibitory activities may be caused by their possible synergistic interactions
between agents. We herein evaluated the synergistic activities between NBT/ATST and
TAN/ATST on cell proliferation inhibition in three human NSCLC cells. To study the effect
of the NBT/ATST combined treatments, cells were treated with serial concentrations of
NBT, ATST, or NBT/ATST combination for 72 hr at a 3.2:1, 15:1, and 2:1 ratio in H460,
H1299, and A549 cells, respectively. We observed the dose-dependent on growth
inhibition in NBT or ATST individual treatment. Importantly, we also observed the
NBT/ATST half dose combination (half concentration of NBT with half concentration of
ATST compared to the full concentration of NBT or ATST) resulted in significantly
stronger cell growth inhibition than those of the individual treatments with NBT or ATST
at full dose produced in all three cells. For example, a combination of 24 μM NBT with
7.5 μM ATST resulted in 1% viable cell in H460, whereas treatment of 48 μM NBT alone
and 15 μM ATST alone led to 92%, and 62% live cell, respectively (Figure 4.1). Similarly,
in H1299, a combination treatment of 15 μM NBT with 1 μM ATST left only 9% viable
cell, while the individual treatment of 30 μM NBT alone and 2 μM ATST alone resulted in
77%, and 70% viable cell, respectively (Figure 4.2). Likewise, in A549, a combined
treatment of 25 μM NBT with 12.5 μM ATST resulted in 10% viable cell, while 50 μM
NBT alone or 25 μM ATST alone resulted in 69%, and 70% viable cell, respectively (Figure
4.3). Overall, we found that half dose combination of NBT/ATST combination
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significantly inhibited NSCLC cells growth.

Figure 4.1 Growth inhibitory effect of the combination of nobiletin (NBT) and
atorvastatin (ATST) on H460 human NSCLC cells. H460 were treated with serial
concentration of NBT, ATST, and their combinations for 72 hr. Viable cells were measure
by cell viability assay as described in section 4.2.2. The NBT/ATST half-dose combination
significantly inhibited the cell growth stronger than those of full-dose individual
treatments of nobiletin and ATST. Data were shown as mean ± SD (n=6), and viable cells
of controls were used as 100%. By using Student’s t-test, * indicated a statistical
significant of the half-dose combination as compared to nobiletin and ATST alone at full
dose of the certain concentrations of nobiletin or ATST (p < 0.01, n = 6).
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Figure 4.2 Growth inhibitory effect of the combination of nobiletin (NBT) and
atorvastatin (ATST) on H1299 human NSCLC cells. H1299 were treated with serial
concentration of NBT, ATST, and their combinations for 72 hr. Viable cells were measure
by cell viability assay as described in section 4.2.2. The NBT/ATST half-dose combination
significantly inhibited the cell growth stronger than those of full-dose individual
treatments of nobiletin and ATST. Data were shown as mean ± SD (n=6), and viable cells
of controls were used as 100%. By using Student’s t-test, * indicated a statistical
significant of the half-dose combination as compared to nobiletin and ATST alone at full
dose of the certain concentrations of nobiletin or ATST (p < 0.01, n = 6).
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Figure 4.3 Growth inhibitory effect of the combination of nobiletin (NBT) and
atorvastatin (ATST) on A549 human NSCLC cells. A549 were treated with serial
concentration of NBT, ATST, and their combinations for 72 hr. Viable cells were measure
by cell viability assay as described in section 4.2.2. The NBT/ATST half-dose combination
significantly inhibited the cell growth stronger than those of full-dose individual
treatments of nobiletin and ATST. Data were shown as mean ± SD (n=6), and viable cells
of controls were used as 100%. By using Student’s t-test, * indicated a statistical
significant of the half-dose combination as compared to nobiletin and ATST alone at full
dose of the certain concentrations of nobiletin or ATST (p < 0.01, n = 6).
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As we observed significant growth inhibitory effects from NBT/ATST
combination, we further investigated if these enhanced activities were additive or
synergistic. We evaluated the mode of interaction between NBT/ATST in inhibiting the
proliferation of human NSCLC cells by utilizing isobologram analysis adapted from Chou
& Talalay’s empirical methods (157) as we described previously (21, 158). The median
effect plot demonstrated that the linear regression model used in the isobologram
analysis was well-fitted to the dose-response relationship of NBT, ATST and NBT/ATST
combination with the concentration ranges exploited herein. On the basis of the median
effect plot, the interaction index of each combination dose pair of NBT/ATST was
calculated as explained in section 2.3. The interaction index was used to determine
additive, synergistic, or antagonistic effects of the combinations at different doses
depending on the interaction index (II) = 1, < 1, or > 1, respectively. Markedly, the II
between 0.1- 0.3 indicates strong synergism. Moreover, II < 0.1 indicates very strong
synergism (157). For NBT/ATST, all dose pairs tested in H460 (Figure 4.4), H1299 (Figure
4.5), and A549 (Figure 4.6) cell lines resulted in the II lower than 1 indicating a
synergistic interaction between NBT and ATST in terms of inhibiting human NSCLC cell
proliferation. Evidently, the II values from NBT/ATST at the highest concentration of
each cell line are below 0.2 suggesting strong synergism, especially in H1299 in which II
from 15 μM NBT and 1 μM ATST was 0.07 indicating very strong synergism. Taken
together, our results demonstrated a synergistic interaction between NBT and ATST in
growth inhibition of H460, H1299, and A549 human NSCLC cells.
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Figure 4.4 Median effect and interaction index plots of nobiletin (NBT), atorvastatin
(ATST), and their combination in H460 human NSCLC cells. Cells were treated with NBT
or ATST alone or in combination at serial concentrations for 72 hr in 96-well plates. Cell
viability was determined by MTT assay as described in section 4.2.2. The median effect
plot and interaction index plot were constructed by using modified Chou and Talalay’s
method as described in section 4.2.3. Synergistic effect of two agents was defined as
interaction index lower than 1.0. Error bars in interaction index plots represented 95%
confidence interval and were calculated using delta method (159).
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Figure 4.5 Median effect and interaction index plots of nobiletin (NBT), atorvastatin
(ATST), and their combination in H1299 human NSCLC cells. Cells were treated with NBT
or ATST alone or in combination at serial concentrations for 72 hr in 96-well plates. Cell
viability was determined by MTT assay as described in section 4.2.2. The median effect
plot and interaction index plot were constructed by using modified Chou and Talalay’s
method as described in section 4.2.3. Synergistic effect of two agents was defined as
interaction index lower than 1.0. Error bars in interaction index plots represented 95%
confidence interval and were calculated using delta method (159).
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Figure 4.6 Median effect and interaction index plots of nobiletin (NBT), atorvastatin
(ATST), and their combination in A549 human NSCLC cells. Cells were treated with NBT
or ATST alone or in combination at serial concentrations for 72 hr in 96-well plates. Cell
viability was determined by MTT assay as described in section 4.2.2. The median effect
plot and interaction index plot were constructed by using modified Chou and Talalay’s
method as described in section 4.2.3. Synergistic effect of two agents was defined as
interaction index lower than 1.0. Error bars in interaction index plots represented 95%
confidence interval and were calculated using delta method (159).
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For TAN/ATST combination, we used the similar approaches as in NBT/ATST
combination. Cells were treated with serial concentrations of TAN and ATST for 72 hr at
ratios of 2.4:1, 15:1, and 2:1 in H460, H1299, and A549 human NSCLC cancer cells,
respectively. Like NBT/ATST combination, our results showed that combinations of half
dose of TAN with a half dose of ATST resulted in significantly stronger growth inhibition
of cell proliferation than those exerted by individual treatment of TAN or ATST at full
concentration in all H460, H1299, and A549 cell lines. For instance, a combined
treatment of 18 μM tangeretin with 7.5 μM ATST spared only 1% viable cell in H460,
whereas 48 μM nobiletin alone and 15 μM ATST alone led to 92%, and 62% viable cell,
respectively (Figure 4.7). Likewise, in H1299, a combined treatment of 15 μM tangeretin
with 1 μM ATST spared only 4% viable cell growth, whereas 30 μM nobiletin alone and 2
μM ATST alone led to 70%, and 70% viable cell in H1299 cells, respectively (Figure 4.8).
Similar results were also observed in A549. A combined treatment of 25 μM tangeretin
with 12.5 μM ATST spared only 8% viable cell growth in H460, whereas 50 μM nobiletin
alone and 25 μM ATST alone led to 53, and 70% viable cell in H460 cells, respectively
(Figure 4.9).
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Figure 4.7 Growth inhibitory effect of the combination of tangeretin (TAN) and
atorvastatin (ATST) on H460 human NSCLC cells. A549 were treated with serial
concentration of TAN, ATST, and their combinations for 72 hr. Viable cells were
measured by cell viability assay as described in section 4.2.2. The TAN/ATST half-dose
combination significantly inhibited the cell growth stronger than those of full-dose
individual treatments of nobiletin and ATST. Data were shown as mean ± SD (n=6), and
viable cells of controls were used as 100%. By using Student’s t-test, * indicated a
statistical significant of the half-dose combination as compared to TAN and ATST alone
at full dose of the certain concentrations of TAN or ATST (p < 0.01, n = 6).
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Figure 4.8 Growth inhibitory effect of the combination of tangeretin (TAN) and
atorvastatin (ATST) on H1299 human NSCLC cells. A549 were treated with serial
concentration of TAN, ATST, and their combinations for 72 hr. Viable cells were measure
by cell viability assay as described in section 4.2.2. The TAN/ATST half-dose combination
significantly inhibited the cell growth stronger than those of full-dose individual
treatments of nobiletin and ATST. Data were shown as mean ± SD (n=6), and viable cells
of controls were used as 100%. By using Student’s t-test, * indicated a statistical
significant of the half-dose combination as compared to TAN and ATST alone at full dose
of the certain concentrations of TAN or ATST (p < 0.01, n = 6).
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Figure 4.9 Growth inhibitory effect of the combination of tangeretin (TAN) and
atorvastatin (ATST) on H1299 human NSCLC cells. A549 were treated with serial
concentration of TAN, ATST, and their combinations for 72 hr. Viable cells were
measured by cell viability assay as described in section 4.2.2. The TAN/ATST half-dose
combination significantly inhibited the cell growth stronger than those of full-dose
individual treatments of nobiletin and ATST. Data were shown as mean ± SD (n=6), and
viable cells of controls were used as 100%. By using Student’s t-test, * indicated a
statistical significant of the half-dose combination as compared to TAN and ATST alone
at full dose of the certain concentrations of TAN or ATST (p < 0.01, n = 6).
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Below 1.0, isobologram analysis of TAN/ATST also indicated that the NSCLC
growth inhibitory effect caused by TAN/ATST combination was synergistic. We observed
that all dose pairs tested in H460 (Figure 3.24), H1299 (Figure 3.25), and A549 (Figure
3.26) led to the interaction index lower than 1 which again suggested that the
interaction between tangeretin/ ATST was also synergistic. Taken together, our results
clearly demonstrated a synergistic interaction between ATST and PMFs, namely
nobiletin and tangeretin in growth inhibition of H460, H1299, and A549 human NSCLC
cells.
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Figure 4.10 Median effect and interaction index plots of tangeretin (TAN), atorvastatin
(ATST), and their combination in H460 human NSCLC cells. Cells were treated with TAN
or ATST alone or in combination at serial concentrations for 72 hr in 96-well plates. Cell
viability was determined by MTT assay as described in section 4.2.2. The median effect
plot and interaction index plot were constructed by using modified Chou and Talalay’s
method as described in section 4.2.3. Synergistic effect of two agents was defined as
interaction index lower than 1.0. Error bars in interaction index plots represented 95%
confidence interval and were calculated using delta method (159).
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Figure 4.11 Median effect and interaction index plots of tangeretin (TAN), atorvastatin
(ATST), and their combination in H1299 human NSCLC cells. Cells were treated with TAN
or ATST alone or in combination at serial concentrations for 72 hr in 96-well plates. Cell
viability was determined by MTT assay as described in section 4.2.2. The median effect
plot and interaction index plot were constructed by using modified Chou and Talalay’s
method as described in section 4.2.3. Synergistic effect of two agents was defined as
interaction index lower than 1.0. Error bars in interaction index plots represented 95%
confidence interval and were calculated using delta method (159).
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Figure 4.12 Median effect and interaction index plots of tangeretin (TAN), atorvastatin
(ATST), and their combination in A549 human NSCLC cells. Cells were treated with TAN
or ATST alone or in combination at serial concentrations for 72 hr in 96-well plates. Cell
viability was determined by MTT assay as described in section 4.2.2. The median effect
plot and interaction index plot were constructed by using modified Chou and Talalay’s
method as described in section 4.2.3. Synergistic effect of two agents was defined as
interaction index lower than 1.0. Error bars in interaction index plots represented 95%
confidence interval and were calculated using delta method (159).
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4.3.2 NBT/ATST and TAN/ATST synergistically inhibit H460 colony formation
To further verify the potency of the inhibitory effects of NBT/ATST and TAN/ATST
on the growth of human NSCLC cells, we conducted colony formation assay on H460
cells. For NBT/ATST combination study, H460 cells were subjected to the treatments of
48 μM NBT, 15 μM ATST, and their combination treatments (12 μM NBT + 3.75 μM
ATST, 24 μM NBT + 7.5 μM ATST, and 48 μM NBT and 15 μM ATST) in serum-completed
media. We found that NBT/ATST combination significantly inhibited H460 colony
formation. The individual treatment of NBT alone at 48 μM and the individual treatment
of ATST alone at 15 μM gradually inhibited H460 colony formation at 23%, and 26%,
respectively. Conversely, the combination of NBT/ATST potently inhibited the formation
of the H460 colonies. For instance, the treatment of 12 μM NBT + 3.75 μM ATST (the
quarter dose combination) inhibited 43% of H460 colony formation. Moreover, the
treatment of 24 μM NBT + 7.5 μM ATST (the half dose combination) inhibited 99% of
H460 colony formation, and markedly, none of the H460 colony was observed in 48μM
NBT +15 μM ATST (the full dose combination). Taken these results together, our results
displayed potent growth inhibitory effect of NBT/ATST combination on H460 human
NSCLC cells colony formation (Figure 4.13).
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Figure 4.13 NBT/ATST combination potently inhibited colony formation of human H460
NSCLC cells. Cells were seeded into 6-well plates. After 24 hrs of incubation, cells were
subjected to treatments with NBT, ATST, or NBT/ATST as shown in the figure 4.2.4. After
12 days of incubation, the numbers of colonies formed was photographed and counted
as described in the methods. Data represent mean  SD (n =3), and the asterisk showed
significant difference in comparison with the control, NBT, and ATST-treated group
based on ANOVA followed by Tukey's HSD post-hoc test (p < 0.01).
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Similar results were also observed in TAN/ATST combination. H460 cells were
subjected to the treatments with 36 μM TAN, 15 μM ATST, and their combination
treatment (9 μM TAN and 3.75 μM ATST, 18 μM TAN and 7.5 μM ATST, and 36 μM TAN
and 15 μM ATST). The individual treatment of TAN alone at 36 μM and the individual
treatment of ATST alone at 15 μM inhibited H460 colony formation at 16%, and 32%,
respectively. In contrast, the combination of TAN and ATST potently inhibited the H460
colony formation. To give an example, the quarter dose combination (9 μM TAN + 3.75
μM ATST) inhibited 27% of H60 colony formation. Furthermore, the treatment of 18 μM
TAN + 7.5 μM ATST (the half dose combination) inhibited 99% of H460 colony formation,
and evidently, none of the H460 colony was observed in 36 μM TAN +15 μM ATST (the
full dose combination). Taken these results together, our results displayed potent
growth inhibitory effect of the combined treatment of NBT/ATST, and TAN/ATST in
H460 human NSCLC cells colony formation (Figure 4.14).
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Figure 4.14 TAN/ATST combination potently inhibited colony formation of human H460
NSCLC cells. Cells were seeded into 6-well plates. After 24 hrs of incubation, cells were
subjected to treatments with TAN, ATST, or TAN/ATST as shown in the figure 4.2.4. After
12 days of incubation, the numbers of colonies formed was photographed and counted
as described in the methods. Data represent mean  SD (n =3), and the asterisk showed
significant difference in comparison with the control, TAN, and ATST-treated group
based on ANOVA followed by Tukey's HSD post-hoc test (p < 0.01).
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4.3.3 NBT/ATST and TAN/ATST synergistically induced G0/G1 cell cycle arrest in
human NSCLC cells
To investigate mechanisms underlying the synergistic action between NBT/ATST
and TAN/ATST in human NSCLC cell growth inhibition, we performed cell cycle analysis
by flow cytometry on H460, H1299, and A549 cells at 24 hr after treatments. We
selected the doses for the treatments based on the results obtained from cell viability
assay shown in section 4.2.1. For NBT/ATST combination, both individual treatments of
NBT or ATST alone at full dose did not cause any significant change in cell cycle
distribution compared to the control, while the combination at half dose of each agent
significantly induced the accumulation of G0/G1 cell population in H460, H1299, and
A549 human NSCLC cells. For example, in H460, the single treatment of 48 μM NBT, and
15 μM ATST alone marginally increased only 6%, and 1% cell population in G0/G1 phase
respectively, while the NBT/ATST half dose combination of the corresponding single
treatment of these two compounds (24 μM NBT + 7.5 μM ATST) induced the cell
accumulation in G0/G1 phase by 29% (Figure 4.15). Similar results were also observed in
H1299, and A549. In H1299, the individual treatments of 30μM NBT or 2μM ATST only
increased the cell population in G0/G1 phase by 5%, and 0.4%, respectively. In contrast,
the half dose combination of each individual agent (15 μM NBT + 1 μM ATST)
significantly induced cell accumulation in G0/G1 phase by 11% (Figure 4.16). In A549,
the individual treatments of 50 μM NBT or 25 μM ATST only increased the cell
population in G0/G1 phase by 3%, and 0.1%, respectively. However, the combined
treatment at half dose of each individual agent (25 μM NBT + 12.5 μM ATST)
significantly induced cell accumulation in G0/G1 phase by 7% (Figure 4.17).
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Figure 4.15 Effects of nobiletin (NBT), atorvastatin (ATST), and NBT/ATST combination
on cell cycle arrest in H460 human NSCLC cells. H460 human NSCLC cells were treated in
6-well plates for 24 hr before cell cycle analyses by using flow cytometer. Our results
showed that the half dose combination of NBT/ATST (24 μM NBT + 7.5 μM ATST)
significantly potentiated cell cycle arrest in G0/G1 phase, whereas both full dose
individual treatments of NBT (48 μM), and ATST (15 μM) did not cause any significant
change in cell cycle distribution. All data represent mean ± SD, and the asterisk in the
bar charts indicated statistical significance of NBT/ATST half-dose combination treated
groups in comparison with the control, NBT-, and ATST- treated group at full
concentrations based on ANOVA followed by Tukey's HSD post-hoc test (p < 0.01, n =
3).
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Figure 4.16 Effects of nobiletin (NBT), atorvastatin (ATST), and NBT/ATST combination
on cell cycle arrest in H1299 human NSCLC cells. H1299 human NSCLC cells were treated
in 6-well plates for 24 hr before cell cycle analyses by using flow cytometer. Our results
showed that the half dose combination of NBT/ATST (15 μM NBT + 1 μM ATST)
significantly potentiated cell cycle arrest in G0/G1 phase, whereas both full dose
individual treatments of NBT (30 μM), and ATST (2 μM) did not cause any significant
change in cell cycle distribution. All data represent mean ± SD, and the asterisk in the
bar charts indicated statistical significance of NBT/ATST half-dose combination treated
groups in comparison with the control, NBT-, and ATST- treated group at full
concentrations based on ANOVA followed by Tukey's HSD post-hoc test (p < 0.01, n =
3).
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Figure 4.17 Effects of nobiletin (NBT), atorvastatin (ATST), and NBT/ATST combination
on cell cycle arrest in A549 human NSCLC cells. A549 human NSCLC cells were treated in
6-well plates for 24 hr before cell cycle analyses by using flow cytometer. Our results
showed that the half dose combination of NBT/ATST (25 μM NBT + 12.5 μM ATST)
significantly potentiated cell cycle arrest in G0/G1 phase, whereas both full dose
individual treatments of NBT (50 μM), and ATST (25 μM) did not cause any significant
change in cell cycle distribution. All data represent mean ± SD, and the asterisk in the
bar charts indicated statistical significance of NBT/ATST half-dose combination treated
groups in comparison with the control, NBT-, and ATST- treated group at full
concentrations based on ANOVA followed by Tukey's HSD post-hoc test (p < 0.01, n =
3).
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For TAN/ATST combined treatment, both individual treatments of tangeretin or
ATST alone at full dose did not cause any significant changes in cell cycle distribution
compared to the control, while to combination at half dose of each agent significantly
induced the accumulation of G0/G1 cell population in H460, H1299, and A549 human
NSCLC cells. For instance, in H460, the individual treatments of 36 μM TAN, and 15 μM
ATST only increased the cell population in G0/G1 phase by 6%, and 3%, respectively.
However, the TAN/ATST combined treatment at half dose of each individual agent (18
μM TAN + 12.5 μM ATST) significantly induced cell accumulation in G0/G1 phase by 13%
(Figure 4.18). Similar trends were also noticed in both H1299, and A549 cells. In H1299,
the individual treatments of 30 μM TAN, and 2 μM ATST only increased the cell
population in G0/G1 phase by 4, and 2%, respectively. On the other hand, the TAN/ATST
combined treatment at half dose of each individual agent (15 μM TAN + 1 μM ATST)
significantly induced cell accumulation in G0/G1 phase by 12% (Figure 4.19). In A549,
the individual treatments of 50 μM TAN, and 25 μM ATST only increased the cell
population in G0/G1 phase by 3%, and 4%, respectively. However, the TAN/ATST
combination at half dose of each individual agent (25 μM TAN + 12.5 μM ATST)
significantly induced the accumulation of cells in G0/G1 phase by 25% (Figure 4.20).
Overall, we found that both NBT and TAN when combined with ATST were
capable to produce strong synergistic effects in inhibiting human NSCLC cells
proliferation by arresting cell cycle at G0/G1 phase.
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Figure 4.18 Effects of tangeretin (TAN), atorvastatin (ATST), and TAN/ATST combination
on cell cycle arrest in H460 human NSCLC cells. H460 human NSCLC cells were treated in
6-well plates for 24 hr before cell cycle analyses by using flow cytometer. Our results
showed that the half dose combination of TAN/ATST (18 μM NBT + 7.5 μM ATST)
significantly potentiated cell cycle arrest in G0/G1 phase, whereas both full dose
individual treatments of TAN (36 μM), and ATST (15 μM) did not cause any significant
change in cell cycle distribution. All data represent mean ± SD, and the asterisk in the
bar charts indicated statistical significance of TAN/ATST half-dose combination treated
groups in comparison with the control, TAN-, and ATST- treated group at full
concentrations based on ANOVA followed by Tukey's HSD post-hoc test (p < 0.01, n =
3).
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Figure 4.19 Effects of tangeretin (TAN), atorvastatin (ATST), and TAN/ATST combination
on cell cycle arrest in H1299 human NSCLC cells. H1299 human NSCLC cells were treated
in 6-well plates for 24 hr before cell cycle analyses by using flow cytometer. Our results
showed that the half dose combination of TAN/ATST (15 μM NBT + 1 μM ATST)
significantly potentiated cell cycle arrest in G0/G1 phase, whereas both full dose
individual treatments of TAN (30 μM), and ATST (2 μM) did not cause any significant
change in cell cycle distribution. All data represent mean ± SD, and the asterisk in the
bar charts indicated statistical significance of TAN/ATST half-dose combination treated
groups in comparison with the control, TAN-, and ATST- treated group at full
concentrations based on ANOVA followed by Tukey's HSD post-hoc test (p < 0.01, n =
3).
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Figure 4.20 Effects of tangeretin (TAN), atorvastatin (ATST), and TAN/ATST combination
on cell cycle arrest in A549 human NSCLC cells. A549 human NSCLC cells were treated in
6-well plates for 24 hr before cell cycle analyses by using flow cytometer. Our results
showed that the half dose combination of TAN/ATST (50 μM NBT + 25 μM ATST)
significantly potentiated cell cycle arrest in G0/G1 phase, whereas both full dose
individual treatments of TAN (50 μM), and ATST (25 μM) did not cause any significant
change in cell cycle distribution. All data represent mean ± SD, and the asterisk in the
bar charts indicated statistical significance of TAN/ATST half-dose combination treated
groups in comparison with the control, TAN-, and ATST- treated group at full
concentrations based on ANOVA followed by Tukey's HSD post-hoc test (p < 0.01, n =
3).
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4.3.4 NBT/ATST and TAN/ATST synergistically induced extensive cellular apoptosis in
human NSCLC cells
Triggering cellular apoptosis has currently been one of the promising cancer
prevention strategies. We examined if NBT/ATST and TAN/ATST combination treatment
synergistically induced extensive cellular apoptosis in human NSCLC cells. H460, H1299,
A549 cells were treated with compounds for 48 hr with the similar doses used in cell
cycle analysis described in section 4.3.3. The harvested cells were subjected to Annexin
V and propidium iodine (PI) co-staining and quantified by flow cytometry analysis
described in section 4.2.6. Annexin V positive and PI negative cells were considered as
early apoptotic cells, while Annexin V positive and PI positive double stained cells were
regarded as late apoptotic cells. As for NBT/ATST combination, the dot intensity of both
early apoptotic cell population (Annexin V positive and PI negative region (Q4)) and late
apoptosis (Annexin V positive and PI positive (Q2)) were gradually increased after the
single treatment of NBT or ATST when compared to control group, whereas the
NBT/ATST combination at half dose of each agent significantly induced higher levels of
early apoptotic cell population in all H460, H1299, and A549 human NSCLC cells when
compared to control, or full doses of NBT or ATST individual treatment. Moreover, half
dose combination of NBT/ATST also significantly increased late apoptotic cells in H460
and A549 when compared to control, or both full dose individual treatments of NBT or
ATST. For example, in H460, the individual treatment of NBT at 48 μM or ATST at 15 μM
induced the early apoptotic cell by 1.5-fold (from 1.3 to 1.9%), and 4.8-fold (from 1.3 to
6.2%), respectively. However, the NBT/ATST half dose combination of the corresponding
single treatment of these two compounds (24 μM NBT + 7.5 μM ATST) significantly
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increased the early apoptotic cells by 11.8-fold (1.3 to 15.3%). Moreover, this half dose
combination of NBT/ATST also induced the late apoptotic cell population by 4.0% (from
1.3 to 5.2%), whereas the single treatment of NBT or ATST at full dose increased the late
apoptotic cell population by 1.1-fold (from 1.3 to 1.4%), and 2.3-fold (from 1.3 to 3.0%),
respectively (Figure 4.21). Similar results were also observed in H1299 and A549 cells. In
H1299, the individual treatment of NBT at 30 μM or ATST at 2 μM induced the early
apoptotic cell by 1.1-fold (from 1.6 to1.8%), and 4.4-fold (from 1.6 to 7.1%),
respectively. However, the half dose combination of the corresponding single treatment
of these two compounds (15 μM NBT + 1 μM ATST) significantly increased the early
apoptotic cells by 11.2-fold (1.6 to 17.9%). In addition, this half dose combination of
NBT/ATST also induced the late apoptotic cell population by 1.9% (from 1.6 to 3.0%),
whereas the single treatment of NBT or ATST at full dose increased the late apoptotic
cell population by 1.9-fold (from 1.6 to 3.0%), and 1.1-fold (from 1.6 to 1.7%),
respectively (Figure 4.22). In A549, the individual treatment of NBT at 50 μM or ATST at
25 μM induced the early apoptotic cell by 1.3-fold (from 1.1 to 1.4%), and 2.3-fold (from
1.1 to 2.5%), respectively. However, the half dose combination of the corresponding
single treatment of these two compounds (25 μM NBT + 12.5 μM ATST) significantly
increased the early apoptotic cells by 10.0-fold (1.1 to 11.0%). Moreover, this half dose
combination of NBT/ATST also induced the late apoptotic cell population by 5.4% (from
1.7 to 9.2%), whereas the single treatment of NBT or ATST at full dose increased the late
apoptotic cell population by 1.5-fold (from 1.7 to 2.6%), and 2.7-fold (from 1.7 to 4.6%),
respectively. Taken together, our results indicated that co-treatment of NBT/ATST were
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able to produce extensive cellular apoptosis on H460, H1299, and A549 human NSCLC
cells (Figure 4.33).

Figure 4.21 Effects of nobiletin (NBT), atorvastatin (ATST), and their half dose
combinations on apoptosis. Cells were treated for 48 hr and then were subjected to
flow cytometry analysis after Annexin-V/PI co-staining as described in section 4.2.6. The
top graph showed the quantification of % early and late apoptotic cell after 48 hr
treatments of NBT, ATST, and NBT/ATST half-dose combination in H460 cells. NBT/ATST
half-dose combination extensively induced early apoptosis significantly stronger than
those produced by ATST or NBT individual treatments. Annexin V/PI intensity dot plots
at the bottom demonstrated significantly increased dot intensity in Q4 region (early
apoptosis) after 48 hr treatment of NBT/ATST half dose combination in H460. All data
represent mean ± SD, and the asterisk in the bar charts indicated statistical significance
of NBT/ATST half-dose combination treated groups in comparison with the control,
NBT-, and ATST- treated groups at full concentrations based on ANOVA followed by
Tukey'sHSD post-hoc test (p < 0.01, n = 3).
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Figure 4.22 Effects of nobiletin (NBT), atorvastatin (ATST), and their half dose
combinations on apoptosis. Cells were treated for 48 hr and then were subjected to
flow cytometry analysis after Annexin-V/PI co-staining as described in section 4.2.6. The
top graph showed the quantification of % early and late apoptotic cell after 48 hr
treatments of NBT, ATST, and NBT/ATST half-dose combination in H1299 cells.
NBT/ATST half-dose combination extensively induced early apoptosis significantly
stronger than those produced by ATST or NBT individual treatments. Annexin V/PI
intensity dot plots at the bottom demonstrated significantly increased dot intensity in
Q4 region (early apoptosis) after 48 hr treatment of NBT/ATST half dose combination in
H1299. All data represent mean ± SD, and the asterisk in the bar charts indicated
statistical significance of NBT/ATST half-dose combination treated groups in
comparison with the control, NBT-, and ATST- treated groups at full concentrations
based on ANOVA followed by Tukey's HSD post-hoc test (p < 0.01, n = 3).
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Figure 4.23 Effects of nobiletin (NBT), atorvastatin (ATST), and their half dose
combinations on apoptosis. Cells were treated for 48 hr and then were subjected to
flow cytometry analysis after Annexin-V/PI co-staining as described in section 4.2.6. The
graph at the top showed the quantification of % early and late apoptotic cell after 48 hr
treatments of NBT, ATST, and NBT/ATST half-dose combination in A549 cells. NBT/ATST
half-dose combination extensively induced early apoptosis significantly stronger than
those produced by ATST or NBT individual treatments. Annexin V/PI intensity dot plots
at the bottom demonstrated significantly increased dot intensity in Q4 region (early
apoptosis) after 48 hr treatment of NBT/ATST half dose combination in A549. All data
represent mean ± SD, and the asterisk in the bar charts indicated statistical significance
of NBT/ATST half-dose combination treated groups in comparison with the control,
NBT-, and ATST- treated groups at full concentrations based on ANOVA followed by
Tukey's HSD post-hoc test (p < 0.01, n = 3).
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For TAN/ATST combination, similar as NBT/ATST combination, the dot intensity
of both early apoptotic cell population (Annexin V positive and PI negative region (Q4))
and late apoptosis (Annexin V positive and PI positive (Q2)) were moderately increased
after the single treatment of TAN or ATST as compared to control. In contrast, the
TAN/ATST combination at half dose of each agent significantly induced higher levels of
early apoptotic cell population in H460, H1299, and A549 human NSCLC cells as
compared to control group or both full dose individual treatments of TAN or ATST.
Furthermore, the half dose combination also significantly induced late apoptotic cells in
H460, and A549 as compared to control or both full dose individual treatments of TAN
or ATST. For instance, in H460 cells, the individual treatment of TAN at 36 μM and ATST
at 15 μM induced the early apoptotic cell by 1.8-fold (from 1.3 to 2.4%), and 4.8-fold
(from 1.3 to 6.2%), respectively. However, the TAN/ATST half dose combination of the
corresponding single treatment of these two compounds (18 μM TAN + 7.5 μM ATST)
significantly increased the early apoptotic cells by 9.2-fold (1.3 to 12.0%). Moreover, this
half dose combination of TAN/ATST also induced the late apoptotic cell population by
5.3% (from 1.3 to 6.9%), whereas the single treatment of TAN and ATST at full dose
increased the late apoptotic cell population by 1.3-fold (from 1.3 to 1.4%), and 2.3-fold
(from 1.3 to 3.0%), respectively (Figure 3.38). In H1299 cells, the individual treatment of
TAN at 30 μM and ATST at 2 μM modestly induced the early apoptotic cell by 1.9-fold
(from 1.3 to2.9%), and 1.9-fold (from 1.3 to 2.9%), respectively. However, the TAN/ATST
half dose combination of the corresponding single treatment of these two compounds
(15 μM TAN + 1 μM ATST) significantly increased the early apoptotic cells by 9.3-fold
115

(1.5 to 9.3%). In addition, this half dose combination of TAN/ATST also induced the late
apoptotic cell population by 1.3% (from 1.0 to 1.3%). The single treatment of TAN at 30
μM increased the late apoptotic cell population by 1.6-fold (from 1.0 to 1.6%), while 2
μM ATST decreased the dot intensity of late apoptotic cells by 0.6-fold (from 1.0 to
0.6%) (Figure 3.39). In A549 cells, the individual treatment of TAN at 50 μM decreased
the early apoptosis cell population by 0.7-fold (from 1.1 to 0.8%), while ATST at 25 μM
induced the early apoptotic cell by 2.3-fold (from 1.1 to 2.5%). The TAN/ATST half dose
combination of the corresponding single treatment of these two compounds (25 μM
TAN + 12.5 μM ATST) significantly increased the early apoptotic cells by 7.4-fold (1.1 to
8.1%). Moreover, the half dose combination of TAN/ATST also induced the late
apoptotic cell population by 6.3% (from 1.7 to 10.7%). In addition, the single treatment
of TAN at 50 μM diminished the late apoptotic cell population down by 0.6-fold (from
1.7 to 1.1%), whereas 2 μM ATST increased the late apoptotic cell population by 2.7-fold
(from 1.7 to 4.6%). Taken together, our results indicated that both NBT and TAN were
able to produce extensive cellular apoptosis on H460, H1299, and A549 human NSCLC
when combined with ATST.
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Figure 4.24 Effects of tangeretin (TAN), atorvastatin (ATST), and their half dose
combinations on apoptosis. Cells were treated for 48 hr and then were subjected to
flow cytometry analysis after Annexin-V/PI co-staining as described in section 4.2.6. The
graph at the top showed the quantification of % early and late apoptotic cell after 48 hr
treatments of TAN, ATST, and TAN/ATST half-dose combination in H460 cells. TAN/ATST
half-dose combination extensively induced early apoptosis significantly stronger than
those produced by ATST or TAN individual treatments. Annexin V/PI intensity dot plots
at the bottom demonstrated significantly increased dot intensity in Q4 region (early
apoptosis) after 48 hr treatment of TAN/ATST half dose combination in H460. All data
represent mean ± SD, and the asterisk in the bar charts indicated statistical significance
of TAN/ATST half-dose combination treated groups in comparison with the control,
TAN-, and ATST- treated groups at full concentrations based on ANOVA followed by
Tukey's HSD post-hoc test (p < 0.01, n = 3).
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Figure 4.25 Effects of tangeretin (TAN), atorvastatin (ATST), and their half dose
combinations on apoptosis. Cells were treated for 48 hr and then were subjected to
flow cytometry analysis after Annexin-V/PI co-staining as described in materials and
methods section. The graph at the top showed the quantification of % early and late
apoptotic cell after 48 hr treatments of TAN, ATST, and TAN/ATST half-dose
combination in H1299 cells. TAN/ATST half-dose combination extensively induced early
apoptosis significantly stronger than those produced by ATST or TAN individual
treatments. Annexin V/PI intensity dot plots at the bottom demonstrated significantly
increased dot intensity in Q4 region (early apoptosis) after 48 hr treatment of TAN/ATST
half dose combination in H1299. All data represent mean ± SD, and the asterisk in the
bar charts indicated statistical significance of TAN/ATST half-dose combination treated
groups in comparison with the control, TAN-, and ATST- treated groups at full
concentrations based on ANOVA followed by Tukey's HSD post-hoc test (p < 0.01, n =
3).
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Figure 4.26 Effects of tangeretin (TAN), atorvastatin (ATST), and their half dose
combinations on apoptosis. Cells were treated for 48 hr and then were subjected to
flow cytometry analysis after Annexin-V/PI co-staining as described in section 4.2.6. The
graph at the top showed the quantification of % early and late apoptotic cell after 48 hr
treatments of TAN, ATST, and TAN/ATST half-dose combination in A549 cells. TAN/ATST
half-dose combination extensively induced early apoptosis significantly stronger than
those produced by ATST or TAN individual treatments. Annexin V/PI intensity dot plots
at the bottom demonstrated significantly increased dot intensity in Q4 region (early
apoptosis) after 48 hr treatment of TAN/ATST half dose combination in A549. All data
represent mean ± SD, and the asterisk in the bar charts indicated statistical significance
of TAN/ATST half-dose combination treated groups in comparison with the control,
TAN-, and ATST- treated groups at full concentrations based on ANOVA followed by
Tukey's HSD post-hoc test (p < 0.01, n = 3).
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4.3.5 NBT/ATST and TAN/ATST modulated key proteins related to cell proliferation
and apoptosis
To elucidate the molecular mechanism governing NSCLC cell inhibition by
NBT/ATST, we analyzed the effects of treatments on key cell cycle regulating proteins or
apoptosis key markers by immunoblotting analysis as previously described in section
4.2.7. One of the cancer cell hallmarks is hyperproliferation due to the dysfunction of
cell cycle regulators. By inhibiting cyclin dependent kinase (CDK) activities, CDK
inhibitors, such as p21Cip1/Waf1 and p27Kip1, act as negative regulators of cell cycle
progression leading to hypo-phosphorylation of retinoblastoma protein (RB) which
eventually results in cell cycle arrest. In all 3 NSCLC cell lines, we observed NBT/ATST
combination treatment at half-dose concentration of each caused upregulation of
p21Cip1/Waf1 and p27Kip1 and significantly decreased levels of phosphorylated Akt (Serine
473), CDK-2, CDK-4, CDK-6, Cyclin D1, and hyper-phosphorylation of RB. In contrast, NBT
at full concentrations (48, 30 or 50 µM in H460, H1299, and A549, respectively) did not
cause any significant changes in most of these proteins except for moderate effects in
increasing p21Cip1/Waf1 and p27Kip1levels in H460 and A549 cells. ATST treatments alone
caused the same effects as those observed in NBT/ATST half dose combination but in
less extent in all three cell lines (Figure 4.27).
To confirm that NBT/ATST combination induced cellular apoptosis, we examined
their effects on Mcl-1, anti-apoptotic protein in lung cancer, caspase-3, one of the
hallmarks of apoptotic protein, and poly ADP ribose polymerase (PARP). Our results
showed that, in all three cells, 48 hr treatment of NBT/ATST combination significantly
decreased Mcl-1 protein expression levels, activated the cleavage of caspase-3 and
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increased the levels of cleaved PARP relatively in higher levels than those affected by
NBT or ATST alone at full concentration suggesting the involvement of mitochondria in
NBT/ATST combination-induced apoptosis mechanism (Figure 4.28). Moreover, we also
observed that TAN/ATST combination activated caspase-3 as well as cleaved PARP.
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Figure 4.27 Effects of NBT, ATST, and NBT/ATST combination in modulating key signaling
protein playing vital roles in cell cycle progression. Immunoblots displayed the
treatment effects of NBT, ATST, and half dose combination of NBT/ATST on
phosphorylated AKT (Ser473), p21, p27, CDK-2, CDK-4, CDK-6, Cyclin D1, hyperphosphorylated RB, and non phosphorylated RB in (A) H460, (B) H1299, and (C) A549
human NSCLC cells. The numbers underneath of the blots represent band intensity
(normalized to β-actin, means of three independent experiments) measured by Image J
software. The standard deviations (all within ± 15% of the means) were not shown. βactin served as an equal loading control.
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Figure 4.28 Effects of NBT, ATST, and NBT/ATST combination in modulating key signaling
protein regulating apoptosis. Immunoblots displayed the treatment effects of NBT,
ATST, and half dose combination of NBT/ATST on Mcl-1, cleaved caspase-3, and cleaved
PARP in (A) H460, (B) H1299, and (C) A549 human NSCLC cells. The numbers underneath
of the blots represent band intensity (normalized to β-actin, means of three
independent experiments) measured by Image J software. The standard deviations (all
within ± 15% of the means) were not shown. β-actin served as an equal loading control.
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Many proteins orchestrating key proliferation signaling are located in cellular
membrane. Next, we investigated if the growth inhibitory effects of NBT/ATST were
involved with the modulation of membrane-bound proteins. We isolated membrane
fraction and performed immmublotting analysis as previously described in membrane
isolation section 4.2.8. We observed that NBT/ATST combination significantly decreased
the expression levels of phophorylated EGFR (Tyr1068) as well as the expression levels
of total membrane-bound EGFR. Moreover, NBT/ATST combination or ATST individual
treatment diminished the expression levels of membrane-bound RhoA in all three cells,
indicating the involvement of RhoA and EGFR in NBT/ATST growth inhibitory effects. In
addition, NBT treatment did not significantly affected any change on these protein levels
(Figure 4.29).
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Figure 4.29 Treatments of NBT/ATST half-dose combination modulated membranebound proteins in (A) H460, (B) H1299, and (C) A549. Membrane fraction of each cell
line was isolated as previously described in materials and methods section. Western
blots revealed that NBT/ATST half-dose combination decrease the expression of
phosphorylated EGFR (Tyr1068), total EGFR, and RhoA in all three cells. The numbers
underneath of the blots represent band intensity (normalized to β-tubulin, means of
three independent experiments) measured by Image J software. The standard
deviations (all within ± 15% of the means) were not shown. β-tubulin served as an equal
loading control.
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4.3.6 Mevalonate and geranylgeranyl pyrophosphate counteracted the cell
proliferation inhibitory effects induced by ATST and the combination treatment
of NBT and ATST
ATST inhibits HMG-CoA reductase and suppresses mevalonate biosynthesis
which subsequently decreases the synthesis of several downstream isoprenoids such as
farnesyl pyrophosphate (Fpp) and geranylgeranyl pyrophosphate (GGpp). As we found
that NBT/ATST combination treatment decreased the membrane-bound RhoA which is
associated to protein prenylation, we investigated if the growth inhibitory effects of
NBT, ATST, or NBT/ATST combined treatments could be counteracted by replenishing
mevalonate or its different intermediated isoprenoids associated with mevalonate
cascade pathway including Fpp, and GGpp into the serum-completed cell culture media.
We also investigated if cholesterol restoration, by squalene supplementation, could
reverse the growth inhibitory effects.
We used the same treatments and ratios utilized in cell viability assay as
described in section 4.3.1. Interestingly, we found that the growth inhibitory effects of
ATST or NBT/ATST half dose co-treatment were significantly deteriorated after
supplementation of mevalonate, GGpp, or Fpp but in less extent in all H460 (Figure
4.30A), H1299 (Figure 4.30B), and A549 (Figure 4.30C) NSCLC cells. Supplementation of
mevalonate can lead to the increase level of GGpp, but not Fpp since isopentenyl
pyrophosphate, which is not available after mevalonate depletion, is necessity in this
restoration. By exogenously supplementing 100 μM mevalonate to treatments, we
investigated if replenishment of mevalonate could counteract growth inhibitory effects
of NBT/ATST combination. Our results showed that, mevalonate fully prevented the
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effect of NBT/ATST combination on cell growth inhibition in H460 and A549, whereas
partially, yet still significantly, reduced cell death in H1299. In H460, supplementation of
100 μM mevalonate to NBT/ATST combination or ATST reduced the inhibition of cell
viability by 57% (from 32% to 89%), and 45% (from 53% to 98%), respectively. In H1299,
the addition mevalonate to NBT/ATST combination or ATST individual treatment
reversed the inhibitory effects of NBT/ATST combination or ATST treatment by 49%
(from 17% to 66%), and 38% (from 44% to 82%), respectively. In A549, restoration of
mevalonate to NBT/ATST combination treatment or ATST treatment counteracted the
growth inhibitory effects by 82% (from 10% to 92%), and 30% (from 46% to 86%),
respectively. As for GGpp, the growth inhibitory effects of ATST and NBT/ATST were
reversed by the exogenously addition of 2 µM GGpp to completed media in all three
NSCLC cells used. For example, in H460, exogenously addition of GGpp reversed the
growth inhibitory effects of NBT/ATST combination and ATST by 25% (from 32% to 57%),
and 16% (from 52% to 68%), respectively. Likewise in H1299 cells, supplementation of
GGpp reversed the growth inhibitory effects of NBT/ATST combination and ATST by 50%
(from 17% to 67%), and 50% (from 44% to 94%), respectively. As for A549 cells,
supplementation of GGpp to NBT/ATST combination or ATST individual treatment
reduced the inhibition of cell viability by results from those treatments by 50% (from
10% to 60%), and 34% (from 46% to 80%), respectively. Unlike GGpp, we found that the
addition of 2 µM Fpp reversed the growth inhibitory effects of NBT/ATST combination in
A549, but not in H460 and H1299. Exogenously replenishment of Fpp reversed the
growth inhibitory effects of NBT/ATST combination or ATST by 18% (from 10% to 28%),
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and 14% (from 46% to 70%), respectively in A549 cells. In H460, addition of Fpp
counteracted the growth inhibitory effects of ATST by 14% (from 53% to 67%) while the
effects of NBT/ATST were not affected. In addition, supplementation of Fpp did not
cause any significant changes in the effect of NBT/ATST combination or ATST in growth
inhibition in H1299. Moreover, treatments of GGpp, Fpp, and mevalonate alone did not
influence the cell viability compared to the control cells in H460, H1299, and A549. We
also investigated if the reduction of cholesterol caused by played important roles in
inhibiting cell proliferation. Even though both mevalonate and squalene reversed the
cellular cholesterol levels that might be diminished by ATST and the combined
treatment, we found that squalene actually did not restore the growth inhibitory effects
caused by ATST and NBT/ATST treatment in H460 and H1299. Moreover, squalene also
did not counteract the growth inhibitory effect influenced by NBT/ATST co-treatment,
yet even augmented the effects in A549. These results indicated that the reduced levels
of cellular cholesterol were not the major factors that played the crucial roles for cell
survival. Taken together, our results suggested that isoprenoids, GGpp and Fpp, played
pivotal roles for NSCLC cell survival, especially GGpp which its supplementation
counteracted the proliferation inhibitory effects of both NBT/ATST combination and
ATST in all three cells. Taken together, these results indicated that NBT/ATST
combination-induced growth inhibitory effects partially involved GGpp, an isoprenoid of
mevalonate cascade pathway (Figure 4.30).
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Figure 4.30 Effects of mevalonate, farnersyl pyrophosphate (Fpp), geranylgeranyl
pyrophosphate (GGpp), and squalene on cell growth inhibition induced by NBT, ATST,
and half-dose combination of NBT/ATST in (A) H460, (B) H1299, and (C) A549. Cells were
treated with compounds in the absence or presence of mevalonate (100 µM), Fpp (2
µM), GGpp (2 µM), or squalene (200 µM). Supplementation of mevalonate or GGpp
significantly reversed the ATST-induced and NBT/ATST-induced growth inhibition in all 3
cells. Replenishment of Fpp reversed NBT/ATST-induced cell inhibitory effects in A549,
and ATST-induced cell growth inhibition in both H460 and A549. In addition, squalene
did not cause any significant effects in all cells. Data were shown as mean ±SD (n=6), and
viable cells of controls were used as 100%. Data represents mean ± SD. *p < 0.01 (n=6)
by Student’s t-test as compared to untreated group of the same treatment.
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4.3.7 NBT/ATST- induced NSCLC cell inhibitory effects associated with
geranylgeranylation of RhoA and RhoA relocalization
Interaction of RhoA with membrane is dependent on geranylgeranyl residue
attachment to the cysteine of RhoA C-terminal CAAX-box for their localization to
membrane to express specific activities (149). ATST prevented RhoA geranylgeranylation
by inhibiting HMG-CoA reductase leading to the blockage of mevalonate cascade
pathway. From section 3.5 and 3.6, we found that NBT/ATST combination as well as
ATST single treatments reduced the levels of membrane-bound RhoA, and
supplementation of mevalonate or GGpp prevented the growth inhibitory effects of
NBT/ATST combination. We therefore further investigated if replenishment of GGpp
could restore RhoA translocation to membrane in NSCLC cells and if this RhoA
translocation prevented NBT/ATST-induced anti-cancer effects. We isolated membrane
fraction as previously described in materials and methods. We selected H1299 (Figure
6A) and A549 (Figure 6B) as representative cells for this study. Treatments with
NBT/ATST combination or ATST resulted in relocalization of RhoA from membrane to
cytosol indicating that inhibition of HMG-CoA reductase by ATST or NBT/ATST
suppressed RhoA geranylgeranylation. We also found that supplementation of GGpp
restored the expression levels of membrane-bound RhoA in ATST and NBT/ATST
combination treatments while diminishing RhoA expression levels in cytosol suggesting
that ATST or NBT/ATST combination induced RhoA relocalization to cytosol could be
counteracted by exogenously GGpp restoration. As the location of active RhoA
determined its functions, we evaluated if relocalization of RhoA to membrane by
restoration of GGpp could prevent any inhibitory effects caused by NBT/ATST
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combination. We observed that exogenously supplementation of GGpp to NBT/ATST
combination or ATST individual treatment refreshed the expression levels of
phosphorylated EGFR (Tyr1068) , EGFR, phosphorylated of the extracellular-signalregulated kinases (ERKs 1/2 (p44 /p42))(Thr202/Tyr204). Moreover, activation of
cascape-3 and cleavage or PARP induced by NBT/ATST combination was entirely
diminished after GGpp replenishment suggesting that NBT/ATST combination induced
apoptosis associated with geranylgeranylation of RhoA (Figure 4.31).
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Figure 4.31 Relocalization of RhoA involves in ATST-induced and NBT/ATST-induced
apoptosis. H1299 (A) and A549 (B) were treated with NBT, ATST, and half dose
combination of NBT/ATST for 24hr and 48hr at the concentration indicated with or
without the supplementation of 2 µM GGpp. The cytosol and membrane fraction were
prepared as described previously in materials and methods section. The levels of
phosphorylated EGFR (Tyr1068), total membrane-bound EGFR, RhoA, phosphorylated
ERK1/2, cleaved caspase-3 and cleaved PARP were determined by immunoblotting
analysis. β-tubulin and β-actin served as equal loading controls for the membrane and
cytosolic fractions, respectively. The numbers underneath of the blots represent band
intensity (normalized to β-tubulin or β-actin , average of two independent experiments)
measured by Image J software.
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4.3.8 NBT/ATST significantly inhibited A549 lung tumorsphere formation and A549
ALDH-positive cells
Lung CSCs were documented to have the ability to proliferate under serum-free
condition supplemented with epidermal growth factor (EGF) and basic fibroblast growth
factor (bFGF) in the form of tumor spheroid bodies known as “tumorspheres” (34, 37).
A549 were seeded in 24-well low attachment plates and were then incubated for 24 hr.
Cells were then treated, and formed tumorspheres were quantified as described in
section 4.2.9. We found that both individual treatments of NBT at 50 µM and ATST at 25
µM decreased the number of tumorspheres by 39% and 50%, respectively. Strikingly,
no tumorsphere was found in both half-dose combination and full-dose combination of
NBT/ATST indicating the very potent inhibitory effects of NBT/ATST against lung
tumorsphere formation (Figure 4.32).
A cell population with high level of ALDH1 enzyme activity was previously
documented to contain a high number of lung CSCs (34, 160). We used the Aldefluor
assay to quantify the percentage of ALDHbr cells in A549 cell population and a
subpopulation of ALDHbr cells was detected by using flow cytometer following
manufacturer’s instruction. We found that NBT, ATST, and NBT/ATST half-dose
combination significantly decreased A549 ALDHbr cells population by 1.5-fold (from
10.1% to 6.9%), 5.1-fold (from 10.1% to 2.0%), and 14.4-fold (from 10.1% to 0.7%),
respectively (Figure 4.33).
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Figure 4.32 Effects of NBT, ATST, and NBT/ATST combination on A549 lung tumorsphere
formation. Tumorspheres were counted as previously described in section 4.2.9. NBT
and ATST significantly decreased the number of tumorspheres while both half-dose and
full-dose combination of NBT/ATST totally abolished A549 tumorspheres formed. The
left top picture showed the single A549 tumorsphere from control group while the top
right picture depicted 3 distinct differentiated tumorspheres after being cultured in 6well plates for 20 hr. All data were shown as mean ± SD, and the asterisk in the bar
charts indicated statistical significance of NBT/ATST half-dose combination and full-dose
combination treated groups in comparison with the control, NBT-, and ATST- treated
groups at full concentrations based on ANOVA followed by Tukey's HSD post-hoc test (p
< 0.01, n = 3).
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Figure 4.33 Effects of NBT, ATST, and half-dose combination of NBT/ATST on A549
ALDHbr cell population. A549 were seed in 10 cm culture dishes for 24 hr, and then were
treated with NBT, ATST, and NBT/ATST combination at half concentration of each agent.
After another 24 hr, cell were collected and subjected to Aldefluor assay using Aldefluor
assay kit. The experiment was conducted by following manufacturer’s instruction.
Diethylaminobenzaldehyde (DEAB) was used as ALDH inhibitor. All data were shown as
mean ± SD, and the * (p < 0.05, n=3), ** (p < 0.01, n=3) in the bar charts indicated
statistical significance of treated groups in comparison with the control based on
ANOVA followed by Dunnett’s post-hoc test.
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4.4 Discussion
In this chapter, we showed that NBT/ATST and TAN/ATST produced synergistic
effects in inhibiting NSCLC cells growth by inducing G0/G1 cell cycle arrest and
apoptosis. In NBT/ATST combined treatment, we also found that these inhibitory
activities involving the EGFR/ERK/RhoA by inhibiting cytosol-to-membrane translocation
of RhoA. NBT and TAN are two of the most abundant polymethoxyflavones found in the
peel of sweet oranges (53, 56). Although we did not find any profound anti-proliferative
effects of NBT or TAN, they were showed to exhibit protective activities against
carcinogenesis by many mechanisms. Morley et al reported that both TAN and NBT
caused G1 cell cycle arrest but not apoptosis in human colon and breast cancer cells at
high concentrations (12). Besides breast and colon cancer cells, NBT was found to
selectively inhibit the growth of mouse and human HL-60 leukemia cells but not the
growth of normal cells (161). NBT also was observed to suppress cell adhesion, invasion,
and migration abilities of human gastric adenocarcinoma AGS cells at low concentration
(2 µM) (162). NBT was also found to exert anti-angiogenesis activities in both live
transgenic zebrafish and human umbilical vein endothelial cells (163). However, NBT
treatments in our previous (14) and present studies at high concentrations (> 30 µM) did
not cause any significant change in cell proliferation, cell cycle distribution, and
apoptosis in all 3 human NSCLC cells suggesting that the cytostatic activities of NBT
could be cell-type specific.
According to the results obtained from cell viability assays and by utilizing Chou
and Talalay’s combination index isobologram analysis for two-drug interaction to
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calculate synergistic actions between two agents (157), we demonstrated that both NBT
and atorvastatin (commercially sold as Lipitor® or Torvast®, ATST) and TAN and ATST
synergistically inhibited human NSCLC cell proliferation as our results obtained from
isobologram analysis displayed that NBT/ATST combination showed strong synergy on
proliferative inhibition of human NSCLC; the calculated interaction index of all dose
pairs of NBT/ATST combination were below 1 in all 3 human NSCLC cell lines used in this
study. We also further observed that both NBT/ATST combination and TAN/ATST
combination at half concentration of each agent, when compared to the individual
compound at full concentration, significantly induced human NSCLC cell cycle arrest in
G0/G1 phase and these effects caused by combined treatments were stronger than
those caused by NBT, TAN, or ATST individual treatment at full concentration.
Furthermore, prolonged treatments of both NBT/ATST and TAN/ATST half-dose
combination extensively induced cellular apoptosis which was also significantly stronger
than those caused by each individual treatment at its full concentration. Overall, the
potent synergy between NBT/ATST and TAN/ATST on cell cycle arrest and cellular
apoptosis is of great magnitude for promising augment of chemoprevention and/or
chemotherapy efficacy by these unique combinations in humans for NSCLC.
Statins are HMG-CoA reductase, the rate-limiting enzyme in cholesterol
biosynthesis pathway, inhibitors. The inhibition of HMG-CoA reductase in turn results in
the reduced level of mevalonate and the formation of its downstream products
including ubiquinone, cholesterol, dolichol and most importantly, the lipid isopreniods
such as farnesyl pyrophosphate (Fpp) and geranylgeranyl pyrophosphate (GGpp) which
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both of them play the crucial roles in post-translational modification of membrane
related proteins related to cell proliferation such as Ras and Rho proteins. Both Fpp and
GGpp prenylate proteins and help facilitate protein translocation from cytosol to
membrane. They also regulate and promote protein-protein, and protein-membrane
interactions and functions (95). The subsequent production of both GGpp and Fpp could
be suppressed by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase activity. Although Fpp is the immediate precursor of GGpp, the addition of
Fpp into the system with statins typically does not restore GGpp and turn around statins
actions including their growth inhibitory effects because isopentenyl pyrophosphate,
which is the upstream process prior to Fpp synthesis is already depleted by blocking
HMG-CoA reductase caused from statins’ activity, is required in order to synthesize
GGpp from Fpp. Therefore, isopentenyl pyrophosphate is not available for converting
Fpp into GGpp and hence, GGpp cannot be restored by adding Fpp, but can be refreshed
by adding mevalonate which sits at the apex of the pathway (164). Post-translational
prenylation by Fpp (farnesylation) or GGpp (geranylgeranylation) is a critical step that
helps anchor the small G-proteins, such as Rho and Ras families, to membrane in order
to perform their functions. Rho proteins such as RhoA could be prenylated by GGpp but
not Fpp (147). Our results from cell viability assay displayed that exogenously addition
of mevalonate, GGpp, or Fpp but in very less extent, significantly counteracted the
growth inhibitory effects of the NBT/ATST combined treatments in all H460, H1299, and
A549 human NSCLC cells. One implication from these results was protein
geranylgeranylation was more critical than protein farnesylation in terms of cell
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proliferation and survival, strengthening the vital involvement of geranylgeranylated
proteins such as RhoA in NSCLC cells growth and survival. Moreover, the cell growth
inhibition caused by NBT/ATST combination was not counteracted by addition of
squalene, indicating that the decreased cellular cholesterol levels, at least in part, did
not play a significant role for cell survival in H460, H1299, and A549 human NSCLC cells.
Protein prenylation is required for proper intracellular localization and function
of regulatory GTPases including RhoA which is documented to influence many cell cycle
regulators. By inhibiting the production of isoprenoids, ATST or NBT/ATST combination
inhibited the geranylgeranylated modification of RhoA, sequestering RhoA in cytosol
and led to the decrease levels of active RhoA in membrane. From western blot analysis,
we observed the significant decreased in RhoA expression levels by half dose combined
treatments of NBT/ATST in all three NSCLC cells in the membrane which is the main
location of RhoA to properly function. In multiple human cancers including lung cancer,
the levels of RhoA has been found elevated and RhoA was also reported to associate
with cell cycle progression as well as driving tumorigenesis and metastasis (95, 165). In
lung cancer malignancy, numerous pathways are dysfunction. Among those, the critical
pathways involve the uncontrollable cell cycle regulation and apoptosis. We found that
NBT/ATST half dose combination significantly induced G0/G1 cell cycle arrest and
extensive cellular apoptosis by modulating key signaling proteins relating in those
events. By suppressing transcription of p21Cip1/Waf1, RhoA was documented to repress
the protein level of p21Cip1/Waf1 which is one of the CDK inhibitors possibly through
influencing phosphorylation of SP1 transcription factors (104, 166). In addition, increase
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in G0/G1 cell cycle arrest and increase in expression of p21Cip1/Waf1 could result from
inhibition of protein geranylgeranylation via p53-independent mechanism (167).
Moreover, it has also been reported that RhoA downregulated protein level of p27 Kip1, a
negative regulator of cell growth, by decreasing the p27Kip1 mRNA transcriptional
efficiency and elevating p27Kip1 degradation (168, 169). Evidence showed that RhoA can
upregulate Cyclin D1 protein expression levels (95, 169, 170). Not only playing a key part
in cell cycle progression (134), cyclin D1 was also reported to significantly influence both
tumor proliferation and metastasis of NSCLC cells (171). Our results showed that
NBT/ATST combined treatment at half concentration of each agent significantly
decreased the expression levels of RhoA in the membrane which was the location of
RhoA for its signaling transduction. Also, we found that half dose combination of
NBT/ATST significantly increased the expression levels of p21Cip1/Waf1 and p27Kip1
whereas decreased the expression levels of cyclin D1 in all three cell lines. Furthermore,
we also observed that NBT/ATST half dose combination significantly decreased the
expression level of CDK-2, CDK-4, and CDK-6, and hyper phosphorylated retinoblastoma
protein which eventually leads to potentiate cell in G0/G1 cell cycle arrest. Taken
altogether, it was likely that the depletion of GGpp by NBT/ATST combination inhibited
RhoA function on the membrane which led to the blockage of cells in G1/S transition
and ultimately resulted in cell cycle arrest at G0/G1 phase.
In NSCLC specimens, immunohistochemical analysis revealed that activated AKT
was associated with induced malignancy and shortened survival rate (172). Also,
activated RhoA was report to activate PI3K/AKT (173). In our study, we observed that
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ATST individual treatment (24 hr) did not significantly inhibit the activation
(phosphorylation) of AKT at full concentration in H460 and A549 NSCLC cells while the
decreased activation levels of AKT was observed in H1299. In addition, individual
treatment of NBT at full concentration did not cause any significant change in
phosphorylated AKT. However, half dose combination of NBT/ATST significantly
inhibited the phosphorylation of AKT in all 3 NSCLC cells. These results indicated that
decrease in AKT activation involved in growth inhibitory effects of NBT/ATST
combination
RhoA inactivation was documented to associate with apoptosis induction (110).
We also observed that half dose combined treatment of NBT/ATST significantly induced
apoptosis through by activating caspase-3 and PARP in all three NSCLC cell lines. We also
suggested that mitochondria were implicated in this NBT/ATST combination- induced
apoptosis signaling as we observed the expression levels of anti-apoptotic Mcl-1 were
decreased in all 3 cells. As H1299 is p53-null while H460 and A549 are p53-wild type,
this indicates that the NBT/ATST combination may trigger cellular apoptosis partially via
p53-independent pathway.
We found that NBT/ATST treatment sequestered RhoA in cytosol and addition of
GGpp led to the increase membrane-bound RhoA as well as counteracting the activation
of EGFR and ERK1/2 induced by NBT/ATST combination treatment, indicating that
geranylgeranylation of small G proteins including RhoA played a pivotal role in cell
survival. Only Rho, Rac, and Cdc42 are subjected to geranylgeranylation (174),
therefore; it is interesting to study if Rac or Cdc42 plays roles in NBT/ATST-induced
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NSCLC cells inhibitory effects. Enhanced expression levels of EGFR-ERK are associated
with cancerous growth including lung tumorigenesis (175). RhoA was documented as a
negative regulator of EGFR endocytosis via its effector Rho kinase (ROCK) to endophilina
A1-mediated crosstalk, and activated RhoA was found to result in increased ERK
activation based on the molecular modeling (176). Moreover, RhoA was also reported to
be involved in inhibiting EGFR dimerization (177). Our results were in accordance to
those findings as replenishment of GGpp brought back both phosphorylation of EGFR
and ERK1/2 activation. We also observed that restoration of protein geranylgeranylation
via GGpp preincubation significantly prevented NBT/ATST combination or ATST induced
caspase-3 activation and cleavage or PARP indicating that the defective isoprenylation
of RhoA induced by NBT/ATST combination might be crucial and sufficient to trigger
apoptosis in NSCLC cells. Even though our results suggested a key role of RhoA in
orchestrating NSCLC cells survival and proliferation, other geranylgeranylated proteins
might also associated, and this warranted further investigation.
Several studies have also reported the potential enhancement of lung cancer
inhibition by using ATST in combination with pharmacological or dietary compounds in
vivo. Pereira et al. demonstrated that the combined treatment of ATST and
suberoylanilide hydroxamic acid (SAHA) potently reduced the multiplicity of lung tumors
induced by vinyl carbamate in A/J mice while treatment of ATST alone did not.
Moreover, the combination also inhibited lung tumor induced by 4(methylnirtrosamino)-1-(3-pyridyl)-1-butanol (NNK) in strain A/J mice model with the
great efficacy while the treatment of ATST alone did not cause any significant change.
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Furthermore, combination of SAHA and ATST also decreased the multiplicity of lung
tumors induced by 1,2-dimethylhydrazine in Swiss-Webster mice while ATST alone did
not (25). Chen et al also demonstrated that the combination of ATST and interferon-γ
resulted in a synergistic inhibition of both in vitro (H358 and H596 NSCLC growth) and in
vivo (H358 and H596 xenograft study) (24). Lu et al. also found that combined
treatment of atorvastatin and polyphenon E synergistically reduced both tumor
multiplicity and tumor burden in NNK induced female A/J mice model (22).
Even though the concentrations for NBT or TAN used in our study were relatively
high, reports showed that NBT or TAN concentrations used in our study were actually
comparable to the achievable levels in vivo. For instance, Kurowska et al. reported that
the levels of TAN in serum reached 21 µM and were in between the range of 16-67 µM
intact TAN in liver in hamsters fed with 1% TAN, TAN/NBT or polymethoxylated flavones
diet for 35 days (16). The highest concentrations of TAN used in combination in our
study were 18, 15, and 24 µM in H460, H1299, and A549 cells, respectively. Therefore,
they were still in the range that can be reachable in vivo. Moreover, a recent study by
Manley et al. indicated that nobiletin indeed was more bioavailable than tangeretin.
Moreover, in their animal study, NBT showed nearly 10-fold high absorption than that of
TAN when being gavaged at identical oral doses (75). In our experiments, the highest
concentrations of NBT used in combination were 24, 15, and 25 µM in H460, H1299, and
A549 cells, respectively which significantly induced both cell cycle arrest at G0/G1 stage
and extensive cellular apoptosis. Indeed, the highest concentration of NBT in NBT/ATST
combined treatment that induced the significant inhibitory effects was 25 µM in A549
143

cells which was considered to be one of resistant lung cancer cells. Actually, both cell
cycle arrest at G0/G1 stage and apoptosis were induced by much lower combinations
treatments (15 µM NBT + 1 µM ATST) in H1299 cells. Therefore, our concentrations
utilized herein were still within that bioavailable range which could be achievable in
vivo. Even though the ATST concentrations utilized in our combination experiments
were higher than the concentration observed in human plasma after administrating
clinical doses of ATST, we believe that the strong synergy observed between NBT/ATST
or TAN/ATST is of important physiological relevance. This is because the effective drug
concentrations used in cell culture studies are typically higher than those observed in
plasma of animals or humans after being administrated (178), and this is probably
because of the shorter exposure time in cell culture system compared to those in clinics.
Metabolites of dietary components could also exert their biological effects, and
are of importance to investigate their mode of actions. NBT or TAN will be undergone
extensive biotransformation after being absorbed into our body. Studies reported that
NBT could be converted to 3´-demethylnobiletin (74), 4´-demethylnobiletin (179), and
3´,4´-didemethylnobiletin (180). Also, TAN could be transformed to 4´-hydroxy-5,6,7,8tetramethoxyflavone (28). Reports also indicated that metabolites of NBT and TAN were
able to promote superior biological activities than those of NBT produced (28, 180).
Therefore; it is interesting to study if metabolites of NBT were able to synergize with
ATST to produce the greater anticancer effects on NSCLC.
Evidence has indicated that tumors comprised of heterogenous population of
cells and tumor progression is only driven by a subpopulation of tumor-initiating cells.
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Cancer stem cells theory states that cancers are maintained by small subpopulation of
tumor cells that possess stem cell and progenitor characteristic. CSCs, also referred as
tumor-initiating cells, refer to a small subset of undifferentiated tumorigenic cells that
have the ability to self-renew and have to capacity to produce diverse population of
cells that constitute a tumor (30, 33, 181, 182). ALDH activity has been involved in
various biochemical pathways and has been utilized to identify potential CSCs including
lung CSCs since ALDH has been recognized to be highly expressed in hematopoietic and
neural stem cells (35, 183). Lung tumorsphere was documented to be used as a model
to study lung CSCs (37). Our results displayed that both A549 lung tumorsphere
formation and A549 ALDHbr cell population was significantly decreased by treatment of
NBT or ATST treatments. These lung CSCs inhibitory effects were even stronger in
NBT/ATST treatments suggesting the promising lung cancer inhibitory properties of
NBT/ATST combination since both normal bulk populations of NSCLC cells as well as lung
CSCs could be inhibited by this unique combined treatment.
In conclusion, we demonstrated that combined treatments of NBT/ASTST
potently inhibited human NSCLC cells growth. Moreover, we also computed the
interaction index plots based on modified Chou and Talalay’s method to illustrate that
the effects produced herein were synergistic. We also showed that the both NBT/ATST
potentiated NSCLC cells at G0/G1 stage and induced apoptosis partially through
mitochondria-mediated pathway and these effects were related to defective protein
prenylation, specifically geranylgeranylation. We identified RhoA as one of the key
players involving in NBT/ATST-induced inhibitory effects in NSCLC cells. Overall, our
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results demonstrated that the combined treatment of NBT and ATST synergistically
produced a very strong and significant growth inhibition of human NSCLC cells at a
relatively low concentration of each individual compound which might help diminishing
the adverse side-effects that might occur from ATST. Our results also indicated that
treatment NBT/ATST combination could be utilized for combating lung CSCs. We also
anticipate that our results will encourage further investigations on the uses of drugs
combination strategy in cancer chemoprevention and chemotherapy.
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CHAPTER 5
ANTI-PROLIFERATIVE EFFECTS OF METABOLITES OF POLYMETHOXYFLAVONES ON
HUMAN NON-SMALL CELL LUNG CANCER CELLS

5.1 Introduction
Epidemiological studies have suggested that certain dietary bioactive agents
derived from fruits and vegetables may prevent disease and promote human health (6).
Orange peels have been utilized as traditional remedy for alleviating many diseases
including stomach upset, and skin inflammation. Chemoprevention has been shown to
be a promising cancer preventive strategy to suppress, delay, or reverse the risk of
human carcinogenesis (5). Almost exclusively found in orange peels,
polymethoxyflavones (PMFs) have been documented to exhibit a broad spectrum of
health-promoting properties including anti-carcinogenic, anti-inflammatory, antimicrobial, anti-diabetics, and anti-tumor metastasis actions (54). Besides exhibiting
direct biological effects, flavonoids including PMFs were also documented to act as proanticarcinogen, which are become active after being converted by selectively
cytochrome P450 1- dependent conversion (27). Nobiletin (NBT) is one of the most
abundant polymethoxyflavones (54). We previously isolated in 5-demethylated
polymethoxyflavones (53) and demonstrated the anti-carcinogenic properties of
including 5-demethylnobiletin (5-hydroxy-6,7,8,4´-tetramethoxyflavone, 5DN) in lung
(14)and colon cancer(13), and 5-demethyltangeretin (5DT) in lung and colon (13) cancer
in inducing extensive cell cycle arrest and apoptosis.
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Biotransformation dictates the fate of biological properties of bioactive
compounds (184). Once absorbed human bodies, PMFs are undergone various
biotransformations leading to the structural changes or breakdown of compounds that
may influence their biological actions. Therefore, it is noteworthy to investigate if the
metabolites of PMFs are also capable to exert anticancer effects. Recently, the
metabolites of PMFs have been identified and studied for their health promotion
actions. For example, 3´-demethylnobiletin (74), 4´-demethylnobiletin (179), and 3´,4´didemethynobiletin(180) were reported as major metabolites from nobiletin. 4´hydroxy-5,6,7,8-tetramethoxyflavone was also reported as one of the metabolites of
tangeretin (28). Several studies reported that the didemethylated metabolites of
nobiletin were found to exert stronger biological activities than those produced by
nobiletin. 3´,4´-didemethynobiletin was documented to exhibit stronger antitumorigenesis (10), anti-inflammatory (9),and antioxidant (29) than those from its
parental compound, nobiletin. We recently isolated and identified three different
demethylated metabolites of 5DN from mouse urine namely 5,4´ -didemethylnobiletin
(5,4´dihydroxy-6,7,8,3´-tetramethoxyflavone, M1), 5, 3´,4´- tridemethylnobiletin (5,
3´,4´- trihydroxy-6,7,8-trimethoxyflavone, M2) ,and 5, 3´-didemethylnobiletin (5, 3´dihydroxy-6,7,8,4´-tetramethoxyflavone, M3), by high liquid chromatography. We also
found that these 5DN’s metabolites produced stronger growth inhibitory effects than
their parental compound, 5DN, against human colon cancer cells (185).
Lung cancer is the top cause of cancer-related mortality in both men and women
globally, with a poor 5 year survival rate that remains stable at 16%. Non-small cell lung
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cancer (NSCLC) is responsible for more than 80% of all lung carcinoma cases (127).
Therefore, the evaluation of the potent agents for combating this disease is critically
needed. In order to fully understand the potential scope of biological actions in
inhibiting human NSCLC cells of 5DN, we investigate the growth inhibitory effects of
5DN and their mode of actions. Herein, we proposed that 5DN’s metabolites had
superior anti-cancer activities than their parental compound, 5DN, in inhibiting human
NSCLC cells.

5.2 Materials and methods
5.2.1 Cell cultures and treatments
H460, H1299, and A549 human NSCLC cell lines were obtained from American
Type Cell Collection (ATCC, Manassas, VA, USA), and maintained in RPMI 1640 media
(Mediatech, Herndon, VA, USA) supplemented with 5% heat-inactivated FBS and
100U/ml of penicillin and 0.1mg/ml of streptomycin at 37oC with 5% CO2 and 95% air.
Cells were kept sub-confluent and media were changed every 3-4 days. All cells used in
experiments were between 4 and 25 passages. NBT, 5DN, M1, M2, and M3 (Figure 1)
were chemically synthesized and identified as previously described (185). DMSO was
used as a vehicle to deliver all treatments to the cells. The final concentration of DMSO
in all experiments was 0.1% v/v in cell culture media.
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Figure 5.1 Chemical structures of nobiletin (NBT), 5-demethylnobiletin (5DN), and 5DN’s
metabolites (M1, M2, and M3)

5.2.2 Cell viability assay
H460 or H1299 (2,000 cells/well) cells were seeded in 96-well plates. After 24
hrs, cells were treated with serial concentrations of treatments in 200 µL of complete
media. After reached desired treatment times, the media were replaced with 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich)-containing
medium for viability test as we previously reported (129).

5.2.3 Colony formation assay
H460 (750 cells/well) cells were seeded in 6-well plates. At 24 hrs, cells were
treated with treatments in 2 mL of serum complete media. The media were refreshed
every 4 days. After 12 days of incubation, media were discarded. Colonies were washed
with PBS, and then were stained with 0.2% crystal violet for 10 minutes. After being
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washed with double distilled water until no residual dye remained, plates were scanned
with a high resolution scanner (HP Inc.) and H460 colonies formed were quantified.

5.2.4 Flow cytometric analysis of cell cycle distribution and apoptosis
H460 or H1299 (5x104 cells/well) were seeded in 6-well plates. After 24 hrs of
incubation for cell attachment, cells were treated with treatments in 2 mL of serum
complete media. Media containing any floating cells were harvested and combined with
adherent cells that were detached by brief trypsinization (0.25% trypsin-EDTA;
Mediatech). Cell pellets were washed with 1 mL of ice-cold PBS then were subjected to
cell cycle and apoptosis analysis as we described previously (14).

5.2.5 Immunoblotting
Whole Cell lysate were prepared as previously described (14). Cells were seeded
in 10 cm culture dishes. After 24 hrs of incubation, cells were treated with 5DN, M1, M2,
and M3. After another 24 or 48 hrs of incubation, cells were washed with ice-cold PBS,
and collected with cell-scrapers. Cells were combined with floating cells, if any, and
subject to western blotting analysis as we previously described (14). Antibodies for Bax,
p21Cip1/Waf1, p53, CDK-4, CDK-6, Cdc-2(CDK-1), cyclin D1, cyclin B1, cleaved caspase-3
(Asp175), and poly ADP ribose polymerase (PARP) were obtained from Cell Signaling
Technology (Beverly, MA, USA). β-Actin (purchased from Sigma-Aldrich) was used as a
loading control.
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5.2.6 Lung tumorsphere formation assay
A549 human NSCLC cells were trypsinized from the petri-dished, washed twice
with PBS, and were then resuspended in serum-free Dulbecco modified Eagle medium:
Nutrient mixture F-12 (DMEM-F12)(Gibco) supplemented with 1x B27 (Invitrogen), 20
ng/mL epidermal growth factor (EGF) (Sigma), 20 ng/mL basic fibroblast growth factor
(bFGF) (Sigma), and /ml of penicillin and 0.1mg/ml of streptomycin (Cellgro). Cells were
then passed through sterile cell strainer (40 μm) in order to acquire single cell
suspension. The A549 single cell suspension then were seeded in 24-well ultra low
attachment plate (5000 cell/well) (Corning) in DMEM-F12 supplemented with 1x B27, 20
ng/mL epidermal growth factor (EGF), 20 ng/mL basic fibroblast growth factor (bFGF),
and /ml of penicillin and 0.1mg/ml of streptomycin. After 24h, treatments were directly
added into the well, and cells were then incubated for 14 days. Tumorspheres were
gently collected with cell strainers, washed with PBS, and then transferred into 6-well
plates that contained RPMI 1640 media supplemented with 5% heat-inactivated FBS and
100U/ml of penicillin and 0.1mg/ml of streptomycin to allow cell attachment and
differentiation. After 20 hr incubation, tumorsphere were counted. A colony that had
cells less than 60 cells was discarded from the count.

5.2.7 Statistical analysis
All data were presented as mean ± SD. Analyses of variance (ANOVA) model was
used to compare the differences among more than two groups followed by a post-hoc
test for multiple comparisons (Dunnett’s test or The Tukey’s Range Honesty Significant
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Difference test as described in figure legends). A 1% significant level was used for all
tests.

5.3 Results
5.3.1 Metabolites of 5DN inhibited growth of NSCLC cells stronger than those
produced by 5DN.
H460 and H1299 NSCLC cells were treated with serial concentrations of NBT (10
– 50 μM), 5DT (3 – 15 μM), M1 (2– 10 μM in H460, and 1 – 5 μM in H1299), M2 (2– 10
μM in H460, and 1 – 5 μM in H1299), and M3 (0.2– 1 μM in H460, and 0.1 –0. 5 μM in
H1299) (Figure 5.2). All treatments showed significant inhibitory effects on all two
genetically different NSCLC cells. 5DN exerted stronger NSCLC growth inhibition than
NBT. At the highest concentration tested (15 μM), 5DN inhibited cell growth by 72% and
51% on H460, and H1299, respectively, after 72 hrs of treatments. Moreover,
metabolites of 5DN even showed more potent proliferation inhibitory effects than those
produced by their parental compound, 5DN. At lower concentrations, M1, M2, and
especially M3 showed much more potent growth inhibition on both NSCLC cells in a
dose-dependent fashion in comparison with their parental compound, 5DN. At 10 μM,
treatments with M1 or M2 for 72 hrs inhibited cell growth by 68% and 90% on H460,
and 70% and 69% on H1299 cells, respectively. Markedly, M3 demonstrated the
strongest growth inhibitory effects in which treatment with M3 at 1 μM and 0.5 μM
inhibited cell proliferation by 85% and 84% in H460, and H1299, respectively. The IC50
values of 5DN, M1, M2, and M3 after 72 hrs of treatment were 12.2 μM, 7.0 μM, 3.8
μM, and 0.46 μM in H460 cells, respectively. Similarly, the IC50 values of 5DN, M1, M2,
153

and M3 after 72 hrs of treatment were and 12.2 μM, 3.3 μM, 2.7 μM, and 0.25 μM in
H1299 cells, respectively. It is noteworthy to mention that the 72 hr IC50 values of M3
were 26.5-fold and 48.8-fold lower than those of 5DN in H460, H1299 cells, respectively.

Figure 5.2 The growth inhibitory effects of NBT, 5DN, and 5DN’s metabolites (M1, M2,
and M3) on H460 and H1299 human NSCLC cells. Cells were treated with serial
concentrations of different PMFs for 72 hr. The growth inhibition was measured by MTT
assay as described in section 5.2.2. 5DN produced stronger growth inhibitory effects
than NBT. All metabolites of 5DN showed superior growth inhibitory effects in
comparison to their parental compound 5DN. Data represent mean  SD (n =6), “a”
showed significant difference between treatments at different concentrations to NBT at
the highest concentration (50 µM) (p < 0.01). “b” showed significant difference between
metabolites of 5DN at different concentrations to 5DN at 12 µM (p < 0.01).
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Figure 5.3 IC50 concentrations of NBT, 5DN, and 5DN’s metabolites (M1, M2, and M3) in
H460 and H1299 human NSCLC cells.

5.3.2 Metabolites of 5DN significantly inhibited NSCLC colony formation.
To further determine the difference between the effects of 5DN and its
metabolites on the growth of human NSCLC cells, we conducted colony formation assay
on H460 cells. H460 cells were subjected to the treatments with NBT (50 μM), 5DN (10
μM), M1 (5 μM), M2 (5 μM), and M3 (0.5 μM). NBT or 5DN did not significantly decrease
the capability of cancer cells to form colonies (Figure 5.3). Conversely, M1, M2, and M3
at lower concentration exerted stronger inhibitory effects on H460 colony formation
than those produced by NBT or 5HN. For instance, M1 or M2 at 5 μM, inhibited the
colony formation by 34% and 77%, respectively. Strikingly, treatment of M3 at only 0.5
μM completely abolished all H460 colony formed. Overall, our results indicated the
stronger anti-proliferative effects of 5DN’s metabolites than 5DN on human NSCLC cells.
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Figure 5.4 Metabolites of 5DN potently inhibited colony formation of human H460
NSCLC cells. Cells were seeded into 6-well plates. After 24 hrs of incubation, cells were
subjected to treatments with NBT, 5DN, M1, M2, and M3 at the indicated
concentrations. After 12 days of incubation, the numbers of colonies formed was
photographed and counted as described in the methods. Data represent mean  SD (n
=3), and the * showed significant difference in comparison with the control group based
on Student’s t-test (p<0.01). The ** showed significant difference in comparison with
control, NBT-, and 5DN- treated groups based on ANOVA followed by Tukey's HSD posthoc test (p < 0.01).
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5.3.3 Metabolites of 5DN significantly induced cell cycle arrest
To demonstrate that the growth inhibitory activities of 5DN’s metabolites were
stronger than their parental compound, 5DN, and elucidate molecular mechanisms
governed these effects in NSCLC cells, we studied NSCLC cell cycle after being treated by
NBT, 5DN, and 5DN’s metabolites. Our results demonstrated that NBT or 5DN did not
cause significant changes in cell cycle distribution of three NSCLC cells in comparison to
the control cells in both H460 and H1299. Conversely, M1, caused significant
accumulation of cells in G0/G1 phase while treatment of M2 (at the same concentration
of 5DN) at and treatment of M3 (at 10-fold lower concentration comparing to 5DN in
the same cell line) potentiated cells in G2/M phase in both H460 (Figure 5.5) and H1299
(Figure 5.6) NSCLC cells . Treatments of M1 induced G0/G1 cell cycle arrest by 1.4-fold
and 1.5-fold compared to the control group in H460, and H1299 cells, respectively.
Furthermore, treatments of M2 accumulated cells in G2/M phase by 2.3-fold, and 5.4fold in H460, respectively. Markedly, treatment of M3 at 10-fold lower concentration of
5DN induced cell cycle arrest in G2/M phase and 4.3-fold and 4.4-fold in H1299 cells,
respectively.
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Figure 5.5 Effects of metabolites of 5DN cell cycle arrest in H460 human NSCLC cells.
H460 cells were treated in 6-well plates for 24 hr before cell cycle analyses by using flow
cytometer. Our results showed that M3 at 10-fold lower concentration than 5DN and
M2 caused G2/M cell cycle arrest while M1 potentiated cell at G0/G1 phase. In addition,
NBT at the concentration 50-fold higher than M3 and 5DN did not cause any significant
changes. All data represent mean ± SD, and the asterisk in the bar charts indicated
statistical significance of metabolites of 5DN treated group in comparison with the
control, TAN-, and ATST- treated group at full concentrations based on ANOVA followed
by Tukey's HSD post-hoc test (p < 0.01, n = 3).
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Figure 5.6 Effects of metabolites of 5DN cell cycle arrest in H1299 human NSCLC cells.
H1299 cells were treated in 6-well plates for 24 hr before cell cycle analyses by using
flow cytometer. Our results showed that M3 at 10-fold lower concentration than 5DN
and M2 caused G2/M cell cycle arrest while M1 potentiated cell at G0/G1 phase. In
addition, NBT at the concentration 50-fold higher than M3 and 5DN did not cause any
significant changes. All data represent mean ± SD, and the asterisk in the bar charts
indicated statistical significance of metabolites of 5DN treated group in comparison with
the control, TAN-, and ATST- treated group at full concentrations based on ANOVA
followed by Tukey's HSD post-hoc test (p < 0.01, n = 3).
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5.3.4 Metabolites of 5DN potently induced cellular apoptosis
Triggering apoptosis is one of the strategies in cancer chemoprevention. We
investigated the effects of 5DN’s metabolites on cellular apoptosis of NSCLC cells, and
compared them with those produced by 5DN or NBT. After 48 hrs of treatments, early
and late apoptotic cells were quantified by flow cytometry method with Annexin
V/Propidium Iodine (PI) double staining assay. As shown in figure 5.7, profoundly
cellular apoptosis was induced in both H460 and H1299 NSCLC cells by treatments of M1
or M2 at that same concentration as 5DN, and by treatment of M3 at the concentration
of 10-fold lower than those in same cell line. In H460 cells, M1 at 10 µM, M2 at 10 µM,
and M3 at only 1 µM increased early apoptotic cell population by 2.8-fold (from 3.0% to
8.5%), 6.1-fold (from 3.0% to 18.2%), and 12.0-fold (from 3.0% to 35.9%) compared to
the control, respectively. In H1299 cells, M1 at 5 µM, M2 at 5 µM, and M3 at only 0.5
µM increased early apoptotic cell population by 5.2-fold (from 1.7% to 8.8%), 15.1-fold
(from 1.7% to 25.7%), and 18.7-fold (from 1.7% to 31.8%) compared to the control,
respectively. Moreover, treatment of M2 and M3 also significantly increased late
apoptotic cells in H1299 by 5.7-fold (from 2.7% to 15.3%), 6.4-fold (from 2.7% to 17.4%).
In contrast, NBT at 50 µM or 5DN (at 10 µM in H460 and 5 µM in H1299) did not cause
any significant change in both early and land apoptotic cell population in H460 or H1299
NSCLC cells indicating the stronger activities of 5DN’s metabolites in stimulating H460
and H1299 NSCLC cells apoptosis.
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Figure5.7 Effects of NBT, 5DN, and 5DN’s metabolites on cellular apoptosis in H460 (A)
and H1299 (B) human NSCLC cells. Cells were treated for 48 hr and then were subjected
to flow cytometry analysis after Annexin-V/PI co-staining as described in section 5.2.5.
Top graphs demonstrated the quantification of % early and % late apoptotic cells in
H460 (A) and H1299 (B). The bottom pictures displayed the dot plot corresponded to
the indicated treatments. In both cell lines, M1 and M2 caused significant induction in
early apoptosis. Markedly, M3, at 10-fold concentration lower than 5DN and 50-fold
concentration lower than NBT, induced extensive cellular apoptosis while NBT or 5DN
did not caused any significant change.
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5.3.5 NBT, 5DN, and 5DN metabolites significantly inhibited A549 human lung
tumorsphere formation
Accumulating evidence has supported that cancer stem cells (CSCs) are initiators
of the occurrence, progression, and recurrence of malignant tumors (186). The ability to
form tumor spheroid bodies under serum-free condition is one of the stem cell and CSCs
properties (33, 182). Lung CSCs were reported to have the capacity to survive under
serum-free condition containing epidermal growth factor (EGF) and basic fibroblast
growth factor (FGF) and proliferate as cellular clusters known as “tumorspheres” (37,
38). We investigated if lung tumorspheres could be inhibited by treatments of NBT,
5DN, or 5DN’s metabolites. Human A549 NSCLC cells were seeded in 24-well ultra-low
attachment plates in the stem cell selective media and treated with PMFs for 12 days,
and the number of tumorspheres in each treatment was quantified as we previously
described in section 5.2.6. We found that all PMFs treatments significantly suppressed
A549 lung tumorsphere formation comparing to control group. NBT at 50 μM inhibited
tumorsphere formations by 50%, while 5DN at 10 μM decreased the number of
formation of A549 tumorspheres by 63%. M3 at the concentration of 2-fold lower than
5DN (5 μM), by far, exhibited the strongest A549 tumorsphere inhibition among all
PMFs tested in which 81% of A549 tumorsphere formation were suppressed (Figure
5.8). Overall, our results showed that treatment PMFs were able to suppress
tumorsphere formation indicating the ability of PMFs to inhibit lung cancer stem cells
growth.
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Figure 5.8 Effects of NBT, 5DN, and 5DN’s metabolites on A549 lung tumorsphere
formation. A549 cells were treated with PMFs in 24-well ultra-low attachment plates in
selective media as we previously explained in section 4.2.6. All PMFs treatments
diminished the number of A549 NSCLC tumorsphere formation. M3, by far, showed the
strongest A549 NSCLC tumorsphere formation inhibition. Data represent mean  SD (n
=3), and the asterisk showed significant difference in comparison with the control group
based on Student’s t-test (p < 0.01).

163

5.3.6 Metabolites of 5DN significantly modulated key signaling related to cell cycle and
apoptosis
In order to further elucidate the molecular mechanisms underlying the inhibitory
effects of 5DN’s metabolites on human NSCLC cells, we compared the effects of 5DN’s
metabolites and 5DN on key protein markers related to cell proliferation and apoptosis.
Since NBT did not cause any significant change in cell cycle arrest or apoptosis, we cut
NBT treatment out from this experiment. Immunoblotting analysis demonstrated that
treatments with 5DN’s metabolites led to extensive alterations in crucial signaling
proteins. In H460, treatment of M3 at 10-fold lower concentration of 5DN significantly
increased expression levels of p53, p21, and decreased expression levels of Cdc-2(CDK1) and cyclin B1. Treatment of M3 was also found to increased Bax, cleaved caspase-3,
and cleaved PARP. Similar results were also observed in treatment of M2 but in less
extent of those produced by treatment of M3 in H460 cells. Treatment of M1
moderately decreased the expression levels of cyclin D1, CDK-6, and CDK-4. Also,
treatment of M1 gradually increased the expression levels of Bax, cleaved caspase-3 and
cleaved PARP. All of these effects of 5DN were much weaker than those produced by
5DN’s metabolites, especially M3 at 10-fold lower concentrations (Figure 5.9).
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Figure 5.9 Effects of 5DN and 5DN’s metabolites (M1, M2, and M3) in modulating key
signaling protein playing vital roles in cell cycle progression and apoptosis. H460 were
seeded in 10 cm culture dishes for 24 hr, and then were treated with 5DN, M1, M2, and
M3. At another 24 or 48 hr of incubation cell were then harvested for western blotting
as described in section 5.2.5. Immunoblots on the left displayed the treatment effects
of 5DN and 5DN’s metabolites on p53, p21, cyclin B1, Cdc-2, cyclin D1, CDK-6, and CDK-4
in H460 human NSCLC cells after being treated for 24 hr, while immunoblots on the right
demonstrated the treatments effects on Bax, cleaved caspase-3, and cleaved PARP after
48 hr treatment time. The numbers underneath of the blots represent band intensity
(normalized to β-actin, means of three independent experiments) measured by Image J
software. The standard deviations (all within ± 15% of the means) were not shown. βactin served as an equal loading control.
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5.4 Discussion
As one of the promising strategies to combat cancer, chemoprevention is gained
public interest as an approach to inhibit, delay, or reverse human carcinogenesis.
Epidemiological studies have provided conceiving evidence that naturally or chemically
synthesis bioactive components can modulate or intervene key molecular signaling
associated in carcinogenesis process including initiation, promotion, progression, or
even metastasis of several types of human cancer (4, 5). In this chapter, we
demonstrated that metabolites of 5DN namely M1, M2, and especially M3 exerted the
NSCLC cell proliferation inhibitory activities including suppressing cell growth and
inducing cell cycle arrest and apoptosis stronger than those produced by their parental
compound, 5DN, and NBT which was one of the most abundant PMFs found in the peel
of sweet oranges.
Accumulating evidence has been revealed that several PMFs showed a broad
spectrum of biological activities including anti-inflammatory, anti-carcinogenesis, and
anti-atherogenic (54). We previously reported that treatments of monodemethylated
PMFs namely 5DN, 5-hydroxy,3,6,7,8,3’,4’-hexamethoxyflavone, and 5demethyltangeretin (5DT) were stronger in inhibiting both human lung (14, 59) and
colon (13, 15) cancer cell growth than treatments of permethoxylated PMFs. Other
groups also reported that 5-demethylated nobiletin derivatives exerted the activity to
inhibit pro-MMP-9 production in the stimulated human lens epithelial cells at the
transcription level (187). Biotransformation dictates the overall biological activities of
bioactive compounds in vivo. Recently, we have identified 3 metabolites of 5DN in mice
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fed with 5DN, and have developed the efficient method to chemically synthesize the
metabolites of 5DN namely M1, M2, and M3. We also found that M1 and M2 showed
stronger growth inhibition on colon cancer cells than their parental compound, 5DN and
M3, by far, showed the strongest growth inhibitory effect on human colon cancer cells
namely SW480 and SW620 (185). Our results herein were in accordance with our
previous results in which M1, M2, and M3 caused more potent growth inhibitory effects
on human NSCLC cells. In addition, M3, by far, produced the strongest growth inhibitory
effects among tested PMFs.
Despite of the difference in one functional group between 5DN and NBT, the IC50
concentration of 5DN was approximately in the range of 4 to 6-fold lower than that of
NBT in H460 and H1299 according to our cell viability results. We also found that 5demethyltangeretin (5DT) exhibited NSCLC cell growth inhibition significantly stronger
than its permethoxylated counterpart, tangeretin (59). This finding reinforced the
notion of our previous results that 5-demethylation could significantly enhance the
inhibitory effects of PMFs against cancer cell growth (13, 59). Our results also further
indicated that demethylation at 3´-, 4´, or both 3´- and 4´-positions could even
significantly augment the inhibitory effects of 5DN. Strikingly, in H460 and H1299 NSCLC
cells, the IC50 concentration of M3, one of the metabolites of 5DN, was approximately in
the range of 26 to 49-fold lower than 5DN, and was about 165 to 219-fold lower than
NBT. All of these results suggested the potently vital role of the demethylation position
of PMFs in dictating their health-promoting properties.
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Induction of cell cycle arrest and extensive cellular apoptosis in cancer cells is
one of the effective strategies to control cancer progression. Several PMFs have been
reported to trigger apoptosis in many difference cancer cells. Demethylation of PMFs,
especially at the 5-position, was found to be critical for augmenting their pro-apoptotic
activities in lung (14, 59), colon (13), and breast cancer cells (41, 188). Our results from
flow cytometry and immunoblotting analysis clearly displayed that treatments of 5DN’s
metabolites (M1, M2, and M3), especially M3 at the doses of 10-fold lower than those in
5DN, not only caused significant cell cycle arrest, but also resulted in extensive
apoptosis in both H460 and H1299 human NSCLC cells.
Cyclins, cyclin dependent kinases (CDKs) and CDK inhibitors are regulators of cell
cycle progression. Cyclin/CDK complexes promote cell cycle progression while CDK
inhibitors induce cell cycle arrest (134, 135). We found that treatment of M3
significantly decreased the expression levels of both cyclin B1 and Cdc2 (cdk-1), which at
least in part, potentiated cells in G2/M phase. One of the reasons for this is the complex
of cyclin B1/Cdc2 is mandatory for a cell to enter into mitosis in G2/M transition (136).
Furthermore, M3 caused potent increase in the expression levels of p53 and p21Cip1/Waf1
in the NSCLC cells, which also contributed to the cell cycle arrest observed. p21Cip1/Waf1 is
a small 165 amino acid CDK inhibitor that inhibits activity of cyclin B1/Cdc2 complex by
directly bound to the complex, which blocks cells in G2/M phase (137, 138). In addition,
p21Cip1/Waf1 can diminish Cdc2 protein levels by decreasing Cdc2 mRNA transcriptions
and its promoter activity (139). H460 cell contains wild-type p53, a tumor suppressor.
Our results showed that M2 and M3 treatments increased expression levels of p53
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which has a diverse spectrum of cellular functions and plays crucial roles in inhibiting
cancer progression (140) by impeding cell cycle progression (137, 141), inducing cellular
apoptosis (142), and DNA repair (143). Increased levels of p53 can lead to G2/M cell
cycle arrest by downregulating transcription of both cyclin B1 and Cdc2 (137, 139, 141,
144). Moreover, p21Cip1/Waf1 is one of the transcriptional targets of p53, and increased
levels of p53 can result in increased levels of p21Cip1/Waf1, which in turn contributes to
induce cell cycle arrest at G2/M phase (137, 145). In M1 treatment, we observed the
decreased in the expression levels of CDK-4, CDK-6, and Cyclin D1. The complex of cyclin
D1/CDK-4 or a complex of cyclin D1/CDK-6 is required for entry into S phase (134).
Therefore, decreasing in these complexes may contribute to the effect of M1 in inducing
G0/G1 cell cycle arrest in H460 NSCLC cells. In addition, we also found that all M1, M2,
and M3 activated caspase 3 and PARP in H460 cells which were the hallmarks of
apoptosis. Moreover, we also observed that all 5DN’s metabolites tested (M1, M2, and
M3) increased the expression levels of Bax which is one of the pro-apoptotic Bcl-2 family
proteins (58). Even though 5DN treatment in the present study did not induce
significant amount of cell cycle arrest and apoptosis as same as our previous report in
which we found that 10 µM of 5DN extensively induced cellular apoptosis in H1299, it is
noteworthy to mention that the 5DN concentration we used in cell cycle analysis and
apoptosis in this present study for 5DN in H1299 cells was 2-fold lower than that we
utilized in our previous study (5 µM vs. 10 µM) (14). Hence, our results suggested that
M1, M2, and M3 were stronger than 5DN in inhibiting NSCLC cell growth by blocking cell
cycle progression and induced apoptosis.
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In spite of only minor structural differences, we observed that different PMFs
induced cell cycle arrest and different phase. We also found that different PMFs
exhibited different levels of apoptosis. It was found that treatment of M1 caused
significant accumulation of cell population in G0/G1 whereas treatment of M2 and M3
significantly potentiated cells in G2/M phase. Moreover, at the same concentration of
M1 and M2, 5DN did not cause any significant change in inducing cell cycle arrest and
apoptosis. We suggest the different in the interactions between each component and its
direct targeted proteins in cancer cells may be one of the reasons behind the profound
effects of 5DN’s metabolites, especially M3, in modulating cell cycle progression and
cellular apoptosis. The binding of PMFs to these signaling proteins could initiate a
cascade of signaling events that lead to physiological outcomes including cell cycle
arrest and apoptosis. Because of the differences in chemical structures, even only
slightly variation, 5DN and 5DN’s metabolites may interact with different proteins
and/or bind to the same proteins but with different affinity levels which ultimately
results in different biological outcomes.
Overall, we found that 5DN metabolites showed more potent anticancer
activities than those from 5DN. M3 which is one of the 5DN’s metabolites that had a
single demethylation at 3´-position caused the most drastic enhancement in inhibitory
effects against NSCLC cells. In order to achieve biological effects in target organs or
tissues in human, bioactive components in the diet must be bioavailable, which means
effectively absorbed, transported into the circulatory system, and finally delivered to
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the appropriate sites. Therefore, further investigations on 5DN’s bioavailability and
toxicity are warranted.
Growing evidence has reported the isolation of lung CSCs from both lung cancer
cell lines (34, 35, 37) and lung solid-tumors (38, 39). Lung tumorsphere formation is one
of the models to investigate lung CSCs (37, 38). We found that NBT, 5DN, and 5DN’s
metabolites were capable to inhibit the tumorsphere formation of A549 NSCLC cells
indicating the potential effects of PMFs, especially M3 which showed the strongest A549
lung CSCs inhibition, to combat lung CSCs.
In conclusion, we demonstrated, for the first time, the potent inhibitory activities
of 5DN’s metabolites namely 5,4´ -didemethylnobiletin (5,4´dihydroxy-6,7,8,3´tetramethoxyflavone, M1), 5, 3´,4´- tridemethylnobiletin (5, 3´,4´- trihydroxy-6,7,8trimethoxyflavone, M2) ,and 5, 3´-didemethylnobiletin (5, 3´-dihydroxy-6,7,8,4´tetramethoxyflavone, M3) on human NSCLC cells. The inhibition on these lung cancer
cells were involved with profound induction of cell cycle arrest and apoptosis as the
result of alteration of oncogenic key signaling proteins. Our results provide fundamental
mechanisms for the pro-cell cycle arrest and pro-apoptotic activities of these 5DN’s
metabolites in NSCLC cells. Future animal and clinical studies will ascertain if these
5DN’s metabolites could be utilized as lung cancer preventive nutraceutical compounds.
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CHAPTER 6
CONCLUDING REMARKS

At present, lung carcinoma is by far the most leading causes of cancer mortalities
among all type of cancer. In this thesis, the chemopreventive properties of
polymethoxyflavones (PMFs) namely nobiletin (NBT), tangeretin (TAN), 5demethylnobiletin (5DN) and 5-demethyltangeretin (5DT) against H460, H1299, and
A549 human non-small cell lung cancer (NSCLC) cells were demonstrated. Both 5DN and
5DT were found to exhibit significantly stronger growth inhibitory effects on NSCLC cells
than their permethoxylated counterpart, NBT and TAN, respectively. The effects of 5DT
were associated with profound cell cycle arrest and apoptosis resulting from modulating
signaling proteins. Bioavailability of bioactive compounds influences the biological
properties of certain agents. Herein, 5DT displayed higher intracellular uptake than its
counterpart, TAN, in lung cancer cells which may increase its anti-carcinogenic activities.
Biotransformation also plays crucial roles in these overall health-promoting effects in
vivo as compounds are undergone diverse reactions after oral ingestion. Metabolites of
5DN namely 5,4´ -didemethylnobiletin (5,4´dihydroxy-6,7,8,3´-tetramethoxyflavone,
M1), 5, 3´,4´- tridemethylnobiletin (5, 3´,4´- trihydroxy-6,7,8-trimethoxyflavone, M2)
,and 5, 3´-didemethylnobiletin (5, 3´-dihydroxy-6,7,8,4´-tetramethoxyflavone, M3) were
found to be more potent than 5DN in inhibiting NSCLC cell proliferation. As chemical
structures of PMFs are slightly different but their levels of inhibitory effects are greatly
wide, this suggests the impact role of the demethylation position of PMFs especially at
the 5-position on the A ring. M3, by far, exhibited the strongest growth inhibitory effects
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against NSCLC cells among all PMFs tested in all of this study. Cancer stem cells (CSCs),
referred as tumor-initiating cells, were reported to be the cause of tumor progression
and recurrence of malignant tumors as treatments usually leave behind this subset of
cells. Recently, lung CSCs have been identified in both lung cancer cell lines and solid
tumors by using cell surface methods, enzymatic activities, and the ability of proliferate
in selective environment. Treatment of PMFs were also found to inhibit lung
tumorsphere formation as well as decrease the number of ALDHbr cells indicating the
potential activities of PMFs to inhibit lung CSCs. Even though further investigations in
animal and clinical research are required, results demonstrated herein showed that
PMFs were capable to inhibit both normal NSCLC cell population as well as selectively
inhibited lung cancer stem cells-like cells suggesting the promising role of PMFs as lung
cancer chemopreventive agents. Combination of different bioactive agent may enhance
their salubrious properties due to synergistic interaction between agents. Confirmed by
isobologram analysis that the inhibitory effects were synergistic, NBT/ATST cotreatments or TAN/ATST at low doses produced much stronger inhibitory effects on all
three cancer cells in comparison to those produced by NBT, TAN or ATST alone at higher
doses. Overall, our results demonstrated strong synergy between NBT/ATST as well as
TAN/ATST in inhibiting human lung cancer cell growth, which warrants future
investigation on the in vivo efficacy of these unique combinations. All in all, PMFs
showed promising anticancer activities that can be utilized as lung cancer
chemopreventive nutraceutical agents.
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